Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Diabetes Obes Metab Retrieve available abstracts of 975 articles: HTML format

Single Articles

November 2025
1. SMOLDEREN KG, Mena-Hurtado C, Zhao Z, Michalak W, et al
   Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
   Diabetes Obes Metab. 2025;27:6691-6704.
   PubMed     Abstract available
   
   
   
2. SAIDI AN, Konings LAM, Dietvorst CAW, de Jong VD, et al
   Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.
   Diabetes Obes Metab. 2025;27:6624-6631.
   PubMed     Abstract available
   
   
   
3. TANG H, Lu Y, Zhang B, Zhou T, et al
   Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.
   Diabetes Obes Metab. 2025;27:6527-6536.
   PubMed     Abstract available
   
   
   
4. HUA R, Yang A, Gao L, Chow E, et al
   Social determinants of health and progression to cardio-renal-metabolic multimorbidity and mortality in people with prediabetes: A prospective cohort study.
   Diabetes Obes Metab. 2025;27:6605-6614.
   PubMed     Abstract available
   
   
   
5. AZEGAMI T, Kaneko H, Okada A, Suzuki Y, et al
   Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real-world database study.
   Diabetes Obes Metab. 2025;27:6294-6303.
   PubMed     Abstract available
   
   
   
6. BRAMLAGE P, Vijayan A, Varghese TP, Melepurakkal Sadanandan D, et al
   Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.
   Diabetes Obes Metab. 2025;27:6254-6263.
   PubMed     Abstract available
   
   
   
7. GAO FM, Kishore K, Pandey D, Jahanabadi H, et al
   Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy.
   Diabetes Obes Metab. 2025;27:6367-6374.
   PubMed     Abstract available
   
   
   
8. CRUTCHLOW M, Liu J, Hernandez-Illas M, Zhang H, et al
   Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
   Diabetes Obes Metab. 2025;27:6264-6274.
   PubMed     Abstract available
   
   
   
9. WONG S, Le GH, Dri CE, Teopiz KM, et al
   Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.
   Diabetes Obes Metab. 2025;27:6105-6115.
   PubMed     Abstract available
   
   
   October 2025
10. BOWE A, Hayes M, John I, Diaz M, et al
    Glucagon-like peptide-1 receptor agonist versus sodium-glucose cotransporter-2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity.
    Diabetes Obes Metab. 2025 Oct 30. doi: 10.1111/dom.70219.
    PubMed     Abstract available
    
    
    
11. GLATZ U, Muller A, Moser O, Aberer F, et al
    Acute and prolonged effects of aerobic endurance training on N-lactoyl-phenylalanine and inflammatory markers in individuals with type 1 diabetes: An exploratory analysis of the ULTRAFLEXI-1 study.
    Diabetes Obes Metab. 2025 Oct 29. doi: 10.1111/dom.70236.
    PubMed    
    
    
    
12. GOLDENBERG RM
    An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 29. doi: 10.1111/dom.70253.
    PubMed    
    
    
    
13. MEFFEN A, Tyrer F, Mbah Mbahnjeck J, Khunti K, et al
    Blood pressure and adverse cardiovascular outcomes in older people with type 2 diabetes and chronic kidney disease: Findings based on the Clinical Practice Research Datalink databases in England.
    Diabetes Obes Metab. 2025 Oct 28. doi: 10.1111/dom.70234.
    PubMed     Abstract available
    
    
    
14. LIN R, Hsu CL, Shih MC, Chien KL, et al
    Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Oct 28. doi: 10.1111/dom.70224.
    PubMed     Abstract available
    
    
    
15. YANG W, Cai X, Ji Q, Tong N, et al
    Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023-2024.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70222.
    PubMed     Abstract available
    
    
    
16. CHAUDHRY A, Thompson DM, Chanoine JP
    Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70240.
    PubMed     Abstract available
    
    
    
17. LAN H, Xu S, Li H, Guo R, et al
    Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70239.
    PubMed     Abstract available
    
    
    
18. PASQUA MR, Tsoukas MA, Haidar A
    Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70213.
    PubMed     Abstract available
    
    
    
19. YONEDA M, Takeuchi M, Oura T, Nakajima A, et al
    Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70225.
    PubMed    
    
    
    
20. DE MEULEMEESTER J, Valgaerts L, Tenoutasse S, Gies I, et al
    One-year effectiveness and safety in young children aged 2-6 years with type 1 diabetes using an automated insulin delivery system: A real-world prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70228.
    PubMed     Abstract available
    
    
    
21. KATO S, Ozu N, Yamakage H, Kato H, et al
    Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2025 Oct 22. doi: 10.1111/dom.70182.
    PubMed     Abstract available
    
    
    
22. LIU Q, Guo S, Tong Y, Qiu L, et al
    Renal lipotoxicity in diabetic and obesity-associated kidney diseases: Molecular mechanisms and therapeutic targeting.
    Diabetes Obes Metab. 2025 Oct 22. doi: 10.1111/dom.70220.
    PubMed     Abstract available
    
    
    
23. HIGHTON PJ, Funnell MP, Tziannou A, Rowlands AV, et al
    Structured group education programme and accompanying mHealth intervention to promote physical activity in women with a history of gestational diabetes (Baby Steps): 4-year follow-up of a randomised controlled trial.
    Diabetes Obes Metab. 2025 Oct 21. doi: 10.1111/dom.70199.
    PubMed    
    
    
    
24. YU M
    iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.
    Diabetes Obes Metab. 2025 Oct 20. doi: 10.1111/dom.70192.
    PubMed     Abstract available
    
    
    
25. ZHANG J, Wang Y, Lu Z, Yang Y, et al
    Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 20. doi: 10.1111/dom.70223.
    PubMed     Abstract available
    
    
    
26. DESHMUKH H, Wilmot EG, Ssemmondo E, Barnes D, et al
    Exploring the interaction between ethnicity, deprivation and the use of CGM on diabetes outcomes-A study from the Association of British Clinical Diabetologists.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70206.
    PubMed     Abstract available
    
    
    
27. WAN S, Yan H, Sun QY, Zhu JQ, et al
    Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70201.
    PubMed     Abstract available
    
    
    
28. TESFAYE H, Paik JM, Wexler DJ, Hathaway JT, et al
    GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70200.
    PubMed     Abstract available
    
    
    
29. ZHOU H, Wang Y, Song X, Xu T, et al
    Independent and joint association of fat-to-muscle mass ratio and cardiorespiratory fitness with type 2 diabetes mellitus incidence: A prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70217.
    PubMed     Abstract available
    
    
    
30. KOUFAKIS T, Sarafidis P, Tsapas A, Doumas M, et al
    Pursuing remission in type 2 diabetes: Competing strategies or complementary paths?
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70212.
    PubMed    
    
    
    
31. WEINREICH AA, Bagger JI, Jorgensen JT, Kristensen PL, et al
    Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70208.
    PubMed    
    
    
    
32. NI J, Chen L, Su H, Cai J, et al
    Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.
    Diabetes Obes Metab. 2025 Oct 15. doi: 10.1111/dom.70214.
    PubMed     Abstract available
    
    
    
33. HTOO PT, Tesfaye H, Schneeweiss S, Wexler DJ, et al
    Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 15. doi: 10.1111/dom.70195.
    PubMed     Abstract available
    
    
    
34. ZAKY A, Nguyen LT, Shi Y, Hou M, et al
    The effect of sugarcane extract supplementation on glycemic control in a mouse model of type 1 diabetes.
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70183.
    PubMed     Abstract available
    
    
    
35. YU M, Wang T, Xu C, Bi Y, et al
    Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70197.
    PubMed     Abstract available
    
    
    
36. GU W, Wu X, Zhang M, Wang X, et al
    Efficacy and safety of iGlarLixi versus IDegAsp by baseline beta-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70181.
    PubMed     Abstract available
    
    
    
37. SKOP V, Lankova I, Antalova S, Miskova I, et al
    Partial non-adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross-sectional study using blood plasma analysis.
    Diabetes Obes Metab. 2025 Oct 10. doi: 10.1111/dom.70174.
    PubMed     Abstract available
    
    
    
38. PASQUA MR, Tsoukas MA, Haidar A
    Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post-hoc analysis from a double-blinded randomized controlled trial.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70185.
    PubMed    
    
    
    
39. BANERJEE M, Pal R, Pal S
    Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70187.
    PubMed     Abstract available
    
    
    
40. ZHONG X, Zheng Y, Wang L, Ouyang B, et al
    Evaluating global epidemiology of type 2 diabetes mellitus among the working-age population: A 60-year study by interpretable machine learning framework.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70155.
    PubMed     Abstract available
    
    
    
41. POHLMANN J, Smith-Palmer J, Serne EH, Tuomaala AK, et al
    A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70161.
    PubMed     Abstract available
    
    
    
42. TUTTLE KR, Ji L, Mathieu C, Rosen J, et al
    Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70180.
    PubMed     Abstract available
    
    
    
43. ALGHAMDI M, Dihoum A, Hakami K, Bhattacharjee A, et al
    Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70164.
    PubMed     Abstract available
    
    
    
44. MONNIER L, Colette C, Benhamou PY, Owens D, et al
    Should glycaemic variability and times spent in levels 1 and 2 hypoglycaemia be revised downward in type 1 diabetes treated with advanced systems of insulin delivery?
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70179.
    PubMed    
    
    
    
45. DI GIOIA L, Di Molfetta S, Caruso I, Caporusso M, et al
    Efficacy and safety of once-weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70176.
    PubMed     Abstract available
    
    
    
46. SCARAMUZZA AE, Cherubini V
    The 'awareness effect': A crucial, un-modelleld economic benefit of national type 1 diabetes screening.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70184.
    PubMed    
    
    
    
47. AL OZAIRI E, Irshad M, Alkandari J, Sojan L, et al
    Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70172.
    PubMed     Abstract available
    
    
    
48. MATHIESEN DS, Hansen JV, Hock A, Nielsen CK, et al
    Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70139.
    PubMed     Abstract available
    
    
    
49. PAN Y, Zhang W, Dai Y, Liu Y, et al
    Association between accelerometer-measured physical activity, genetic risk, and incident type 2 diabetes: A prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 3. doi: 10.1111/dom.70166.
    PubMed     Abstract available
    
    
    
50. MANCHANDA Y, Jones B, Carrat G, Ramchunder Z, et al
    Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP-1R/GIPR dual agonist, HISHS-2001.
    Diabetes Obes Metab. 2025;27:5938-5949.
    PubMed     Abstract available
    
    
    
51. LIN YL, Hung YJ, Chen JH, Sung JY, et al
    Protective effect of metformin against dementia in patients with obesity: Results from a global federated health network analysis.
    Diabetes Obes Metab. 2025;27:5899-5909.
    PubMed     Abstract available
    
    
    
52. FERNANDEZ C, Nacher M, Rivera K, Marin-Canas S, et al
    Loss of beta-cell identity in human islets treated with glibenclamide.
    Diabetes Obes Metab. 2025;27:5782-5792.
    PubMed     Abstract available
    
    
    
53. WANG Z, Jin Z, Xiong Z
    Research progress of epidermal growth factor receptor in metabolic dysfunction-associated steatotic liver disease and related diseases.
    Diabetes Obes Metab. 2025;27:5418-5431.
    PubMed     Abstract available
    
    
    
54. WEN Y, Lemen D, Lin Y, Chen YQ, et al
    Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
    Diabetes Obes Metab. 2025;27:5985-5995.
    PubMed     Abstract available
    
    
    
55. AKINRIMISI OI, Koning M, Scheijen JLJM, Meijnikman AS, et al
    Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals.
    Diabetes Obes Metab. 2025;27:5878-5888.
    PubMed     Abstract available
    
    
    
56. ZHOU J, Husain M, Li Y, Liu W, et al
    Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.
    Diabetes Obes Metab. 2025;27:5706-5715.
    PubMed     Abstract available
    
    
    
57. CARLIER L, De Ponthaud C, Jacqueminet S, Phan F, et al
    Perioperative use and accuracy of continuous glucose monitoring: A systematic review.
    Diabetes Obes Metab. 2025;27:5393-5408.
    PubMed     Abstract available
    
    
    
58. SATTAR N, Garcia-Perez LE, Rodriguez A, Kapoor R, et al
    Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.
    Diabetes Obes Metab. 2025;27:5386-5392.
    PubMed     Abstract available
    
    
    September 2025
59. DI MOLFETTA S, Di Gioia L, Caruso I, Caporusso M, et al
    Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70150.
    PubMed     Abstract available
    
    
    
60. CHANG Y, Hsieh MH, Ju PC, Chang CC, et al
    Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70175.
    PubMed     Abstract available
    
    
    
61. CHEN MH, Lin LY, Hung TY, Lin TC, et al
    Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70157.
    PubMed     Abstract available
    
    
    
62. ZHOU Z, Gao N, Liu J, Ma X, et al
    An interpretable machine learning model for predicting metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70168.
    PubMed     Abstract available
    
    
    
63. HANKOSKY ER, Lebrec J, Lee CJ, Dimitriadis GK, et al
    Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70143.
    PubMed     Abstract available
    
    
    
64. FADINI GP, Longato E, Poletto S, Giaccari A, et al
    Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70151.
    PubMed     Abstract available
    
    
    
65. CASTRILLON F, Carter B, McClure A, Welk B, et al
    The impact of semaglutide on peri-operative cardiovascular outcomes in diabetes.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70145.
    PubMed    
    
    
    
66. CHENG J, Yu H, Gu Y, Ma C, et al
    Diabetes remission and diabetic complications of bariatric surgery vs. medical management in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70152.
    PubMed     Abstract available
    
    
    
67. ZHANG L, Wang J, Zheng W, Yuan X, et al
    Probiotics and dietary fibre fermented milk supplementation initiated in the first trimester to prevent gestational diabetes mellitus in overweight and obese pregnant women: A randomized controlled trial.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70158.
    PubMed     Abstract available
    
    
    
68. BELAND-BONENFANT S, Denimal D, Pais-de-Barros JP, Choubley H, et al
    Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70156.
    PubMed     Abstract available
    
    
    
69. SUN Y, Li H, Yan X, Ma G, et al
    Unveiling urinary diagnostic biomarkers for diabetic kidney disease using metabolomics and machine learning approaches.
    Diabetes Obes Metab. 2025 Sep 21. doi: 10.1111/dom.70138.
    PubMed     Abstract available
    
    
    
70. MURUGAVEL S, Retnakaran R, Feig DS, Zinman B, et al
    Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70146.
    PubMed     Abstract available
    
    
    
71. GURUNG RL, Zheng H, Tan JLI, Liu S, et al
    Integrative metabolomic and proteomic analysis of diabetic kidney disease progression with younger-onset type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70153.
    PubMed     Abstract available
    
    
    
72. RITTENHOUSE BE, Alolayan S, Segal AR, Eguale T, et al
    Reply to "A comment on 'Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was'".
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70149.
    PubMed    
    
    
    
73. DIONNE V, Iglesies-Grau J, Latour E, Besnier F, et al
    Optimizing cardiovascular health with a type 2 diabetes remission program: Ultraprocessed food-intake reduction, Mediterranean diet, chrononutrition and physical training-The DIABEPIC-2 pilot study.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70142.
    PubMed     Abstract available
    
    
    
74. QU HQ, Hakonarson H
    Sex as a modifier of genetic risk for type 1 diabetes.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70124.
    PubMed     Abstract available
    
    
    
75. LEE BW, Lee CB, Lim S, Kim SG, et al
    Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70111.
    PubMed     Abstract available
    
    
    
76. HOO JX, Yang YF, Lau ESH, Ibrahim L, et al
    A 7-year prospective analysis of sustained benefits of multicomponent risk assessment and data-driven care in patients with type 2 diabetes: The Malaysian JADE Program.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70125.
    PubMed     Abstract available
    
    
    
77. XUE X, Li J, Zheng W, Zhang B, et al
    Contributions of 2-h post-load glucose, fasting blood glucose and glycosylated haemoglobin elevations to the prevalence of diabetes and pre-diabetes in adults: A systematic analysis of global data.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70130.
    PubMed     Abstract available
    
    
    
78. LI X, Zhang Y, Bi Y, Lu J, et al
    Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70132.
    PubMed     Abstract available
    
    
    
79. CRUTCHLOW M, Liu J, Romero C, Watkins E, et al
    Combined agonism of nutrient receptors GPR40 and GPR119 with K-757 and K-833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70120.
    PubMed     Abstract available
    
    
    
80. LI J, Liu Y, Xing W, Jiang Y, et al
    Blood glucose trajectories in diabetes patients receiving CAPDCA model of personalised patient education: A cluster randomised controlled trial.
    Diabetes Obes Metab. 2025 Sep 14. doi: 10.1111/dom.70119.
    PubMed     Abstract available
    
    
    
81. LI W, Huang L, Wang R, Peng P, et al
    Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Sep 11. doi: 10.1111/dom.70084.
    PubMed     Abstract available
    
    
    
82. LEE YT, Wu JY, Chang TW, Hung CH, et al
    Impact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.
    Diabetes Obes Metab. 2025 Sep 11. doi: 10.1111/dom.70131.
    PubMed     Abstract available
    
    
    
83. CHENG X, Fu Z, Chen Y, Wang J, et al
    Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro.
    Diabetes Obes Metab. 2025 Sep 10. doi: 10.1111/dom.70107.
    PubMed     Abstract available
    
    
    
84. ZHANG A, Zhichen B, Kidoguchi S, Nishiyama A, et al
    An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats.
    Diabetes Obes Metab. 2025 Sep 10. doi: 10.1111/dom.70118.
    PubMed     Abstract available
    
    
    
85. LIU A, Shao Y, Chen J, Ng CS, et al
    The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.
    Diabetes Obes Metab. 2025 Sep 10. doi: 10.1111/dom.70081.
    PubMed     Abstract available
    
    
    
86. HASEBE M, Su CY, Keidai Y, Minamino H, et al
    Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.
    Diabetes Obes Metab. 2025 Sep 9. doi: 10.1111/dom.70121.
    PubMed     Abstract available
    
    
    
87. JOUBERT M, Meyer L, Bekka S, Rakotoarisoa L, et al
    Hypoglycemia incidence and behavioural adjustments during free-living unstructured physical activity in adults with type 1 diabetes using AID systems: Results from the RAPPID study.
    Diabetes Obes Metab. 2025 Sep 9. doi: 10.1111/dom.70122.
    PubMed     Abstract available
    
    
    
88. GUAN H, Jiang H, Yuan H, Sun J, et al
    Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.
    Diabetes Obes Metab. 2025 Sep 9. doi: 10.1111/dom.70047.
    PubMed     Abstract available
    
    
    
89. SCHIERBAUER J, Sanfilippo S, Wachsmuth N, Moser O, et al
    Association between glycated haemoglobin A(1c) and total haemoglobin mass in adults with type 1 diabetes mellitus. A proof-of-concept study.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70007.
    PubMed    
    
    
    
90. FJAELDSTAD AW, Norman K, Bjerg L
    Subjective smell- and taste loss in diabetes-A questionnaire-based study on 47 011 individuals with diabetes and matched controls.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70099.
    PubMed     Abstract available
    
    
    
91. ZHANG Y, Zhou J, Chen X, Huang H, et al
    Optimal type and dose of exercise to improve glycated haemoglobin in individuals with type 1 diabetes: A systematic review and Bayesian dose-response network meta-analysis of RCTs.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70115.
    PubMed     Abstract available
    
    
    
92. DAVIDSEN L, Jensen MH, Drewes AM, Knop FK, et al
    Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70106.
    PubMed     Abstract available
    
    
    
93. RABBONE I, Tinti D, Rigamonti A, Mossetto C, et al
    Comparable glycemic outcomes with insulin glargine and insulin degludec during exercise in adolescents with type 1 diabetes using a standardized management protocol.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70108.
    PubMed    
    
    
    
94. SHARMA A, Ali Baig S, Thayakaran R, Rengarajan L, et al
    Clinical characteristics and outcomes of diabetes-related ketoacidosis (DKA) in sodium-glucose co-transporter-2 inhibitor (SGLT2i) users with type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70098.
    PubMed     Abstract available
    
    
    
95. KANU C, Boye KS, Poon JL, Goetz I, et al
    Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70097.
    PubMed     Abstract available
    
    
    
96. PENG Y, Li J, Deng Y, Zhou Z, et al
    The protective role of TIGIT+ B cells in attenuating type 1 diabetes progression.
    Diabetes Obes Metab. 2025 Sep 5. doi: 10.1111/dom.70092.
    PubMed     Abstract available
    
    
    
97. CHAO Y, Tong X, Zhang B, Yang H, et al
    Olfactory training improves cognition and modifies brain networks in type 2 diabetes patients with mild cognitive impairment: A 16-week randomised controlled trial.
    Diabetes Obes Metab. 2025 Sep 5. doi: 10.1111/dom.70103.
    PubMed     Abstract available
    
    
    
98. SOLA C, Lundemose SB, McCarthy OM, Norgaard K, et al
    Post-exercise glycaemic control for 24 h: Fasted morning exercise with and without glucagon in adults with type 1 diabetes using automated insulin delivery.
    Diabetes Obes Metab. 2025 Sep 4. doi: 10.1111/dom.70085.
    PubMed    
    
    
    
99. IPAYE T, Goldney J, Wilkinson TJ, Zaccardi F, et al
    Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
    Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70090.
    PubMed     Abstract available
    
    
    
100. THAMMAKOSOL K, Jantarapootirat M, Traiwanatham S, Sriphrapradang C, et al
     Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.
     Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70101.
     PubMed     Abstract available
     
     
     
101. XIAO Q, Zhang C, Jiang Y, Suo C, et al
     Identification of subtypes of type 2 diabetes in the Chinese population and their distinct complication risk profiles.
     Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70056.
     PubMed     Abstract available
     
     
     
102. ARD J, Lee CJ, Gudzune K, Addison B, et al
     Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
     Diabetes Obes Metab. 2025;27:5064-5071.
     PubMed     Abstract available
     
     
     
103. WANG J, Lin C, Cai X, Wang Y, et al
     Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
     Diabetes Obes Metab. 2025;27:5042-5051.
     PubMed     Abstract available
     
     
     
104. TANS R, Schipper A, de Vaan E, Kusters R, et al
     A personalized approach to classify the degree of liver insulin resistance in children with obesity.
     Diabetes Obes Metab. 2025;27:5225-5234.
     PubMed     Abstract available
     
     
     
105. MOCHIZUKI K, Fuchigami A, Hirose T, Uchino H, et al
     Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study.
     Diabetes Obes Metab. 2025;27:5099-5107.
     PubMed     Abstract available
     
     
     
106. BERGET C, Cobry E, Escobar E, Towers L, et al
     Sustained improvements in glycaemic and psychosocial outcomes for youth and caregivers using Omnipod 5 AID for 12 months.
     Diabetes Obes Metab. 2025;27:4942-4949.
     PubMed     Abstract available
     
     
     
107. SIMENTAL-MENDIA LE, Simental-Mendia M, Barragan-Zuniga LJ, Arce-Quinones M, et al
     Effect of saroglitazar on glycaemic parameters: A systematic review and meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2025;27:4627-4642.
     PubMed     Abstract available
     
     
     
108. GUO R, Pandey A, Chandramouli C, Wu MZ, et al
     The effect of sodium-glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM.
     Diabetes Obes Metab. 2025;27:4720-4728.
     PubMed     Abstract available
     
     
     
109. CHO Y, Jhee JH, Jhee JH, Park HS, et al
     Beyond BMI: The role of diabetes and central obesity in fracture risk-Insights from the UK biobank.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70074.
     PubMed     Abstract available
     
     
     
110. ALHAMAR G, Fallucca S, Richardson SJ, Torabi F, et al
     Raised levels of Interleukin-8 and myeloperoxidase in patients with recent onset type 1 diabetes.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70048.
     PubMed     Abstract available
     
     
     
111. SSEMMONDO E, Newham M, Deshmukh H, Wilmot EG, et al
     Baseline clinical factors associated with diabetes distress in dialysis patients: Insights from the ABCD audit data.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70076.
     PubMed     Abstract available
     
     
     
112. YU B, Li J, Yu Y, Sun Y, et al
     Proteomics-enabled learning machine algorithms enhance the prediction of cardiovascular diseases in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70064.
     PubMed     Abstract available
     
     
     
113. WANG B, Liu KSN, Mak IL, Choi EPH, et al
     Impact of onset age of type 2 diabetes mellitus on risk of renal complications compared to age-matched non-diabetic patients: Two cohort studies in the United Kingdom and Hong Kong.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70061.
     PubMed     Abstract available
     
     
     
114. WEI J, Wu H, Wang N, Zhu J, et al
     Integrative proteomic analysis provides novel therapeutic insights for etiological subtypes of diabetes.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70088.
     PubMed     Abstract available
     
     
     
115. 
     Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind tria
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70086.
     PubMed    
     
     
     
116. HOLMAN N, Young B, Gregg EW, Wareham N, et al
     Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009-2019.
     Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70025.
     PubMed     Abstract available
     
     
     August 2025
117. NUYUJUKIAN DS, Zhou JJ, Koska J, Reaven PD, et al
     Triglyceride variability and risk of heart failure events in type 2 diabetes: Results from the ACCORD trial.
     Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70083.
     PubMed    
     
     
     
118. WEN Y, Zeng S
     Advancing AI-driven biomarker discovery in diabetic nephropathy: A framework for robustness and interpretability.
     Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70087.
     PubMed    
     
     
     
119. ADOLFSSON P, Guerci B, Hartvig NV, Kaas A, et al
     Glycaemic control after connected insulin pen initiation in people living with diabetes: Results from a real-world setting.
     Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70051.
     PubMed     Abstract available
     
     
     
120. YAU YK, Li M, Quan J, Grepin KA, et al
     Disrupted specialist outpatient services and alternative modes of service for patients with diabetes mellitus: A population-based, retrospective cohort study in Hong Kong.
     Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70069.
     PubMed     Abstract available
     
     
     
121. LAVENS A, De Block C, Oriot P, Philips JC, et al
     Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study.
     Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70049.
     PubMed     Abstract available
     
     
     
122. KANAZAWA K, Hayashi K, Xinyi C, Hijikata M, et al
     Effectiveness and predictors of weight reduction with low-dose tirzepatide in Japanese patients with type 2 diabetes: A pilot retrospective cohort study.
     Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70062.
     PubMed    
     
     
     
123. GIANGRECO F, Tura A, Parenti M, Cappelli S, et al
     GLP-1 receptor agonist therapy for relapsed diabetes following 6q24-related transient neonatal diabetes due to paternal uniparental disomy: A case report.
     Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70065.
     PubMed    
     
     
     
124. JI L, Huang D, Lin X, Dong X, et al
     Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomise
     Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70036.
     PubMed     Abstract available
     
     
     
125. VARGAS KG, Siemes B, Rutten T, Brockmeyer M, et al
     Assessment of precision medicine potential in diabetes mellitus: A meta-regression analysis of dose-dependent glycaemic control data from 44 randomised controlled trials.
     Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70066.
     PubMed    
     
     
     
126. YEN FS, Wang SI, Hung YM, Hsu CC, et al
     Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes.
     Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70034.
     PubMed     Abstract available
     
     
     
127. COSSU L, Facchinetti A, Bally L
     CGM profiling in Roux-en-Y gastric bypass, type 1 diabetes and healthy adults: Unmasking deviations from normoglycaemia.
     Diabetes Obes Metab. 2025 Aug 26. doi: 10.1111/dom.70059.
     PubMed    
     
     
     
128. AL-OZAIRI E, Al-Awadhi A, Mashankar A, Alroudhan D, et al
     Association of device-based measurement of physical activity with liver fat and stiffness in type 2 diabetes and obesity.
     Diabetes Obes Metab. 2025 Aug 26. doi: 10.1111/dom.70038.
     PubMed    
     
     
     
129. CAO Y, Widyahening I, Sun X, Li S, et al
     Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment.
     Diabetes Obes Metab. 2025 Aug 26. doi: 10.1111/dom.70060.
     PubMed     Abstract available
     
     
     
130. ANANDHAKRISHNAN A, Liarakos AL, Dhatariya K, Gallen G, et al
     Hybrid closed-loop systems in UK type 1 diabetes care: National survey of healthcare professional awareness, confidence, and training needs.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70027.
     PubMed     Abstract available
     
     
     
131. JI L, Yuan G, Liu J, Zhang B, et al
     Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70031.
     PubMed     Abstract available
     
     
     
132. SARABHAI T, Kostev K
     SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70057.
     PubMed     Abstract available
     
     
     
133. CAI Z, Du M, Chen M, Ni G, et al
     An MRI study of pancreatic atrophy in children with type 1 diabetes: Heterogeneity, disease duration effects, and progression prediction models.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70055.
     PubMed     Abstract available
     
     
     
134. KANG S, Chen S, Lin Z, Zhang M, et al
     Association between Chinese visceral adiposity index and heart failure in diabetic patients.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70053.
     PubMed     Abstract available
     
     
     
135. LOGAN BK, Larsen R, Sacre JW, Cohen ND, et al
     Interrupting prolonged sitting reduces postprandial GIP but not GLP-1 responses in type 2 diabetes.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70046.
     PubMed    
     
     
     
136. SHEU WH, Lee CY, Wang YW, Liao CS, et al
     Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes.
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70023.
     PubMed     Abstract available
     
     
     
137. GAO L, Ji L, Yan X, Cheng Z, et al
     Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study).
     Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70009.
     PubMed     Abstract available
     
     
     
138. LIU Y, Wang Q
     Increased risk of type 1 diabetes in patients with autoimmune conditions-Further nuance needed.
     Diabetes Obes Metab. 2025 Aug 20. doi: 10.1111/dom.70041.
     PubMed    
     
     
     
139. LI X, Zhao W, Zhao L, Sun T, et al
     Cardiovascular disease risk estimates for primary prevention in the US prediabetes and diabetes population using the PREVENT equation.
     Diabetes Obes Metab. 2025 Aug 20. doi: 10.1111/dom.70043.
     PubMed     Abstract available
     
     
     
140. WU B, Nieman K, Sandoval R
     High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2025 Aug 18. doi: 10.1111/dom.70032.
     PubMed     Abstract available
     
     
     
141. TREVINO-ALVAREZ AM, Cabeza de Baca T, Stinson EJ, Gluck ME, et al
     Acidosis is associated with lower insulin sensitivity and incident type 2 diabetes in indigenous Americans: A prospective cohort study.
     Diabetes Obes Metab. 2025 Aug 18. doi: 10.1111/dom.70037.
     PubMed     Abstract available
     
     
     
142. WANG D, Morton JI, Magliano DJ, Shaw JE, et al
     Comparison of subcutaneous, visceral, liver and muscle fat depots in relation to prevalent and incident diabetes.
     Diabetes Obes Metab. 2025 Aug 18. doi: 10.1111/dom.70021.
     PubMed     Abstract available
     
     
     
143. LI CE, Yang DW, Guo QQ
     Cardiac repolarization in type 1 diabetes: Considerations beyond the clamp.
     Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.70042.
     PubMed    
     
     
     
144. ROSENSTOCK J, Robins DA, Duffin KL, Wilson JM, et al
     Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of beta-cell function and insulin sensitivity in type 2 diabetes.
     Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.70022.
     PubMed     Abstract available
     
     
     
145. DEPOORTER L, Laghrib Y, De Fijter JW, Hellemans R, et al
     Diabetes screening in dialysis populations with a glucose challenge test and continuous glucose monitoring-DIGEST study.
     Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.16656.
     PubMed     Abstract available
     
     
     
146. CHO YK, Cho JH, Hong SM, Park JH, et al
     Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial.
     Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.70030.
     PubMed     Abstract available
     
     
     
147. BAJAJ HS, Bennedsen LV, Donatsky AM, Martiny JHJ, et al
     Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive individuals with type 2 diabetes: Post hoc analysis of ONWARDS 5.
     Diabetes Obes Metab. 2025 Aug 13. doi: 10.1111/dom.16597.
     PubMed     Abstract available
     
     
     
148. ANDERSEN JA, Suvitaival T, Trost K, Romero-Lado MJ, et al
     Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes.
     Diabetes Obes Metab. 2025 Aug 12. doi: 10.1111/dom.70001.
     PubMed     Abstract available
     
     
     
149. CARUSO I, Giordano F, Matichecchia II, Di Gioia L, et al
     Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.
     Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.70005.
     PubMed     Abstract available
     
     
     
150. CHANG H, Wang R
     Screening for type 1 diabetes in patients with celiac or thyroid disease: Practical considerations.
     Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.70018.
     PubMed    
     
     
     
151. GEORGIANOS PI, Koufakis T, Arampatzis S, Liakopoulos V, et al
     CONFIDENCE in the safety and efficacy of dual therapy with an SGLT-2 inhibitor and finerenone in patients with chronic kidney disease and type 2 diabetes.
     Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.70026.
     PubMed    
     
     
     
152. MALIK RA, Anderson J, Russo G, Amani MEA, et al
     Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.
     Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.16591.
     PubMed     Abstract available
     
     
     
153. PICO ML, Maindal HT, Grunnet LG, Damm P, et al
     Prevalence and concordance of cardiometabolic risk markers and health behaviour among couples after a gestational diabetes mellitus-affected pregnancy.
     Diabetes Obes Metab. 2025 Aug 8. doi: 10.1111/dom.70017.
     PubMed     Abstract available
     
     
     
154. BRYANT CLN, Colbert K, Hompesch M, Chaves S, et al
     GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.
     Diabetes Obes Metab. 2025 Aug 6. doi: 10.1111/dom.16664.
     PubMed     Abstract available
     
     
     
155. CHAKRAVARTHY MV, Elliott MA, Acosta L, Sonnenberg GE, et al
     Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.
     Diabetes Obes Metab. 2025 Aug 5. doi: 10.1111/dom.70006.
     PubMed     Abstract available
     
     
     
156. TATSUMI T, Takatsuna Y, Ishibashi R, Koshizaka M, et al
     Sodium-glucose co-transporter 2 inhibitors reduce the intravitreal anti-VEGF treatment necessity in eyes with early diabetic macular oedema: A post-hoc analysis focusing on the fellow eye of the COMET trial.
     Diabetes Obes Metab. 2025 Aug 4. doi: 10.1111/dom.16636.
     PubMed     Abstract available
     
     
     
157. ARONSON R, Abitbol A, Bajaj HS, Cheng AYY, et al
     Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials.
     Diabetes Obes Metab. 2025 Aug 4. doi: 10.1111/dom.70008.
     PubMed     Abstract available
     
     
     
158. WANG HW, Tsai MH, Fang YW, Lu KC, et al
     Association between sodium-glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection.
     Diabetes Obes Metab. 2025 Aug 4. doi: 10.1111/dom.70003.
     PubMed     Abstract available
     
     
     
159. MOLANI-GOL R, Rafraf M, Asghari Jafarabadi M, Aftabi-Yousefabad S, et al
     The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic biomarkers, omentin-1 levels and anthropometric measures in women with prediabetes: A double-blind randomized controlled trial.
     Diabetes Obes Metab. 2025;27:4522-4536.
     PubMed     Abstract available
     
     
     
160. PAN Q, Ai W, Chen Y, Shen Z, et al
     CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination.
     Diabetes Obes Metab. 2025;27:4499-4510.
     PubMed     Abstract available
     
     
     
161. SILVERII GA, Marinelli C, Bettarini C, Del Vescovo GG, et al
     GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2025;27:4454-4468.
     PubMed     Abstract available
     
     
     
162. ALAMMARI N, Alshehri A, Al Khalaf A, Alamri RA, et al
     Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025;27:4387-4400.
     PubMed     Abstract available
     
     
     
163. CONNOLLY EL, Liu AH, Woodman RJ, Shafaei A, et al
     Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study.
     Diabetes Obes Metab. 2025;27:4300-4310.
     PubMed     Abstract available
     
     
     
164. SCHEEN AJ
     Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.
     Diabetes Obes Metab. 2025;27:4083-4091.
     PubMed     Abstract available
     
     
     
165. PARKER CH, Slattery C, Brennan DJ, le Roux CW, et al
     Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials.
     Diabetes Obes Metab. 2025;27:4102-4108.
     PubMed     Abstract available
     
     
     
166. AAMODT KI, Powers AC
     The pathophysiology, presentation and classification of Type 1 diabetes.
     Diabetes Obes Metab. 2025;27 Suppl 6.
     PubMed     Abstract available
     
     
     
167. HORVATH L, Novodvorsky P, Haluzik M
     Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.
     Diabetes Obes Metab. 2025;27 Suppl 7.
     PubMed     Abstract available
     
     
     
168. FRIAS JP
     What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.
     Diabetes Obes Metab. 2025;27 Suppl 7.
     PubMed     Abstract available
     
     
     July 2025
169. VILSBOLL T, Malecki MT, Sharma P, Thieu VT, et al
     HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
     Diabetes Obes Metab. 2025 Jul 31. doi: 10.1111/dom.16592.
     PubMed     Abstract available
     
     
     
170. HAGELQVIST PG, Schwarz CR, Maytham K, Hamid YH, et al
     The impact of plasma glucose decline rate on cardiac repolarisation in individuals with type 1 diabetes.
     Diabetes Obes Metab. 2025 Jul 31. doi: 10.1111/dom.16607.
     PubMed     Abstract available
     
     
     
171. O'CONNOR E, Kiely C, Gildea N, O'Shea D, et al
     Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes.
     Diabetes Obes Metab. 2025 Jul 30. doi: 10.1111/dom.16648.
     PubMed     Abstract available
     
     
     
172. AL ASHI S, Shah R, Iftikhar N, Lingvay I, et al
     Association of GLP1-receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes.
     Diabetes Obes Metab. 2025 Jul 30. doi: 10.1111/dom.16657.
     PubMed     Abstract available
     
     
     
173. SARWAL A, Singh R, Wei G, Shen J, et al
     Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jul 30. doi: 10.1111/dom.16642.
     PubMed     Abstract available
     
     
     
174. MA J, Fan W
     Towards precision obesity management in diabetes: methodological considerations and future directions.
     Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16655.
     PubMed    
     
     
     
175. STOUGAARD EB, Andersen MR, Bagger JI, Sondergaard E, et al
     The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.
     Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16606.
     PubMed     Abstract available
     
     
     
176. HONG EG, Min KW, Chun S, Chung CH, et al
     Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.
     Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16625.
     PubMed     Abstract available
     
     
     
177. KIM J, Kim YS, Hwang YC, Yim JE, et al
     Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years.
     Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16659.
     PubMed    
     
     
     
178. LIU J, Liu Y, Xu W, Zhang M, et al
     Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time-in-ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli-D study.
     Diabetes Obes Metab. 2025 Jul 25. doi: 10.1111/dom.16646.
     PubMed    
     
     
     
179. PETERMANN-ROCHA F, Diaz-Toro F, Nazar G, Apolinar-Jimenez E, et al
     Diabetes is one of the main drivers of mortality in Mexico: A latent class analysis of chronic diseases using the Mexico City Prospective Study.
     Diabetes Obes Metab. 2025 Jul 25. doi: 10.1111/dom.16644.
     PubMed     Abstract available
     
     
     
180. DE HOOGH IM, Snel T, Kamstra RJM, Krone T, et al
     Differential effects of lifestyle interventions on continuous glucose monitoring metrics in persons with type 2 diabetes: Potential for personalised treatment.
     Diabetes Obes Metab. 2025 Jul 25. doi: 10.1111/dom.16654.
     PubMed     Abstract available
     
     
     
181. GALINDO RJ, Lee CJ, Allen SE, Dib A, et al
     Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.
     Diabetes Obes Metab. 2025 Jul 24. doi: 10.1111/dom.16620.
     PubMed     Abstract available
     
     
     
182. GONG JY, Salim A, Magliano DJ, Shaw JE, et al
     Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial.
     Diabetes Obes Metab. 2025 Jul 24. doi: 10.1111/dom.16650.
     PubMed     Abstract available
     
     
     
183. PASHA R, Kamath A, Linn Z, Kalteniece A, et al
     Statin therapy and neuropathy in type 1 diabetes: A cross-sectional study.
     Diabetes Obes Metab. 2025 Jul 24. doi: 10.1111/dom.16617.
     PubMed     Abstract available
     
     
     
184. QUINN LM, Boiko O, Elliott J, Randell M, et al
     Treatment acceptability for disease-modifying therapy for type 1 diabetes (T1D)-Views from parents of children with presymptomatic T1D.
     Diabetes Obes Metab. 2025 Jul 23. doi: 10.1111/dom.16639.
     PubMed    
     
     
     
185. OLSEN MT, Jensen SH, Rasmussen LM, Klarskov CK, et al
     The association between inflammation and glucose levels in hospitalised patients with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jul 23. doi: 10.1111/dom.16640.
     PubMed     Abstract available
     
     
     
186. JANG SA, Kwon SJ, Kim CS, Park SW, et al
     Exploring the value of ChatGPT in selecting antidiabetic agents for type 2 diabetes.
     Diabetes Obes Metab. 2025 Jul 23. doi: 10.1111/dom.16630.
     PubMed     Abstract available
     
     
     
187. PAN Y, Li Y, Cui M, He G, et al
     Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021.
     Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16588.
     PubMed     Abstract available
     
     
     
188. HUGHES MS, Morgan M, Liu YT, Lee MY, et al
     Diabetes technology use in U.S. hospitals: A survey of user experiences.
     Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16634.
     PubMed    
     
     
     
189. NAJA K, Elashi AA, Anwardeen N, Razzaq A, et al
     N-lactoyl amino acids are potential biomarkers for insulin resistance and diabetic complications.
     Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16633.
     PubMed     Abstract available
     
     
     
190. LEE D, Seo G, Kim Y, Min JY, et al
     Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 Jul 21. doi: 10.1111/dom.16635.
     PubMed     Abstract available
     
     
     
191. LOW JL, Hesketh K, Falkenhain K, Jung ME, et al
     Improved glycemic regulation on exercise compared to non-exercise days in a real-world setting in individuals recently diagnosed with type 2 diabetes: A secondary analysis of the MOTIVATE T2D randomised controlled trial.
     Diabetes Obes Metab. 2025 Jul 21. doi: 10.1111/dom.16623.
     PubMed    
     
     
     
192. BOLLI GB, Porcellati F, Lucidi P, Fanelli CG, et al
     An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16616.
     PubMed     Abstract available
     
     
     
193. HAN S, Hu X, Zhang Z, Li Y, et al
     Cognitive reserve, genetic risk, and lifestyle in the incidence and progression of type 2 diabetes: A large community-based longitudinal study.
     Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16622.
     PubMed     Abstract available
     
     
     
194. CHERUBINI V, Scaramuzza AE, Agrimi U, Bonfanti R, et al
     Initial observations on the frequency of diabetic ketoacidosis following pilot screening for type 1 diabetes in the general Italian population.
     Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16611.
     PubMed    
     
     
     
195. WERKMAN NCC, Nielen JTH, Tapia-Galisteo J, Somolinos-Simon FJ, et al
     Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.
     Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16598.
     PubMed     Abstract available
     
     
     
196. WALLACE H, Wick J, Neuen BL, Buizen L, et al
     Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.
     Diabetes Obes Metab. 2025 Jul 16. doi: 10.1111/dom.16608.
     PubMed     Abstract available
     
     
     
197. KLEPSER NS, Weber ES, Li L, Fleischmann KE, et al
     Adherence to GLP-1 receptor agonists and SGLT2 inhibitors by out-of-pocket spending among Medicare beneficiaries with diabetes.
     Diabetes Obes Metab. 2025 Jul 16. doi: 10.1111/dom.16619.
     PubMed     Abstract available
     
     
     
198. WHYTE MB, Heald AH
     Could continuous subcutaneous glucose sensors (CGMS) be repurposed to diagnose diabetes in equivocal or challenging cases?
     Diabetes Obes Metab. 2025 Jul 15. doi: 10.1111/dom.16624.
     PubMed    
     
     
     
199. SUGIMOTO T, Omura T, Araki A, Haneda C, et al
     Differential effects of a multidomain intervention on cognitive decline in older adults with type 2 diabetes according to white matter hyperintensity status: A secondary analysis of the J-MIND-Diabetes.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16605.
     PubMed     Abstract available
     
     
     
200. HUANG C, Chen Y, Britton A
     Changes in adiposity indices over 10 years and risk of type 2 diabetes: The Whitehall II cohort study.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16615.
     PubMed     Abstract available
     
     
     
201. NEVES JS, Vale C, Leite AR, Ferreira JP, et al
     Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16603.
     PubMed    
     
     
     
202. AL OZAIRI E, Irshad M, Alkandari J, Taghadom E, et al
     Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16584.
     PubMed     Abstract available
     
     
     
203. GOYAL A, Kubihal S, Gupta Y, Shalimar, et al
     Hepatic steatosis index for prediction of metabolic dysfunction-associated steatotic liver disease (MASLD) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16595.
     PubMed    
     
     
     
204. DE WIT DF, Fuhri Snethlage CM, Minab R, Rampanelli E, et al
     Persisting plasma proinsulin levels in a cohort of 482 individuals with long-standing type 1 diabetes mellitus.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16604.
     PubMed     Abstract available
     
     
     
205. STOCHL J, Clarke N, Green D, Comins J, et al
     Psychometric evaluation of the Adelphi Adherence Questionnaire (ADAQ(c)) in a type 2 diabetes mellitus population as a new measure of adherence and the complex factors influencing adherence in routine care.
     Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16551.
     PubMed     Abstract available
     
     
     
206. SVENSSON CH, Fabricius TW, Verhulst C, Tack CJ, et al
     Association between recent real-life exposure to hypoglycaemia and cognitive function during hypoglycaemia in people with type 1 diabetes: Findings from the Hypo-RESOLVE clamp study.
     Diabetes Obes Metab. 2025 Jul 11. doi: 10.1111/dom.16587.
     PubMed     Abstract available
     
     
     
207. ANANDHAKRISHNAN A, Pender S, Johnston T, Hyslop R, et al
     Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed-loop system (Omnipod(R) 5) in adults with type 1 diabetes.
     Diabetes Obes Metab. 2025 Jul 9. doi: 10.1111/dom.16553.
     PubMed     Abstract available
     
     
     
208. CARUSO P, Angelino S, Matrone R, Scappaticcio L, et al
     Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.
     Diabetes Obes Metab. 2025 Jul 7. doi: 10.1111/dom.16594.
     PubMed     Abstract available
     
     
     
209. ALGUWAIHES AM, Alotaibi MS, Alqumaidi H, Batais MA, et al
     Potential benefits of hybrid closed-loop systems for managing moderate- to high-risk individuals with type 1 diabetes during Ramadan fasting.
     Diabetes Obes Metab. 2025 Jul 7. doi: 10.1111/dom.16573.
     PubMed     Abstract available
     
     
     
210. LEE HA
     Sex- and age-specific determinants of diabetes: Insights from BKMR and cox modelling of metabolic and lifestyle risk factors in a Korean cohort.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16577.
     PubMed     Abstract available
     
     
     
211. TRBOVICH M, Hoekstra S, Gastaldelli A, Salehi M, et al
     Reduced prandial insulin secretion contributes to prandial hyperglycaemia in non-diabetic individuals with spinal cord injury.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16563.
     PubMed    
     
     
     
212. VOSS EA, Yuan Z, Ali SR, Bosan R, et al
     A study on the utilization of canagliflozin in type 1 diabetes mellitus using real-world data from four European countries.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16574.
     PubMed     Abstract available
     
     
     
213. GETHER IM, Gilliam-Vigh H, Kliim-Hansen V, Hartmann B, et al
     Oxytocin mRNA is expressed throughout the small intestine in individuals with and without type 2 diabetes, and circulating neurophysin I declines after Roux-en-Y gastric bypass surgery.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16571.
     PubMed    
     
     
     
214. WANG S, Fan D, Yao Q, Sun X, et al
     The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16580.
     PubMed     Abstract available
     
     
     
215. YU C, Zhou Z, Neumann JT, Lin T, et al
     Genomic risk prediction for type 2 diabetes in Australian individuals aged 70 years and older.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16579.
     PubMed     Abstract available
     
     
     
216. FADINI GP, Longato E, Morieri ML, Broglio F, et al
     Long-term preservation of kidney function with SGLT-2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16569.
     PubMed     Abstract available
     
     
     
217. SHAO X, Xu H, Chen L, Bai P, et al
     Multi-modal models using fMRI, urine and serum biomarkers for classification and risk prognosis in diabetic kidney disease.
     Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16572.
     PubMed     Abstract available
     
     
     
218. BEEN RA, van Helsdingen MRX, Zammit D, Grzegorczyk M, et al
     The efficacy of intermittent scanning continuous glucose monitoring in the elderly: A case-control study.
     Diabetes Obes Metab. 2025;27:3882-3890.
     PubMed     Abstract available
     
     
     
219. KO HY, Jung K, Cho Y, Bea S, et al
     Association between the body mass index and risk of cardiovascular events in sodium-glucose cotransporter 2 inhibitor users compared with dipeptidyl-peptidase 4 inhibitor users: A nationwide cohort study in Korea.
     Diabetes Obes Metab. 2025;27:3869-3881.
     PubMed     Abstract available
     
     
     
220. MURRAY-THOMAS T, Dcruz JM, Harder-Lauridsen NM, Olsen AH, et al
     Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.
     Diabetes Obes Metab. 2025;27:3705-3713.
     PubMed     Abstract available
     
     
     
221. RICHARDSON KM, Schembre SM, Jospe MR, Widmer A, et al
     The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
     Diabetes Obes Metab. 2025;27:3725-3735.
     PubMed     Abstract available
     
     
     
222. KANG YM, Punov V, Lim S, Nauck MA, et al
     Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
     Diabetes Obes Metab. 2025;27:3736-3746.
     PubMed     Abstract available
     
     
     
223. SUN M, Wang X, Lu Z, Yang Y, et al
     Sodium-glucose cotransporter-2 inhibitors and subtype-specific dementia risk: A multinational and multiethnic cohort study.
     Diabetes Obes Metab. 2025;27:3766-3779.
     PubMed     Abstract available
     
     
     
224. O'HARA DV, Jardine MJ
     A review of the safety of sodium-glucose co-transporter-2 inhibitors.
     Diabetes Obes Metab. 2025;27:3598-3606.
     PubMed     Abstract available
     
     
     
225. MCEWAN P, Evans M
     The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.
     Diabetes Obes Metab. 2025;27 Suppl 5.
     PubMed     Abstract available
     
     
     
226. YANG A, Yu J, Cheung JTK, Chan JCN, et al
     Real world evidence of insulin and biosimilar insulin therapy-Opportunities to improve adherence, outcomes and cost-effectiveness.
     Diabetes Obes Metab. 2025;27 Suppl 5.
     PubMed     Abstract available
     
     
     
227. HEISE T, DeVries JH
     Biosimilar insulins: Narrative review of the regulatory framework and registration studies.
     Diabetes Obes Metab. 2025;27 Suppl 5.
     PubMed     Abstract available
     
     
     
228. HOME PD
     An overview of insulin therapy for the non-specialist.
     Diabetes Obes Metab. 2025;27 Suppl 5.
     PubMed     Abstract available
     
     
     
229. ABITBOL A, Chu L
     What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups-Sharing Canadian perspectives.
     Diabetes Obes Metab. 2025;27 Suppl 5:36-44.
     PubMed     Abstract available
     
     
     
230. JANUSZEWSKI AS, Snaith JR, Grzelka-Wozniak A, Simonsen JRA, et al
     No evidence from euglycaemic-hyperinsulinaemic clamp studies for greater insulin sensitivity in adults with type 1 diabetes using insulin pump versus multiple daily insulin injections-Post hoc meta-analysis.
     Diabetes Obes Metab. 2025 Jul 1. doi: 10.1111/dom.16487.
     PubMed    
     
     
     June 2025
231. VALLIVAARA HL, Leppanen HA, Mustonen J, Saari A, et al
     Long-term health economic evaluation of automated insulin delivery system compared with continuous subcutaneous insulin infusion pumps and CGM in a real-world setting in Finnish paediatric and adult individuals with type 1 diabetes.
     Diabetes Obes Metab. 2025 Jun 27. doi: 10.1111/dom.16520.
     PubMed     Abstract available
     
     
     
232. MORRISON DJ, Vogrin S, Zaharieva DP, Manos G, et al
     Glycaemic impact of the pre-exercise timing of an elevated glucose target implemented using an automated insulin delivery system in adults with type 1 diabetes.
     Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16567.
     PubMed     Abstract available
     
     
     
233. DIALLO A, Villard O, Carlos-Bolumbu M, Duc P, et al
     Blood glucose and body weight reduction for the prevention of clinical events and mortality in patients with type 2 diabetes: A meta-analysis and meta-regression of 44 randomized controlled trials.
     Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16561.
     PubMed     Abstract available
     
     
     
234. FRANC S, Charpentier G
     Emotional distress as a therapeutic target against persistent poor glycaemic control in subjects with type 1 diabetes: A systematic review.
     Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16540.
     PubMed     Abstract available
     
     
     
235. JUN JE, Choi SH, Moon MK, Ko SH, et al
     EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study).
     Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16557.
     PubMed    
     
     
     
236. BORG MJ, Xie C, Chen C, Bound MJ, et al
     Metformin slows intestinal glucose absorption in type 2 diabetes, irrespective of the timing of its administration.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16570.
     PubMed    
     
     
     
237. SOLIMAN Y, Everett K, Shulman R, Austin PC, et al
     Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16547.
     PubMed     Abstract available
     
     
     
238. JAMIOLKOWSKA-SZTABKOWSKA M, Noiszewska K, Polkowska A, Zasim A, et al
     Get ahead of the disease: Islet cell autoimmunity and preclinical phase of type 1 diabetes in general population of 1-9 year-old children in the north-eastern region of Poland-A summary of the first 18 months of the study.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16560.
     PubMed     Abstract available
     
     
     
239. REWERS M
     Health economic considerations of screening for early type 1 diabetes.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16522.
     PubMed     Abstract available
     
     
     
240. DELGADO ALVAREZ E, Morales Portillo C, Abreu Padin C, Aliaga Verdugo A, et al
     PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16523.
     PubMed     Abstract available
     
     
     
241. GHARIBZADEH S, Lee J, Highton P, Greenlaw N, et al
     Risk factors for development of diabetic foot ulcer disease in two large contemporary UK cohorts.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16519.
     PubMed     Abstract available
     
     
     
242. KIM MJ, Cho YK, Kim S, Moon JY, et al
     Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta-analysis with focus on an Asian subpopulation.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16550.
     PubMed     Abstract available
     
     
     
243. LI K, Tang H, Wang Y, Wang X, et al
     Identification of hub genes involved in the pathogenesis of diabetic nephropathy: A multi-omics study integrating machine learning, mendelian randomization and mediation analysis.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16536.
     PubMed     Abstract available
     
     
     
244. MUSTAFA S, Mayo C, Paul R, Rodrigues M, et al
     Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.
     Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16558.
     PubMed    
     
     
     
245. NI W, Chen Z, Zhu M, Li Y, et al
     Gestational diabetes risk associated with early pregnancy blood pressure characteristics and trajectories: A Chinese prospective cohort study.
     Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16555.
     PubMed     Abstract available
     
     
     
246. CIUDIN A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, et al
     Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
     PubMed     Abstract available
     
     
     
247. DE LEIJER JF, Pham SDT, Vissers TACM, Exalto LG, et al
     Association between retinal microvasculature and cerebral small vessel function in type 2 diabetes: An ultrahigh field MRI study.
     Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16546.
     PubMed    
     
     
     
248. TSUR A, Leibowitz G, Cohen MJ, Cahn A, et al
     Predictors of diabetic ketoacidosis in patients with insulin-deficient diabetes phenotype initiating SGLT2 inhibitors.
     Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16545.
     PubMed     Abstract available
     
     
     
249. BELL KJ, Lain SJ
     The Changing Epidemiology of Type 1 Diabetes: A Global Perspective.
     Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16501.
     PubMed     Abstract available
     
     
     
250. STEENS ILM, Schram MT, Houben AJHM, Berendschot TTJM, et al
     Type 2 diabetes and depression via microvascular dysfunction, neurodegeneration, inflammation, advanced glycation end products (AGEs), arterial stiffness.
     Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16527.
     PubMed     Abstract available
     
     
     
251. LEKVA T, Roland MCP, Qvigstad E, Khan Y, et al
     Oxidative stress, senescence and mRNA decay in peripheral blood mononuclear cells of women with gestational diabetes mellitus-link to increased cardiovascular disease risk.
     Diabetes Obes Metab. 2025 Jun 17. doi: 10.1111/dom.16521.
     PubMed     Abstract available
     
     
     
252. GUO Y, Zhang X, Li W, Zhou Y, et al
     Trajectories of body mass index and diabetes mellitus risk among elderly Chinese adults: A 10-year longitudinal study.
     Diabetes Obes Metab. 2025 Jun 17. doi: 10.1111/dom.16530.
     PubMed     Abstract available
     
     
     
253. LEI M, Ling P, Lin B, Lv J, et al
     Efficacy and safety of a tubeless open-source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26-week, free-living, randomized crossover trial.
     Diabetes Obes Metab. 2025 Jun 17. doi: 10.1111/dom.16505.
     PubMed     Abstract available
     
     
     
254. ADAMS RN, Athinarayanan SJ, Zoller AR, McKenzie AL, et al
     Sustained metabolic improvements in a remotely delivered ketogenic nutrition programme for veterans with type 2 diabetes: A 3-year observational study.
     Diabetes Obes Metab. 2025 Jun 16. doi: 10.1111/dom.16525.
     PubMed     Abstract available
     
     
     
255. INOUE M, Kusunoki Y, Ohigashi M, Osugi K, et al
     Continuous glucose monitoring-derived time in range is associated with changes in cognitive function test scores in Japanese patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2025 Jun 16. doi: 10.1111/dom.16511.
     PubMed     Abstract available
     
     
     
256. SCHMEDT N, Alhamdow A, Tskhvarashvili G, Saarelainen L, et al
     Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.
     Diabetes Obes Metab. 2025 Jun 13. doi: 10.1111/dom.16477.
     PubMed     Abstract available
     
     
     
257. COWART K, Carris NW
     Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?
     Diabetes Obes Metab. 2025 Jun 11. doi: 10.1111/dom.16502.
     PubMed     Abstract available
     
     
     
258. SUN CJ, Lochnan H, Sorisky A, Shaw J, et al
     A simplified protocol based on a standardized meal-stimulated beta-cell response to stratify people living with non-insulin-treated type 2 diabetes.
     Diabetes Obes Metab. 2025 Jun 11. doi: 10.1111/dom.16528.
     PubMed    
     
     
     
259. HIGHTON P, Abdala R, Evley R, Balasubramanian V, et al
     The use of SGLT2 inhibitors in people with diabetes-related foot disease: A Delphi-based consensus study.
     Diabetes Obes Metab. 2025 Jun 11. doi: 10.1111/dom.16498.
     PubMed     Abstract available
     
     
     
260. SU H, Ni J, Peng D, He X, et al
     Association of time in tight range and 1,5-anhydroglucitol in type 2 diabetes.
     Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16515.
     PubMed     Abstract available
     
     
     
261. YAMAUCHI T, Asakura T, Shingaki T, Oura T, et al
     Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
     Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16500.
     PubMed     Abstract available
     
     
     
262. DUBSKY M, Sojakova D, Husakova J, Nemcova A, et al
     Long-term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb-threatening ischaemia.
     Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16510.
     PubMed     Abstract available
     
     
     
263. ASSALIA NAFFA M, Ayada G, Zolotov S, Shehadeh N, et al
     Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence.
     Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16516.
     PubMed    
     
     
     
264. WEI X, Zhao J, Zhu P, Niu W, et al
     Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross-sectional study from China.
     Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16514.
     PubMed     Abstract available
     
     
     
265. ALIYU U, Umlai UI, Al-Thani NM, Toor SM, et al
     Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes.
     Diabetes Obes Metab. 2025 Jun 5. doi: 10.1111/dom.16490.
     PubMed     Abstract available
     
     
     
266. RETNAKARAN R, Pu J, Hanley AJ, Zinman B, et al
     A1c versus oral glucose tolerance test for chronic glycemic surveillance in women with previous gestational diabetes.
     Diabetes Obes Metab. 2025 Jun 5. doi: 10.1111/dom.16513.
     PubMed     Abstract available
     
     
     
267. CUI K, Fu R, Yang J, Xu H, et al
     Haemoglobin glycation index and in-hospital mortality after acute myocardial infarction in patients with/without diabetes: A prospective, nationwide and multicentre registry.
     Diabetes Obes Metab. 2025 Jun 3. doi: 10.1111/dom.16495.
     PubMed     Abstract available
     
     
     
268. LUEDDE M, Sedighi J, Hippe HJ, Sossalla S, et al
     SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus.
     Diabetes Obes Metab. 2025 Jun 3. doi: 10.1111/dom.16494.
     PubMed    
     
     
     
269. ZARGAR AH, Bhansali A, Majumdar A, Maheshwari A, et al
     Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.
     Diabetes Obes Metab. 2025 Jun 2. doi: 10.1111/dom.16496.
     PubMed     Abstract available
     
     
     
270. TANG M, Shi L, Guan D, Winberg D, et al
     Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.
     Diabetes Obes Metab. 2025 Jun 2. doi: 10.1111/dom.16466.
     PubMed     Abstract available
     
     
     
271. NANNA MG, Doan QV, Fabricatore A, Faurby M, et al
     Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.
     Diabetes Obes Metab. 2025;27:3442-3452.
     PubMed     Abstract available
     
     
     
272. BERGET C, Annan SF, Biester T, Choudhary P, et al
     Practical considerations for using the Omnipod(R) 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe.
     Diabetes Obes Metab. 2025;27:2909-2919.
     PubMed     Abstract available
     
     
     
273. TEOH KW, Baek Y, Ademi Z, Lee SWH, et al
     A cost-effectiveness analysis alongside trial of a digital health-supported and community pharmacy-based prediabetes management programme (PRIME Programme) in Malaysia.
     Diabetes Obes Metab. 2025;27:3324-3334.
     PubMed     Abstract available
     
     
     
274. IGARASHI A, Capucci S, Ota R, Wada S, et al
     Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study.
     Diabetes Obes Metab. 2025;27:3017-3024.
     PubMed     Abstract available
     
     
     
275. SIMONSEN E, Lund LC, Ernst MT, Hjellvik V, et al
     Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.
     Diabetes Obes Metab. 2025;27:3094-3103.
     PubMed     Abstract available
     
     
     
276. WITT C, Renfroe LG, Lyons TS
     Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review.
     Diabetes Obes Metab. 2025;27:2940-2954.
     PubMed     Abstract available
     
     
     
277. BERGMAN BK, Rosenstock J, Garvey WT, Batterham RL, et al
     Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
     Diabetes Obes Metab. 2025;27:3223-3232.
     PubMed     Abstract available
     
     
     
278. SASAKI N, Ueno Y, Ozono R, Nakano Y, et al
     Insulin resistance in adipose tissue and fatty liver, but not fat mass, are involved in worsening glycaemic status: The Hiroshima study on glucose metabolism and cardiovascular diseases.
     Diabetes Obes Metab. 2025;27:3025-3035.
     PubMed     Abstract available
     
     
     
279. HUA R, Shi M, Chow E, Yang A, et al
     Genetic evidence for the effects of glucokinase activation on frailty-related outcomes: A Mendelian randomisation study.
     Diabetes Obes Metab. 2025;27:3072-3083.
     PubMed     Abstract available
     
     
     
280. LIM BSY, Chen M, Li HY, Li LJ, et al
     Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri-menopausal women.
     Diabetes Obes Metab. 2025;27 Suppl 3.
     PubMed     Abstract available
     
     
     
281. SAADATI S, Mason T, Godini R, Vanky E, et al
     Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges.
     Diabetes Obes Metab. 2025;27 Suppl 3.
     PubMed     Abstract available
     
     
     
282. MAYADUNNE T, Saadati S, Asmelash D, Mason T, et al
     Long-term effects of metformin on offspring health: A review of current evidence and future directions.
     Diabetes Obes Metab. 2025;27 Suppl 3.
     PubMed     Abstract available
     
     
     
283. MCEVOY RP, Newman C, Egan AM, Dunne FP, et al
     A narrative review of metformin in pregnancy: Navigating benefit and uncertainty.
     Diabetes Obes Metab. 2025;27 Suppl 3.
     PubMed     Abstract available
     
     
     
284. LIN L, Chen P, Zhang Y, Long J, et al
     Burden of type 2 diabetes mellitus and risk factor attribution among older adults: A global, regional, and national analysis from 1990 to 2021, with projections up to 2040.
     Diabetes Obes Metab. 2025 Jun 1. doi: 10.1111/dom.16471.
     PubMed     Abstract available
     
     
     
285. MAVROMATIS LA, Surapaneni A, Mehta S, Xu Y, et al
     Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.
     Diabetes Obes Metab. 2025 Jun 1. doi: 10.1111/dom.16445.
     PubMed    
     
     
     May 2025
286. BEERNINK JM, Jongs N, Mosterd CM, Scholtes RA, et al
     Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
     Diabetes Obes Metab. 2025 May 30. doi: 10.1111/dom.16478.
     PubMed     Abstract available
     
     
     
287. LIU JJ, Liu S, Lee J, Zheng H, et al
     Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of chronic kidney disease progression in patients with type 2 diabetes.
     Diabetes Obes Metab. 2025 May 29. doi: 10.1111/dom.16486.
     PubMed     Abstract available
     
     
     
288. EDELMAN SV, Agardh D, Cui N, Hao L, et al
     Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease-An observational study.
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16454.
     PubMed     Abstract available
     
     
     
289. KONANTAMBIGI A, Wang W, Boggild D, Rana A, et al
     Real-world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia.
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16485.
     PubMed     Abstract available
     
     
     
290. TOUZOT M, Voican A, Potier L, Beaussier H, et al
     Efficacy and tolerance of liraglutide for weight loss in obese, type 2 diabetes and haemodialysis patients.
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16484.
     PubMed    
     
     
     
291. ZHANG Y, Gao W, Li B, Liu Y, et al
     The association between the visceral obesity indices and the future diabetes mellitus risk: A prospective cohort study.
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16492.
     PubMed     Abstract available
     
     
     
292. YIN M, Fan W, Yu Y, Liu Z, et al
     Disparities in diabetes burden in China and globally, with projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021.
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16482.
     PubMed    
     
     
     
293. COLLIER JJ, Wasserfall CH, Brehm MA, Karlstad MD, et al
     Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period?
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16480.
     PubMed     Abstract available
     
     
     
294. FAN W, Deng C, Xu R, Liu Z, et al
     Fully automated insulin delivery systems in type 1 diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16499.
     PubMed     Abstract available
     
     
     
295. WU D, Wang X, Liu Q, Luo X, et al
     Comparative efficacy and safety of oral hypoglycaemic drugs as adjunctive therapy in the management of type 1 diabetes mellitus: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 May 23. doi: 10.1111/dom.16474.
     PubMed     Abstract available
     
     
     
296. HAN X, Pang L, Zhang X, Gao H, et al
     Impact of bariatric surgery on glycaemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: A meta-analysis.
     Diabetes Obes Metab. 2025 May 23. doi: 10.1111/dom.16475.
     PubMed     Abstract available
     
     
     
297. DALY T, Okholm S, Imbimbo BP
     Beyond diabetes: Testing long-term metformin adherence for dementia prevention.
     Diabetes Obes Metab. 2025 May 23. doi: 10.1111/dom.16472.
     PubMed    
     
     
     
298. CARROLL OU, Bidulka P, Basu A, Adler AI, et al
     Long-term outcomes following alternative second-line oral glucose-lowering treatments: Results from the real-world progression in type 2 diabetes mellitus United Kingdom (RAPIDS-UK) model.
     Diabetes Obes Metab. 2025 May 21. doi: 10.1111/dom.16447.
     PubMed     Abstract available
     
     
     
299. SU HY, Chew KY, Graves N, Ou HT, et al
     Cost-effectiveness of ON101 with general wound care for diabetic foot ulcers among patients with type 2 diabetes in Singapore: Analysis of a multi-ethnic country in Asia.
     Diabetes Obes Metab. 2025 May 21. doi: 10.1111/dom.16473.
     PubMed     Abstract available
     
     
     
300. WASEHUUS V, Smeijer JD, Ambery P, Greasley PJ, et al
     Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.
     Diabetes Obes Metab. 2025 May 21. doi: 10.1111/dom.16468.
     PubMed     Abstract available
     
     
     
301. HAUGHTON S, Riley D, Berry S, Arshad MF, et al
     The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study.
     Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16455.
     PubMed     Abstract available
     
     
     
302. HEALEY E, Morato C, Murillo J, Kohane I, et al
     Heterogeneity of continuous glucose monitoring features and their clinical associations in a type 2 diabetes population.
     Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16432.
     PubMed     Abstract available
     
     
     
303. OKADA A, Otsuka Y, Inoue R, Hashimoto Y, et al
     Adherence to physician visits for diabetes care and cardiovascular disease risk: A retrospective cohort study using an administrative claims database.
     Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16479.
     PubMed    
     
     
     
304. NOKIHARA M, Fujihara K, Yaguchi Y, Takizawa H, et al
     The associations of body mass index and waist circumference with the risk of diabetic complications in people with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2025 May 16. doi: 10.1111/dom.16461.
     PubMed     Abstract available
     
     
     
305. CARDOSO P, Young KG, Hopkins R, Mateen BA, et al
     Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.
     Diabetes Obes Metab. 2025 May 16. doi: 10.1111/dom.16470.
     PubMed     Abstract available
     
     
     
306. MAUVAIS FX, van Endert PM
     Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians.
     Diabetes Obes Metab. 2025 May 15. doi: 10.1111/dom.16460.
     PubMed     Abstract available
     
     
     
307. ANTAKLY HANON Y, Moeuf Y, Garcon P, Kalaydjian A, et al
     Progression of cardiac dysfunction in patients with type 2 diabetes without overt cardiovascular disease: A three-year follow-up echocardiographic study (DIACAR).
     Diabetes Obes Metab. 2025 May 14. doi: 10.1111/dom.16457.
     PubMed    
     
     
     
308. CAI Y, Liu J, Wang Q, Ren X, et al
     Mechanisms of vascular endothelial cell injury triggered by blood glucose changes in gestational diabetes mellitus.
     Diabetes Obes Metab. 2025 May 13. doi: 10.1111/dom.16450.
     PubMed     Abstract available
     
     
     
309. GIULIO F, Andrea R, Riccardo B
     Letter to the editor to "Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system".
     Diabetes Obes Metab. 2025 May 9. doi: 10.1111/dom.16459.
     PubMed    
     
     
     
310. CHEN LL, Tohit NM, Ludin AFM, Manaf ZA, et al
     Efficacy of diabetes-specific partial meal replacement on glycemic and weight control in type 2 diabetes: A randomized controlled trial.
     Diabetes Obes Metab. 2025 May 9. doi: 10.1111/dom.16446.
     PubMed     Abstract available
     
     
     
311. SUN M, Wang X, Lu Z, Yang Y, et al
     Long-term delirium and survival outcomes in patients treated with GLP-1 receptor agonists versus metformin in type 2 diabetes: A population-based cohort study.
     Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16434.
     PubMed     Abstract available
     
     
     
312. ZHAO J, Zhang J, Xuan Y, Huang C, et al
     Clinical observation and experimental study on the role of choroid-to-retina volume ratio in diabetic retinopathy.
     Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16444.
     PubMed     Abstract available
     
     
     
313. REHNI AK, Cho S, Liu A, Lo J, et al
     Recurrent hypoglycemia exposure increases the risk of platelet activation and thrombosis in insulin-treated diabetic rats.
     Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16440.
     PubMed     Abstract available
     
     
     
314. DUNN TJ, Tan X, Harton J, Kim S, et al
     Macrovascular and microvascular complications in US Medicare enrollees with type 2 diabetes with and without atherosclerotic cardiovascular disease.
     Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16441.
     PubMed     Abstract available
     
     
     
315. ZHAO L, Tao F, Cheng Z, Lu Y, et al
     Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
     Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16439.
     PubMed     Abstract available
     
     
     
316. VAN BAAR MJB, Muskiet MHA, Scholtes RA, Touw DJ, et al
     Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.
     Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16431.
     PubMed     Abstract available
     
     
     
317. TINTI D, Castorani V, Nobili C, Felappi B, et al
     Omnipod 5 in children and adolescents with type 1 diabetes: Improved outcomes with fewer boluses.
     Diabetes Obes Metab. 2025 May 5. doi: 10.1111/dom.16436.
     PubMed    
     
     
     
318. HANKOSKY ER, He X, Malik R, Fraseur Brumm J, et al
     Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.
     Diabetes Obes Metab. 2025 May 5. doi: 10.1111/dom.16401.
     PubMed     Abstract available
     
     
     
319. PANCHAL K, Lawson CA, Shabnam S, Khunti K, et al
     Mortality risk following ischaemic and non-ischaemic heart failure in people with type 2 diabetes: Observational study in England, 2000-2021.
     Diabetes Obes Metab. 2025 May 2. doi: 10.1111/dom.16413.
     PubMed     Abstract available
     
     
     
320. GU W, Lu Y, Ye X, Yuan G, et al
     Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
     Diabetes Obes Metab. 2025;27:2540-2551.
     PubMed     Abstract available
     
     
     
321. ZHANG Z, Wang C, Zhao L, Wang Z, et al
     Association of depression, traditional risk factor control and genetic risk with incident cardiovascular disease among individuals with prediabetes: A population-based prospective study from UK biobank.
     Diabetes Obes Metab. 2025;27:2833-2843.
     PubMed     Abstract available
     
     
     
322. KARAKASIS P, Patoulias D, Rizzo M, Fragakis N, et al
     Association between remnant cholesterol and chronic kidney disease: Systematic review and meta-analysis.
     Diabetes Obes Metab. 2025;27:2573-2583.
     PubMed     Abstract available
     
     
     
323. CAMPBELL K, Ashton N, Peddie MC, Ma'ia'i K, et al
     A DiRECT approach to weight loss in a culturally diverse, low-income population: Pilot randomised controlled trial and meta-analysis of similar interventions.
     Diabetes Obes Metab. 2025;27:2442-2453.
     PubMed     Abstract available
     
     
     
324. WOLPERT H, Rodbard D, Xue J, Johnson J, et al
     Characterizing insulin dosing behaviour and glycaemic excursions: Development of metrics using connected insulin pen and continuous glucose monitoring.
     Diabetes Obes Metab. 2025;27:2507-2514.
     PubMed     Abstract available
     
     
     
325. ZHUO L, Zhang B, Yin Y, Sun Y, et al
     Use of sodium-glucose cotransporter-2 inhibitors and risk of dementia: A population-based cohort study.
     Diabetes Obes Metab. 2025;27:2430-2441.
     PubMed     Abstract available
     
     
     April 2025
326. YU N, Xu W, Guo X, Xu M, et al
     Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
     Diabetes Obes Metab. 2025 Apr 30. doi: 10.1111/dom.16427.
     PubMed     Abstract available
     
     
     
327. KHODABANDEHLOO P, Fakembe P, Senga J, Shulman R, et al
     Social disadvantage and technology use among adults with type 1 diabetes in Quebec: A cross-sectional study using data from the Canadian T1D (BETTER) Registry.
     Diabetes Obes Metab. 2025 Apr 29. doi: 10.1111/dom.16426.
     PubMed     Abstract available
     
     
     
328. FIELD BCT
     The BIG D-FOOT randomized, double-blinded, controlled trial of bio-absorbable antibiotic delivery in calcium sulphate granules for the treatment of diabetic foot osteomyelitis.
     Diabetes Obes Metab. 2025 Apr 29. doi: 10.1111/dom.16423.
     PubMed    
     
     
     
329. MONAMI M, Mannucci E
     Reply to Dr. Field on 'The BIG D-FOOT randomized, double-blinded, controlled trial of bio-absorbable antibiotic delivery in calcium sulphate granules for the treatment of diabetic foot osteomyelitis'.
     Diabetes Obes Metab. 2025 Apr 29. doi: 10.1111/dom.16428.
     PubMed    
     
     
     
330. HE J
     Remnant cholesterol trajectories and diabetes risk: A letter to the editor commenting on "Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies".
     Diabetes Obes Metab. 2025 Apr 28. doi: 10.1111/dom.16430.
     PubMed    
     
     
     
331. SNOEK F, Galstyan G, Khan N, Tirosh A, et al
     Clinically meaningful improvements in treatment satisfaction in insulin-naive people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study.
     Diabetes Obes Metab. 2025 Apr 28. doi: 10.1111/dom.16415.
     PubMed    
     
     
     
332. CARUSO P, Maiorino MI, Longo M, Maio A, et al
     Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.
     Diabetes Obes Metab. 2025 Apr 25. doi: 10.1111/dom.16419.
     PubMed     Abstract available
     
     
     
333. ZHANG Z, Huang Z, Xi Y, Han S, et al
     Association between adherence to the EAT-Lancet diet and risk of microvascular complications in type 2 diabetes: A cohort study.
     Diabetes Obes Metab. 2025 Apr 23. doi: 10.1111/dom.16414.
     PubMed     Abstract available
     
     
     
334. LEE CMY, Gibson AA, Nassar N, Colagiuri S, et al
     Long-term adherence to glucose-lowering medications in adults with diabetes: A data linkage study.
     Diabetes Obes Metab. 2025 Apr 23. doi: 10.1111/dom.16408.
     PubMed     Abstract available
     
     
     
335. 
     Correction to "A micro-randomized pilot study to examine the impact of just-in-time nudging on after-dinner snacking in adults with type 2 diabetes: A study protocol".
     Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16412.
     PubMed    
     
     
     
336. DE RUITER SC, Tschiderer L, Grobbee DE, Ruigrok YM, et al
     Diabetes, glycaemic traits and cardiovascular disease in females and males: Observational and Mendelian randomisation analyses in the UK Biobank.
     Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16406.
     PubMed     Abstract available
     
     
     
337. HAMAMOTO Y, Usui R
     Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion.
     Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16397.
     PubMed    
     
     
     
338. GUO Z, Wallace AS, Rooney MR, Wang D, et al
     Ultra-processed food consumption among adults with prediabetes and diabetes, 2001-2018.
     Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16411.
     PubMed     Abstract available
     
     
     
339. YANO Y, Okami S, Kanegae H, Oberprieler NG, et al
     Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan.
     Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16394.
     PubMed     Abstract available
     
     
     
340. LI MN, Jin FX, Zhao JJ, Wang Y, et al
     Recurrent hypoglycaemia leads to impairment in glucagon-mediated hepatic glycogenolysis in type 1 diabetic mice.
     Diabetes Obes Metab. 2025 Apr 20. doi: 10.1111/dom.16409.
     PubMed     Abstract available
     
     
     
341. FANG X, Zhang Y, Huang X, Miao R, et al
     Gut microbiome research: Revealing the pathological mechanisms and treatment strategies of type 2 diabetes.
     Diabetes Obes Metab. 2025 Apr 15. doi: 10.1111/dom.16387.
     PubMed     Abstract available
     
     
     
342. REN Y, Chen Y, Zheng W, Kong W, et al
     The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 Apr 15. doi: 10.1111/dom.16366.
     PubMed     Abstract available
     
     
     
343. EVANS-MOLINA C, Oram RA
     Type 1 diabetes presenting in adults: Trends, diagnostic challenges and unique features.
     Diabetes Obes Metab. 2025 Apr 15. doi: 10.1111/dom.16402.
     PubMed     Abstract available
     
     
     
344. GONZALEZ-VIDAL T, Rivas-Otero D, Ramos-Ruiz G, Agueria-Cabal P, et al
     Duration of type 1 diabetes and glycaemic control in adults: A nonlinear relationship.
     Diabetes Obes Metab. 2025 Apr 14. doi: 10.1111/dom.16392.
     PubMed    
     
     
     
345. LO SW, Ko A, Lin J, Tu YF, et al
     Comments on 'Propensity score matching methodology in Riley et al.'s study on type 2 diabetes and obstructive sleep apnoea'.
     Diabetes Obes Metab. 2025 Apr 14. doi: 10.1111/dom.16396.
     PubMed    
     
     
     
346. PAL A, Rawat D, Sadananda S, Goyal A, et al
     Pregnancy and postpartum cardiometabolic outcomes among women with overt diabetes compared to women with normoglycaemia, gestational diabetes and pre-existing diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 Apr 11. doi: 10.1111/dom.16400.
     PubMed     Abstract available
     
     
     
347. LATRES E, Plum-Moerschel L, Murugesan SMN, Lou O, et al
     An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability.
     Diabetes Obes Metab. 2025 Apr 10. doi: 10.1111/dom.16327.
     PubMed     Abstract available
     
     
     
348. 
     Correction to "Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study".
     Diabetes Obes Metab. 2025 Apr 8. doi: 10.1111/dom.16381.
     PubMed    
     
     
     
349. ZHOU X, Chen S, Savitz B, Yu N, et al
     Comparative efficacy of different functional hydrogel dressings in healing diabetic foot ulcer: A systematic review and network meta-analysis.
     Diabetes Obes Metab. 2025 Apr 8. doi: 10.1111/dom.16367.
     PubMed     Abstract available
     
     
     
350. XIE R, Li T, Gao H, Xie C, et al
     Single-cell transcriptional profiling reveals cellular senescence and inflammatory persistence as key features of type 1 diabetes partial remission.
     Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16384.
     PubMed     Abstract available
     
     
     
351. JEON J, Lee K, Lee JE, Huh W, et al
     Frequency and sequence of proteinuria positivity and clinical outcomes in patients with diabetes: A nationwide cohort study.
     Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16345.
     PubMed     Abstract available
     
     
     
352. ROSAS-GUZMAN J, Navarro-Lara A, Sanudo-Maury ME, Anguiano L, et al
     Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico.
     Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16357.
     PubMed     Abstract available
     
     
     
353. SHAO Y, Li Z, Sun M, Wu Q, et al
     Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies.
     Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16383.
     PubMed     Abstract available
     
     
     
354. MODY R, Desai K, Teng CC, Reznor G, et al
     Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.
     Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16372.
     PubMed     Abstract available
     
     
     
355. HOME P, Lauand F, Djaballah K, Li XT, et al
     Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.
     Diabetes Obes Metab. 2025 Apr 2. doi: 10.1111/dom.16360.
     PubMed     Abstract available
     
     
     
356. TINTI D, Nobili C, Bettin G, Roggero E, et al
     Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system-A preliminary report.
     Diabetes Obes Metab. 2025 Apr 2. doi: 10.1111/dom.16377.
     PubMed    
     
     
     
357. LIU J, Shang X, Zhang X, Chen Y, et al
     Metabolomic network reveals novel biomarkers for type 2 diabetes mellitus in the UK Biobank study.
     Diabetes Obes Metab. 2025 Apr 2. doi: 10.1111/dom.16351.
     PubMed     Abstract available
     
     
     
358. CENGIZ A, Wu CC, Lawley SD
     Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy.
     Diabetes Obes Metab. 2025;27:2251-2258.
     PubMed     Abstract available
     
     
     
359. AN X, Sun W, Wen Z, Duan L, et al
     Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
     Diabetes Obes Metab. 2025;27:1735-1751.
     PubMed     Abstract available
     
     
     
360. JO S, Jing G, Chen J, Xu G, et al
     Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity.
     Diabetes Obes Metab. 2025;27:2223-2231.
     PubMed     Abstract available
     
     
     
361. IMMANUEL J, Kongbrailatpam T, Rajagopal R, Simmons D, et al
     Evaluation of the analytical and clinical accuracy of four blood glucose meters in pregnant women with hyperglycaemia.
     Diabetes Obes Metab. 2025;27:2131-2137.
     PubMed     Abstract available
     
     
     
362. HAYMAN MME, Jones W, Aman A, Ward J, et al
     Association of GLP1R locus with mental ill-health endophenotypes and cardiometabolic traits: A trans-ancestry study in UK Biobank.
     Diabetes Obes Metab. 2025;27:1845-1858.
     PubMed     Abstract available
     
     
     
363. XU M, Lv D, Wei H, Li Z, et al
     Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review.
     Diabetes Obes Metab. 2025;27:1693-1707.
     PubMed     Abstract available
     
     
     
364. HIRAYAMA K, Koshizaka M, Ishibashi R, Shoji M, et al
     Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study.
     Diabetes Obes Metab. 2025;27:2059-2069.
     PubMed     Abstract available
     
     
     
365. SIRIWARDANA A, Buizen L, Jun M, Kotwal S, et al
     Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.
     Diabetes Obes Metab. 2025;27:1972-1979.
     PubMed     Abstract available
     
     
     
366. THOMSEN RW, Mailhac A, Lohde JB, Pottegard A, et al
     Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
     Diabetes Obes Metab. 2025;27 Suppl 2.
     PubMed     Abstract available
     
     
     
367. BLUHER M
     An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.
     Diabetes Obes Metab. 2025;27 Suppl 2.
     PubMed     Abstract available
     
     
     
368. FORST T, De Block C, Del Prato S, Frias J, et al
     Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.
     Diabetes Obes Metab. 2025;27 Suppl 2:48-65.
     PubMed     Abstract available
     
     
     March 2025
369. ZHU Y, Jun M, Fletcher RA, Arnott C, et al
     Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial.
     Diabetes Obes Metab. 2025 Mar 27. doi: 10.1111/dom.16363.
     PubMed    
     
     
     
370. DAI L, Wang Q
     Two-pronged approach: Therapeutic effect of biological scaffold combined with immune intervention and beta-cell replacement on type 1 diabetic mice.
     Diabetes Obes Metab. 2025 Mar 27. doi: 10.1111/dom.16373.
     PubMed     Abstract available
     
     
     
371. MELIN EO, Thunander M, Wanby P, Holmberg S, et al
     Low levels of soluble neuropilin-1 were associated with depression in adults with newly diagnosed type 2 diabetes.
     Diabetes Obes Metab. 2025 Mar 27. doi: 10.1111/dom.16347.
     PubMed     Abstract available
     
     
     
372. BONIFACIO E, Ziegler AG
     Type 1 diabetes risk factors, risk prediction and presymptomatic detection: Evidence and guidance for screening.
     Diabetes Obes Metab. 2025 Mar 25. doi: 10.1111/dom.16354.
     PubMed     Abstract available
     
     
     
373. RAJAB AM, Pearson S, Ajjan RA
     Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks.
     Diabetes Obes Metab. 2025 Mar 25. doi: 10.1111/dom.16332.
     PubMed     Abstract available
     
     
     
374. RANJAN AG, Schmidt S, Norgaard K
     Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial.
     Diabetes Obes Metab. 2025 Mar 24. doi: 10.1111/dom.16326.
     PubMed     Abstract available
     
     
     
375. RATZKI-LEEWING A, Harris SB, Rabasa-Lhoret R, Poon Y, et al
     FRONTIER: FReeStyle Libre system use in Ontario among people with diabetes in the IC/ES database-Evidence from real-world practice: Patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies.
     Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16266.
     PubMed     Abstract available
     
     
     
376. MELIS P, Lucijanic M, Kranjcec B, Cigrovski Berkovic M, et al
     The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus-A pilot study.
     Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16368.
     PubMed    
     
     
     
377. SUN J, Hu W, Ye S, Xu M, et al
     Global, regional and country-specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study.
     Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16358.
     PubMed     Abstract available
     
     
     
378. KAKU K, Shimoda M, Osonoi T, Iwamoto M, et al
     Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial.
     Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16336.
     PubMed     Abstract available
     
     
     
379. GUAN J, Qiu J, Li L, Fu M, et al
     A meta-analysis of adverse offspring health outcomes in patients with gestational diabetes mellitus.
     Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16341.
     PubMed     Abstract available
     
     
     
380. COON SA, White RT, Pagnozzi D, Cowart K, et al
     Real-world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre-diabetes.
     Diabetes Obes Metab. 2025 Mar 19. doi: 10.1111/dom.16349.
     PubMed    
     
     
     
381. ASVOLD BO, Skaro M, Valle C, Grytli B, et al
     Long-term effects of continuous glucose monitoring on glycaemic control: Real-world evidence in a general adult population with type 1 diabetes in Norway.
     Diabetes Obes Metab. 2025 Mar 18. doi: 10.1111/dom.16334.
     PubMed    
     
     
     
382. DAVIDSEN L, Cichosz SL, Staehr PB, Vestergaard P, et al
     Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin-treated diabetes: A randomised, open-label, crossover trial.
     Diabetes Obes Metab. 2025 Mar 18. doi: 10.1111/dom.16356.
     PubMed     Abstract available
     
     
     
383. VILSBOLL T, Fu A, Kellerer M, Kumar B, et al
     Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysi
     Diabetes Obes Metab. 2025 Mar 17. doi: 10.1111/dom.16328.
     PubMed     Abstract available
     
     
     
384. HALUZIK M, Cypryk K, Alvarez A, Lauand F, et al
     Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.
     Diabetes Obes Metab. 2025 Mar 17. doi: 10.1111/dom.16276.
     PubMed     Abstract available
     
     
     
385. SOURIJ H, Azhar K, Aberer F, Sourij C, et al
     Impact of level 2 hypoglycaemia on neuroaxonal damage biomarker in individuals with type 2 diabetes: A stepwise hypoglycaemic clamp study.
     Diabetes Obes Metab. 2025 Mar 17. doi: 10.1111/dom.16340.
     PubMed    
     
     
     
386. TSUR A, Cahn A, Hanoch L, Pollack R, et al
     Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: A real world analysis.
     Diabetes Obes Metab. 2025 Mar 14. doi: 10.1111/dom.16329.
     PubMed     Abstract available
     
     
     
387. HUNTER GIBBLE T, Chinthammit C, Ward JM, Cappell K, et al
     Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm(R) database.
     Diabetes Obes Metab. 2025 Mar 14. doi: 10.1111/dom.16330.
     PubMed     Abstract available
     
     
     
388. 
     Correction to "The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes".
     Diabetes Obes Metab. 2025 Mar 13. doi: 10.1111/dom.16323.
     PubMed    
     
     
     
389. VERGANI M, Borella ND, Rizzo M, Conti M, et al
     Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi-centre cross-sectional study.
     Diabetes Obes Metab. 2025 Mar 13. doi: 10.1111/dom.16333.
     PubMed     Abstract available
     
     
     
390. PETERSEN MC, Jones KE, Markov AM, Salam M, et al
     Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial.
     Diabetes Obes Metab. 2025 Mar 13. doi: 10.1111/dom.16324.
     PubMed     Abstract available
     
     
     
391. XI JY, Wang YJ, Li XH, Sun NM, et al
     Impact of healthy lifestyles on the risk of metabolic dysfunction-associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle-aged and elderly cohort in South China.
     Diabetes Obes Metab. 2025 Mar 7. doi: 10.1111/dom.16289.
     PubMed     Abstract available
     
     
     
392. COSTA S, Miranda C, Elefante A, Vallone V, et al
     Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.
     Diabetes Obes Metab. 2025 Mar 6. doi: 10.1111/dom.16314.
     PubMed     Abstract available
     
     
     
393. CARIOU B, Thys A, Oliveira AR, Letertre MPM, et al
     Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial.
     Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16305.
     PubMed     Abstract available
     
     
     
394. RETNAKARAN R, Pu J, Emery A, Kramer CK, et al
     The coordinated changes in insulin sensitivity and insulin secretion associated with the remission of type 2 diabetes following short-term insulin therapy.
     Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16315.
     PubMed    
     
     
     
395. FABRICIUS TW, Verhulst C, Svensson CH, Wienberg M, et al
     Effects of insulin-induced hypoglycaemia on cardiac function in people with type 1 and type 2 diabetes and people without diabetes.
     Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16283.
     PubMed     Abstract available
     
     
     
396. KO JH, Moon SJ, Ajjan RA, Lee MY, et al
     Workplace-based continuous glucose monitoring with structured education for pre-diabetes and type 2 diabetes: A prospective community cohort study.
     Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16304.
     PubMed     Abstract available
     
     
     
397. EL GHANDOUR S, Akbarpoor F, Malik M, Kalsekar M, et al
     Effect of tirzepatide on weight and metabolism in a multiethnic cohort with and without diabetes.
     Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16287.
     PubMed    
     
     
     
398. BHATTACHARJEE A, Ali MR, Kloecker D, Ling S, et al
     Five-year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England.
     Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16288.
     PubMed    
     
     
     
399. XU Y, Echouffo Tcheugui JB, Coresh J, Grams ME, et al
     Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States.
     Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16300.
     PubMed     Abstract available
     
     
     
400. WYSHAM C, Bindal A, Levrat-Guillen F, Kostadinova D, et al
     A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus.
     Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16282.
     PubMed     Abstract available
     
     
     
401. MATHER KJ, Mari A, Weerakkody G, Heise T, et al
     Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
     Diabetes Obes Metab. 2025;27:1507-1514.
     PubMed     Abstract available
     
     
     
402. MANTOVANI A, Lunardi G, Bonapace S, Molinero AE, et al
     Ceramide-based risk score CERT-1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study.
     Diabetes Obes Metab. 2025;27:1488-1497.
     PubMed     Abstract available
     
     
     
403. TANG H, Zhang B, Lu Y, Donahoo WT, et al
     Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.
     Diabetes Obes Metab. 2025;27:1444-1455.
     PubMed     Abstract available
     
     
     
404. JIA Q, Zuo A, Song H, Zhang C, et al
     Effects of sodium-glucose cotransporter-2 inhibitors in myocardial infarction patients: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025;27:1276-1286.
     PubMed     Abstract available
     
     
     
405. WEN J, Razick A, How-Volkman C, Bernstein E, et al
     An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review.
     Diabetes Obes Metab. 2025;27:1113-1122.
     PubMed     Abstract available
     
     
     
406. OO TT
     Repurposing metformin: A potential off-label indication for ischaemic stroke?
     Diabetes Obes Metab. 2025;27:1065-1078.
     PubMed     Abstract available
     
     
     
407. CAESAR R
     The impact of novel probiotics isolated from the human gut on the gut microbiota and health.
     Diabetes Obes Metab. 2025;27 Suppl 1.
     PubMed     Abstract available
     
     
     February 2025
408. GROBMAN B, Mansur A, Lu CY
     Disparities in heart failure deaths among people with diabetes in the United States: 1999-2020.
     Diabetes Obes Metab. 2025 Feb 28. doi: 10.1111/dom.16301.
     PubMed     Abstract available
     
     
     
409. TESFAYE H, Paik JM, Zakoul H, Schmedt N, et al
     Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.
     Diabetes Obes Metab. 2025 Feb 28. doi: 10.1111/dom.16303.
     PubMed    
     
     
     
410. OP DEN KAMP-BRULS YMH, Op den Kamp YJM, Veeraiah P, Zapata Perez R, et al
     Carnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes.
     Diabetes Obes Metab. 2025 Feb 28. doi: 10.1111/dom.16298.
     PubMed     Abstract available
     
     
     
411. SONG L, Yuan X, Huang S, Zhang Y, et al
     iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.
     Diabetes Obes Metab. 2025 Feb 27. doi: 10.1111/dom.16260.
     PubMed     Abstract available
     
     
     
412. PANG X, Dan W, Lin L, Li H, et al
     Association of normal range of urinary albumin-to-creatinine ratio with all-cause mortality among diabetic adults with preserved kidney function: National Health and Nutrition Examination Survey (NHANES) 2003-2018.
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16269.
     PubMed     Abstract available
     
     
     
413. OLSEN MT, Jensen SH, Rasmussen LM, Klarskov CK, et al
     Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point-of-care glucose testing in a non-intensive care unit setting: A heterogeneity of treatment effect analysis.
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16297.
     PubMed     Abstract available
     
     
     
414. GOSHRANI A, Lin R, O'Neal D, Ekinci EI, et al
     Time in range-A new gold standard in type 2 diabetes research?
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16279.
     PubMed     Abstract available
     
     
     
415. HANKOSKY ER, Chinthammit C, Meeks A, Huang A, et al
     Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16290.
     PubMed     Abstract available
     
     
     
416. OKTAVIAN P, Kencono Wungu CD, Mudjanarko SW, Amin IM, et al
     A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16268.
     PubMed     Abstract available
     
     
     
417. ROBERTS CGP, Athinarayanan SJ, Ratner RE, Umpierrez GE, et al
     Illnesses associated with ketosis including diabetic ketoacidosis during very low carbohydrate and ketogenic diets.
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16252.
     PubMed     Abstract available
     
     
     
418. BERRY SA, Liarakos AL, Koutroukas V, Choudhary P, et al
     The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice.
     Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16284.
     PubMed     Abstract available
     
     
     
419. TOSHIMITSU T, Irie J
     An update and overview of the various health-related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes.
     Diabetes Obes Metab. 2025 Feb 24. doi: 10.1111/dom.16273.
     PubMed     Abstract available
     
     
     
420. YANG X, Cao Y, Cao X, Wang L, et al
     Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: A Bayesian network meta-analysis.
     Diabetes Obes Metab. 2025 Feb 20. doi: 10.1111/dom.16270.
     PubMed     Abstract available
     
     
     
421. MONAMI M, Bordoni L, Ragghianti B, Silverii GA, et al
     Efficacy and safety of a bio-absorbable antibiotic delivery in calcium sulphate granules for the treatment of osteomyelitis in patients with diabetic foot: A randomized, double blinded, controlled clinical study The BIG D-FOOT study.
     Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16254.
     PubMed     Abstract available
     
     
     
422. SOURIJ H, Bracken RM, Carstensen L, Pagliaro Rocha TM, et al
     No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6.
     Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16265.
     PubMed    
     
     
     
423. LEWIS GA, Hughes DM, Irving G, Wilding J, et al
     Association between diabetes self-management education attendance, hospital admissions and mortality in type 2 diabetes: A cohort analysis protocol.
     Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16257.
     PubMed     Abstract available
     
     
     
424. GIUGLIANO D, Longo M, Caruso P, Gicchino M, et al
     Effect of SGLT-2 Inhibitors Versus DPP-4 Inhibitors on Peripheral Artery Disease Risk Among People With Type 2 Diabetes: A 48-Month Prospective Study.
     Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16277.
     PubMed    
     
     
     
425. VIJAYAN A, Lanzinger S, Forestier N, Hess G, et al
     Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type-2 diabetes and chronic kidney disease: DPV registry study.
     Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16245.
     PubMed     Abstract available
     
     
     
426. SHIKAMURA M, Takayama A, Yokogawa K, Kawakami K, et al
     Temporal risk patterns of severe hypovolemia associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A self-controlled case series study.
     Diabetes Obes Metab. 2025 Feb 18. doi: 10.1111/dom.16259.
     PubMed     Abstract available
     
     
     
427. SAHAY R, Gangwani D, Singh M, Gupta S, et al
     Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.
     Diabetes Obes Metab. 2025 Feb 14. doi: 10.1111/dom.16218.
     PubMed     Abstract available
     
     
     
428. SHAH VN, Dex T, Meneghini L, Rodrigues A, et al
     Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.
     Diabetes Obes Metab. 2025 Feb 14. doi: 10.1111/dom.16251.
     PubMed     Abstract available
     
     
     
429. ZOU Y, Zhuo M, Chen W, Song W, et al
     Multiomics analysis of O-GlcNAcylation in podocytes of diabetic kidney disease.
     Diabetes Obes Metab. 2025 Feb 14. doi: 10.1111/dom.16274.
     PubMed     Abstract available
     
     
     
430. O'DONNELL HK, Simmons KM, Gitelman SE, Dex T, et al
     Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.
     Diabetes Obes Metab. 2025 Feb 13. doi: 10.1111/dom.16246.
     PubMed     Abstract available
     
     
     
431. ISHIBASHI R, Takatsuna Y, Koshizaka M, Tatsumi T, et al
     Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial.
     Diabetes Obes Metab. 2025 Feb 11. doi: 10.1111/dom.16244.
     PubMed     Abstract available
     
     
     
432. BELLEMARE M, Bourcier L, Iglesies-Grau J, Boulet J, et al
     Mechanisms of diabetic cardiomyopathy: Focus on inflammation.
     Diabetes Obes Metab. 2025 Feb 10. doi: 10.1111/dom.16242.
     PubMed     Abstract available
     
     
     
433. ROSSING P, Benamar M, Cheng AYY, Kumar B, et al
     Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials.
     Diabetes Obes Metab. 2025 Feb 10. doi: 10.1111/dom.16231.
     PubMed     Abstract available
     
     
     
434. HOWELL CR, Tanaka S, Zhang L, Carson AP, et al
     Adding social determinants of health to the equation: Development of a cardiometabolic disease staging model using clinical and social determinants of health to predict type 2 diabetes.
     Diabetes Obes Metab. 2025 Feb 10. doi: 10.1111/dom.16241.
     PubMed     Abstract available
     
     
     
435. POON ET, Li HY, Kong APS, Little JP, et al
     Efficacy of high-intensity interval training in individuals with type 2 diabetes mellitus: An umbrella review of systematic reviews and meta-analyses.
     Diabetes Obes Metab. 2025 Feb 5. doi: 10.1111/dom.16220.
     PubMed     Abstract available
     
     
     
436. HA KH, Jang Y, Kim DJ
     Effectiveness of gemigliptin on risk of major adverse kidney events in people with type 2 diabetes: A Korean cohort study.
     Diabetes Obes Metab. 2025 Feb 5. doi: 10.1111/dom.16230.
     PubMed    
     
     
     
437. SMANIOTTO V, Heller S, O'Neal D, Jendle J, et al
     MiniMed 780G system performance in older users with type 1 diabetes: Real-world evidence and the case for stricter glycaemic targets.
     Diabetes Obes Metab. 2025 Feb 4. doi: 10.1111/dom.16227.
     PubMed     Abstract available
     
     
     
438. FRIAS JP, Ratzki-Leewing A, Dex T, Meneghini L, et al
     Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.
     Diabetes Obes Metab. 2025 Feb 4. doi: 10.1111/dom.16214.
     PubMed     Abstract available
     
     
     
439. LIU D, Yu S, Zhang Y, Li Q, et al
     Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6-year prospective study.
     Diabetes Obes Metab. 2025 Feb 3. doi: 10.1111/dom.16224.
     PubMed     Abstract available
     
     
     
440. IKEDA K, Mano-Usui F, Kishimoto Y, Yabe D, et al
     Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high-dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia.
     Diabetes Obes Metab. 2025 Feb 3. doi: 10.1111/dom.16221.
     PubMed    
     
     
     
441. MATSUSHIRO M, Yamaguchi Y, Kuwata H, Hamamoto Y, et al
     Short-term outcomes of switching from GLP-1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice.
     Diabetes Obes Metab. 2025 Feb 2. doi: 10.1111/dom.16237.
     PubMed    
     
     
     
442. COSENTINO F, Dagogo-Jack S, Frederich R, Cannon CP, et al
     Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
     Diabetes Obes Metab. 2025;27:583-594.
     PubMed     Abstract available
     
     
     
443. HE Q, Cheng Z, Li Y, Xing X, et al
     A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
     Diabetes Obes Metab. 2025;27:965-975.
     PubMed     Abstract available
     
     
     
444. MORENO-LOPEZ M, Louvet I, Delalleau N, Acosta-Montalvo A, et al
     The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition.
     Diabetes Obes Metab. 2025;27:885-898.
     PubMed     Abstract available
     
     
     
445. CERSOSIMO E, YueJuan Q, Baskoy G, Chavez A, et al
     Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients.
     Diabetes Obes Metab. 2025;27:944-952.
     PubMed     Abstract available
     
     
     
446. NEYER M, Vogel JB, Elsner P, Kuehrer H, et al
     Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.
     Diabetes Obes Metab. 2025;27:835-844.
     PubMed     Abstract available
     
     
     
447. USUI R, Hamamoto Y, Imura M, Omori Y, et al
     Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.
     Diabetes Obes Metab. 2025;27:856-865.
     PubMed     Abstract available
     
     
     
448. ZHANG M, Lin C, Cai X, Jiao R, et al
     One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
     Diabetes Obes Metab. 2025;27:806-815.
     PubMed     Abstract available
     
     
     
449. SONG ZQ, Chen YQ, Xuan CH, Ni TT, et al
     Effect of smoking behaviour and related blood DNA methylation on visceral adipose tissues.
     Diabetes Obes Metab. 2025;27:619-628.
     PubMed     Abstract available
     
     
     
450. AO N, Du J, Jin S, Suo L, et al
     The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease.
     Diabetes Obes Metab. 2025;27:457-467.
     PubMed     Abstract available
     
     
     
451. HAGGAG AZ, Xu J, Butcher L, Pagnussat S, et al
     Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
     Diabetes Obes Metab. 2025;27:551-562.
     PubMed     Abstract available
     
     
     January 2025
452. BOMBACI B, Passanisi S, Calderone M, Macri F, et al
     Long-term use of Minimed 780G in children and adolescents with type 1 diabetes under real-world conditions: The benefits of optimal settings.
     Diabetes Obes Metab. 2025 Jan 31. doi: 10.1111/dom.16226.
     PubMed    
     
     
     
453. XU Z, Fang J, Wang Y, Wu X, et al
     Targeted metabolomics reveals novel biomarkers for gestational diabetes mellitus.
     Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16213.
     PubMed     Abstract available
     
     
     
454. STEENS ILM, Ji Y, Sedaghat S, Pankow J, et al
     Diabetes and incident stroke and mediation by microvascular dysfunction: Pooled analysis of three population-based studies.
     Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16217.
     PubMed    
     
     
     
455. NGUYEN TTD, Chen HM, Lin HW, Ou HT, et al
     Clinical effectiveness and cost-effectiveness of first-line early combination of dipeptidyl peptidase 4 inhibitors and metformin in patients with type 2 diabetes in Taiwan: A modelling study.
     Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16215.
     PubMed     Abstract available
     
     
     
456. SHEN J, Sarwal A, Singh R, Hartsell SE, et al
     Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16207.
     PubMed     Abstract available
     
     
     
457. YAMAMOTO K, Ihana-Sugiyama N, Sugiyama T, Yamaoka T, et al
     Recognition of ophthalmology consultation and fundus examination among individuals with diabetes in Japan: A cross-sectional study using claims-questionnaire linked data.
     Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16164.
     PubMed     Abstract available
     
     
     
458. CHENG AYY, Heine RJ, Del Prato S, Green JB, et al
     Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review.
     Diabetes Obes Metab. 2025 Jan 28. doi: 10.1111/dom.16206.
     PubMed     Abstract available
     
     
     
459. CAI J, Liu J, Lu J, Ni J, et al
     Impact of time in tight range on all-cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study.
     Diabetes Obes Metab. 2025 Jan 27. doi: 10.1111/dom.16212.
     PubMed     Abstract available
     
     
     
460. DOVC K, Spanbauer C, Chiarle E, Bratina N, et al
     Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery.
     Diabetes Obes Metab. 2025 Jan 27. doi: 10.1111/dom.16211.
     PubMed     Abstract available
     
     
     
461. GULATI K, Wijndaele K, Webb J, von Arx LB, et al
     Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study.
     Diabetes Obes Metab. 2025 Jan 22. doi: 10.1111/dom.16201.
     PubMed     Abstract available
     
     
     
462. AKERKAR A, Ronn PF, Kosjerina V, Hansen CS, et al
     Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study.
     Diabetes Obes Metab. 2025 Jan 22. doi: 10.1111/dom.16200.
     PubMed    
     
     
     
463. ZHOU Y, Boucsein A, Michaels VR, Gray MK, et al
     Predictors of glycaemic improvement in children and young adults with type 1 diabetes and very elevated HbA1c using the MiniMed 780G system.
     Diabetes Obes Metab. 2025 Jan 20. doi: 10.1111/dom.16210.
     PubMed     Abstract available
     
     
     
464. MCEWAN P, Foos V, Roberts G, Jenkins RH, et al
     Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.
     Diabetes Obes Metab. 2025 Jan 19. doi: 10.1111/dom.16141.
     PubMed     Abstract available
     
     
     
465. LEITE NC, Villela-Nogueira CA, Santos LV, Cardoso CRL, et al
     Prognostic value of changes in vibration-controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: The Rio de Janeiro
     Diabetes Obes Metab. 2025 Jan 16. doi: 10.1111/dom.16195.
     PubMed     Abstract available
     
     
     
466. SUN M, Liu Q, Liu Y, Ning N, et al
     Baseline and cumulative Chinese visceral adiposity index and diabetic kidney disease: A prospective cohort study.
     Diabetes Obes Metab. 2025 Jan 15. doi: 10.1111/dom.16184.
     PubMed     Abstract available
     
     
     
467. MATSUBAYASHI Y, Fujihara K, Khin L, Ferreira ED, et al
     Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.
     Diabetes Obes Metab. 2025 Jan 15. doi: 10.1111/dom.16196.
     PubMed     Abstract available
     
     
     
468. SUZUKI R, Shoji S, Yoshinaga Y, Kosakai Y, et al
     Risk of insulin initiation with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A real-world claims database study in Japan.
     Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16188.
     PubMed     Abstract available
     
     
     
469. WU X, Huang Q, Ding Y, Cao Q, et al
     Effect of insulin sensitivity, insulin secretion, and beta cell function on the remission of type 2 diabetes: A post hoc analysis of the IDEATE trial.
     Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16180.
     PubMed     Abstract available
     
     
     
470. LIN CM, Chen JC, Meyerowitz-Katz G, Huang YN, et al
     Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.
     Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16191.
     PubMed     Abstract available
     
     
     
471. LU W, Xie L, Zhang Y, Gao H, et al
     Long-term blood glucose control via glucose-activated transcriptional regulation of insulin analogue in type 1 diabetes mice.
     Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16197.
     PubMed     Abstract available
     
     
     
472. WANG Y, Lin T, Lu J, He W, et al
     Trends and analysis of risk factor differences in the global burden of chronic kidney disease due to type 2 diabetes from 1990 to 2021: A population-based study.
     Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16183.
     PubMed     Abstract available
     
     
     
473. 
     Correction to "Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study".
     Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16204.
     PubMed    
     
     
     
474. FIORE V, Carbotta G, Barraco S, Falasca P, et al
     Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly).
     Diabetes Obes Metab. 2025 Jan 10. doi: 10.1111/dom.16174.
     PubMed     Abstract available
     
     
     
475. RUBINO DM, Pedersen SD, Connery L, Cao D, et al
     Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
     Diabetes Obes Metab. 2025 Jan 9. doi: 10.1111/dom.16176.
     PubMed     Abstract available
     
     
     
476. TANG C, Hao J, Tao F, Feng Q, et al
     Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16192.
     PubMed     Abstract available
     
     
     
477. HANSEN AL, Andersen MK, Engelhard LM, Brons C, et al
     Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16193.
     PubMed     Abstract available
     
     
     
478. ALKHUZAM K, Li P, Abuloha S, Xue Q, et al
     Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes.
     Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16168.
     PubMed     Abstract available
     
     
     
479. STICE E, Rohde P, Desjardins CD, Gee K, et al
     A preliminary randomized trial of a brief dissonance-based type 2 diabetes prevention programme for adults with pre-diabetes.
     Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16170.
     PubMed     Abstract available
     
     
     
480. ZHAO J, Sun Z, Li Z, Xu M, et al
     MicroRNA-mediated Ets1 repression in retinal endothelial cells: A novel anti-angiogenic mechanism in nonproliferative diabetic retinopathy.
     Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16182.
     PubMed     Abstract available
     
     
     
481. SON H, Sohn SH, Kim HA, Choe HJ, et al
     Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial.
     Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16177.
     PubMed     Abstract available
     
     
     
482. VERMILLAC G, Lafont C, Godot C, Kerbourc'h S, et al
     Paediatric-to-adult transition in type 1 diabetes: A two-centre experience of a structured program, 2014 to 2022.
     Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16140.
     PubMed     Abstract available
     
     
     
483. CHEN M, Dou C, Ye C, Kong L, et al
     Socioeconomic and mental health inequalities in global burden of type 2 diabetes: Evidence from the Global Burden of Disease Study 2021.
     Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16173.
     PubMed     Abstract available
     
     
     
484. HOPKINS R, Young KG, Thomas NJ, Jones AG, et al
     Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study.
     Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16163.
     PubMed     Abstract available
     
     
     
485. SEUFERT J, Wiesner T, Pegelow K, Kenzler J, et al
     Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
     Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16161.
     PubMed     Abstract available
     
     
     
486. PODOBNIK J, Prentice KJ
     Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.
     Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16154.
     PubMed     Abstract available
     
     
     
487. KIM MK, Kim J, Park SJ, Song YJ, et al
     Impact of caloric restriction on diabetes remission in Korean adults with obesity (CREDO-K study).
     Diabetes Obes Metab. 2025 Jan 3. doi: 10.1111/dom.16166.
     PubMed    
     
     
     
488. HALLIG SJ, Aalders J, Christensen MH, Andersen MS, et al
     The cardio-metabolic protein profile is associated with development of type 2 diabetes at long term follow-up after gestational diabetes mellitus: Results from the OGFUS study.
     Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16148.
     PubMed     Abstract available
     
     
     
489. AZHAR K, Ramirez-Obermayer A, Sourij C, Knoll L, et al
     Sustained weight reduction following 12 weeks of intermittent fasting intervention in people with insulin-treated type 2 diabetes-Two-year follow-up of the randomised controlled InterFast-2 trial.
     Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16158.
     PubMed    
     
     
     
490. LEE DY, Moon JS, Jung I, Chung SM, et al
     Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease.
     Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16165.
     PubMed     Abstract available
     
     
     
491. SANTOS-BAEZ LS, Diaz-Rizzolo DA, Borhan R, Popp CJ, et al
     Predictive models of post-prandial glucose response in persons with prediabetes and early onset type 2 diabetes: A pilot study.
     Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16160.
     PubMed     Abstract available
     
     
     
492. GROSICKI GJ, Thomas JG, Dhurandhar NV, Lofton H, et al
     Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.
     Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16151.
     PubMed    
     
     
     
493. LOU Y, Xie Y, Jiang Q, Huang S, et al
     The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study.
     Diabetes Obes Metab. 2025;27:291-299.
     PubMed     Abstract available
     
     
     
494. JIAO R, Lin C, Cai X, Wang J, et al
     Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.
     Diabetes Obes Metab. 2025;27:259-267.
     PubMed     Abstract available
     
     
     December 2024
495. XIE C, Iroga P, Bound MJ, Grivell J, et al
     Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes.
     Diabetes Obes Metab. 2024 Dec 27. doi: 10.1111/dom.16169.
     PubMed    
     
     
     
496. BAECHLE C, Rosenbauer J, Stahl-Pehe A, Seufert J, et al
     Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study.
     Diabetes Obes Metab. 2024 Dec 27. doi: 10.1111/dom.16149.
     PubMed    
     
     
     
497. WONG HJ, Lin NHY, Teo YH, Yeo BSY, et al
     Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.
     Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16136.
     PubMed     Abstract available
     
     
     
498. FUKUNAGA K, Morishita A, Imachi H, Oura K, et al
     Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study.
     Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16157.
     PubMed     Abstract available
     
     
     
499. TAKAHASHI A, Nomoto H, Yokoyama H, Yokozeki K, et al
     Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel
     Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150.
     PubMed     Abstract available
     
     
     
500. BORYSOWSKI J, Klosowska D, Paczek L, Ordak M, et al
     Exclusion of older persons from randomized controlled trials in type 2 diabetes: A cross-sectional study.
     Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16137.
     PubMed     Abstract available
     
     
     
501. XU Z, Wen S, Dong M, Zhou L, et al
     Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes.
     Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16146.
     PubMed     Abstract available
     
     
     
502. ZHAO X, Xu X, Wang S, Zhang X, et al
     Heterogeneous blood pressure treatment effects on cognitive decline in type 2 diabetes: A machine learning analysis of a randomized clinical trial.
     Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16145.
     PubMed     Abstract available
     
     
     
503. GUO L, Chen L, Zhao F, Liu X, et al
     Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.
     Diabetes Obes Metab. 2024 Dec 20. doi: 10.1111/dom.16139.
     PubMed     Abstract available
     
     
     
504. SOHN M, Park YH, Lim S
     Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial.
     Diabetes Obes Metab. 2024 Dec 20. doi: 10.1111/dom.16131.
     PubMed     Abstract available
     
     
     
505. WANG Y, Lu J, Yu J, Ni J, et al
     Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes.
     Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16143.
     PubMed     Abstract available
     
     
     
506. MOURA FA, Kamanu FK, Wiviott SD, Giugliano RP, et al
     Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers.
     Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16123.
     PubMed     Abstract available
     
     
     
507. HERMAN WH, Kuo S, Zhang P
     A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was".
     Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16124.
     PubMed    
     
     
     
508. CHEN L, Wan H, Han J, Yang C, et al
     Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study.
     Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16144.
     PubMed     Abstract available
     
     
     
509. GARGOURI I, Charfi H, Belabed W, Outenah C, et al
     Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed 780G according to patient characteristics.
     Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16118.
     PubMed     Abstract available
     
     
     
510. YANG S, Yuan Y, Zhang B, Wu T, et al
     Identification of adipose tissue-derived exosomal microRNA as a novel causal biomarker for cognitive impairment in type 2 diabetes mellitus: Triangulating evidence from Mendelian randomization and multicentre population studies.
     Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16121.
     PubMed     Abstract available
     
     
     
511. HUANG CC, Hsu RF, Chen WM, Shia BC, et al
     Metformin lowers risk of hearing loss and mortality in type 2 diabetes.
     Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16128.
     PubMed     Abstract available
     
     
     
512. ERWIN AP, Patrie JT, Horton WB
     Heart failure phenotypes in people with type 1 diabetes.
     Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16133.
     PubMed    
     
     
     
513. MOURA FS, Amaral MJM, Lima LCV, Souza M, et al
     Prevalence of MASLD in children and adolescents with type 1 diabetes: A meta-analysis.
     Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16125.
     PubMed    
     
     
     
514. YU YH, Platt RW, Reynier P, Yu OHY, et al
     Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population-based cohort study.
     Diabetes Obes Metab. 2024 Dec 16. doi: 10.1111/dom.16115.
     PubMed     Abstract available
     
     
     
515. SSEMMONDO E, Shah N, Newham M, Rigby A, et al
     Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non-insulin therapies-A randomised controlled trial.
     Diabetes Obes Metab. 2024 Dec 11. doi: 10.1111/dom.16116.
     PubMed     Abstract available
     
     
     
516. WANG Y, Wen Q, Lu Y, Yang J, et al
     Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial.
     Diabetes Obes Metab. 2024 Dec 9. doi: 10.1111/dom.16111.
     PubMed     Abstract available
     
     
     
517. BAEK S, Park J, Chung JY, Kwak SH, et al
     Short-term efficacy and safety of metformin in individuals with type 2 diabetes and mild hepatic impairment: A propensity score-matched real-world study.
     Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16108.
     PubMed    
     
     
     
518. WANG G, Fu J, Li X, Wang J, et al
     Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: A network meta-analysis.
     Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16114.
     PubMed     Abstract available
     
     
     
519. BAO Y, Hu Y, Shi M, Zhao Z, et al
     SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.
     Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16107.
     PubMed     Abstract available
     
     
     
520. LI M, Yu H, Wan S, Hu F, et al
     The fibrosis investigating navigator in diabetes (FIND): A tool to predict liver fibrosis risk in subjects with diabetes.
     Diabetes Obes Metab. 2024 Dec 5. doi: 10.1111/dom.16109.
     PubMed     Abstract available
     
     
     
521. FINKELSTEIN EA, Gardner DS, Tham KW, Gandhi M, et al
     Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial.
     Diabetes Obes Metab. 2024 Dec 5. doi: 10.1111/dom.16067.
     PubMed     Abstract available
     
     
     
522. WANG X, Pei J, Zheng K, Liu M, et al
     The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Dec 3. doi: 10.1111/dom.16112.
     PubMed     Abstract available
     
     
     
523. MEULMEESTER FL, van Dijk KW, van Heemst D, Noordam R, et al
     Association of a composite trait for anthropometrics, adiposity and energy expenditure with cardiometabolic diseases: An age-stratified cohort and genetic risk score analysis.
     Diabetes Obes Metab. 2024;26:5922-5930.
     PubMed     Abstract available
     
     
     
524. DUBIN RL, Heymsfield SB, Ravussin E, Greenway FL, et al
     Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
     Diabetes Obes Metab. 2024;26:5503-5518.
     PubMed     Abstract available
     
     
     
525. CHEN C, Liu X, Zhang J, Hu S, et al
     Changes in insulin utilization in China from 2020 to 2022.
     Diabetes Obes Metab. 2024;26:5681-5689.
     PubMed     Abstract available
     
     
     
526. GABE MBN, Fuhr R, Sinn A, Eliasen A, et al
     Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
     Diabetes Obes Metab. 2024;26:5805-5811.
     PubMed     Abstract available
     
     
     
527. ZOU Y, Jiang F, Sun C, Zhao C, et al
     Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.
     Diabetes Obes Metab. 2024 Dec 1. doi: 10.1111/dom.16080.
     PubMed     Abstract available
     
     
     
528. LIU R, Zhang J, Chen S, Xiao Y, et al
     Intestinal mucosal immunity and type 1 diabetes: Non-negligible communication between gut and pancreas.
     Diabetes Obes Metab. 2024 Dec 1. doi: 10.1111/dom.16101.
     PubMed     Abstract available
     
     
     
529. AJJAN RA
     The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.
     Diabetes Obes Metab. 2024;26 Suppl 7.
     PubMed     Abstract available
     
     
     
530. BENHALIMA K, Yamamoto JM
     Use of continuous glucose monitoring and hybrid closed-loop therapy in pregnancy.
     Diabetes Obes Metab. 2024;26 Suppl 7:74-91.
     PubMed     Abstract available
     
     
     
531. KONG YW, Morrison D, Lu JC, Lee MH, et al
     Continuous ketone monitoring: Exciting implications for clinical practice.
     Diabetes Obes Metab. 2024;26 Suppl 7.
     PubMed     Abstract available
     
     
     
532. ANANDHAKRISHNAN A, Hussain S
     Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes.
     Diabetes Obes Metab. 2024;26 Suppl 7:27-46.
     PubMed     Abstract available
     
     
     November 2024
533. KRISTENSEN DK, Mose FH, Buus NH, Duus CL, et al
     SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial.
     Diabetes Obes Metab. 2024 Nov 29. doi: 10.1111/dom.16097.
     PubMed     Abstract available
     
     
     
534. WU A, Pu J, Emery A, Harris SB, et al
     Role of the liver in the sustained normalisation of A1c over 2 years following short-term insulin therapy in early type 2 diabetes.
     Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16099.
     PubMed     Abstract available
     
     
     
535. WANG W, Han Y, Jiang X, Shao J, et al
     Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials.
     Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16095.
     PubMed     Abstract available
     
     
     
536. ARMSTRONG MJ, Okanoue T, Sundby Palle M, Sejling AS, et al
     Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
     Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16065.
     PubMed     Abstract available
     
     
     
537. VALE C, Lourenco IM, Jordan G, Golovaty I, et al
     Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes.
     Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16077.
     PubMed     Abstract available
     
     
     
538. ADDALA A, Ritter V, Schneider-Utaka AK, Alamarie SA, et al
     Psychosocial outcomes in a diverse sample of youth and their families who initiated continuous glucose monitoring within the first year of type 1 diabetes diagnosis.
     Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16093.
     PubMed     Abstract available
     
     
     
539. ENG PC, Lee SH, Der Teo AE, Lim DST, et al
     Postnatal glycaemic outcomes in women with high-risk gestational diabetes: Identifying key predictors for early intervention.
     Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16085.
     PubMed     Abstract available
     
     
     
540. LUNDEMOSE SB, McCarthy OM, Christensen MB, Laugesen C, et al
     Is low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G, an automated insulin delivery system?
     Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16103.
     PubMed     Abstract available
     
     
     
541. WHELEHAN G, Dirks ML, West S, Abdelrahman DR, et al
     High-protein vegan and omnivorous diets improve peripheral insulin sensitivity to a similar extent in people with type 2 diabetes.
     Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16100.
     PubMed     Abstract available
     
     
     
542. UMPIERREZ G, Gill J, Hood D, Li X, et al
     Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
     Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16075.
     PubMed     Abstract available
     
     
     
543. KASTRATI L, Alvarez-Martinez M, Thomas A, Thevis M, et al
     Effect of exercise on plasma insulin levels in individuals with type 1 diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16088.
     PubMed     Abstract available
     
     
     
544. JIANG Y, Zhu H, Gong F
     Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
     Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16106.
     PubMed     Abstract available
     
     
     
545. GENG J, Ruan X, Wu X, Chen X, et al
     Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease.
     Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16087.
     PubMed     Abstract available
     
     
     
546. SINGH J, Adel FW, Scott CG, Chen HH, et al
     Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.
     Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16073.
     PubMed     Abstract available
     
     
     
547. DICEMBRINI I, Cavallo G, Ranaldi F, Scoccimarro D, et al
     Glycaemic response to pasta from three different wheat varieties in individuals with type 2 diabetes.
     Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16082.
     PubMed    
     
     
     
548. LIU W, Hu X, Fang Y, Hong S, et al
     Development and external validation of an algorithm for self-identification of risk for microvascular complications in patients with type 1 diabetes.
     Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16068.
     PubMed     Abstract available
     
     
     
549. SHAH R, Finlay AY, Ali FM, Otwombe K, et al
     Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross-sectional study.
     Diabetes Obes Metab. 2024 Nov 24. doi: 10.1111/dom.16058.
     PubMed     Abstract available
     
     
     
550. ZOU Y, Yang Q, Lang Y, Liu K, et al
     The prognostic impact of the Stress Hyperglycemia Ratio on End-Stage Renal Disease among patients with Diabetic Kidney Disease.
     Diabetes Obes Metab. 2024 Nov 21. doi: 10.1111/dom.16056.
     PubMed     Abstract available
     
     
     
551. TYRER F, Gharibzadeh S, Gillies C, Lawson C, et al
     Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study.
     Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16071.
     PubMed     Abstract available
     
     
     
552. SRIDHAR VS, Davies MJ, Banks P, Girard M, et al
     Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4.
     Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16079.
     PubMed    
     
     
     
553. FU X, Zhao Y, Wu Y, Wen L, et al
     Relationship between trajectory of Chinese visceral adiposity index and risk of type 2 diabetes mellitus: Evidence from the China-PAR project.
     Diabetes Obes Metab. 2024 Nov 19. doi: 10.1111/dom.16074.
     PubMed     Abstract available
     
     
     
554. VAN HECK JIP, Ajie M, Joosten LAB, Tack CJ, et al
     Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications.
     Diabetes Obes Metab. 2024 Nov 19. doi: 10.1111/dom.16066.
     PubMed     Abstract available
     
     
     
555. ZHENG T, Yang R, Li X, Dai Z, et al
     Integrative transcriptome analysis reveals Serpine2 promotes glomerular mesangial cell proliferation and extracellular matrix accumulation via activating ERK1/2 signalling pathway in diabetic nephropathy.
     Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16069.
     PubMed     Abstract available
     
     
     
556. 
     Correction to "Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus".
     Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16083.
     PubMed    
     
     
     
557. SARABHAI T, Kostev K
     Incidence and risk factors of new-onset diabetes mellitus: A five-year follow-up study in solid organ transplant recipients in Germany.
     Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16072.
     PubMed    
     
     
     
558. GOLUBIC R, Car J, Nicolaides K
     Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies.
     Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16070.
     PubMed    
     
     
     
559. GETHER IM, Andersen ES, Foghsgaard S, Ellegaard AM, et al
     Increased gallbladder emptying and reduced GLP-1 response in pregnancy with and without gestational diabetes mellitus.
     Diabetes Obes Metab. 2024 Nov 14. doi: 10.1111/dom.16064.
     PubMed     Abstract available
     
     
     
560. RODRIGUEZ P, Breslaw N, Xiao H, Bena J, et al
     De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
     Diabetes Obes Metab. 2024 Nov 12. doi: 10.1111/dom.16057.
     PubMed     Abstract available
     
     
     
561. RILEY DR, Henney A, Anson M, Hernadez G, et al
     The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes.
     Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16059.
     PubMed     Abstract available
     
     
     
562. ZHANG Z, Wang Y, Lu J, Zhou J, et al
     Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics.
     Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16033.
     PubMed     Abstract available
     
     
     
563. MAGAGNOLI J, Cummings TH, Hardin JW, Ambati J, et al
     Targeting the cholinergic anti-inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study.
     Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16060.
     PubMed     Abstract available
     
     
     
564. GOLOMB RC, Tittel SR, Welters A, Karges W, et al
     Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria.
     Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16048.
     PubMed     Abstract available
     
     
     
565. MILDER TY, Lin J, Pearson SA, de Oliveira Costa J, et al
     Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
     Diabetes Obes Metab. 2024 Nov 7. doi: 10.1111/dom.16061.
     PubMed    
     
     
     
566. GREGORIC N, Sikonja J, Janez A, Jensterle M, et al
     Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
     Diabetes Obes Metab. 2024 Nov 7. doi: 10.1111/dom.16042.
     PubMed     Abstract available
     
     
     
567. SMEIJER JD, Gomez MF, Rossing P, Heerspink HJL, et al
     The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.
     Diabetes Obes Metab. 2024 Nov 6. doi: 10.1111/dom.16041.
     PubMed     Abstract available
     
     
     
568. HE B, Lam HS, Qiu X, Shen S, et al
     Association and mediation pathways of maternal hyperglycaemia and liability to gestational diabetes with neonatal outcomes: A two-sample Mendelian randomization study.
     Diabetes Obes Metab. 2024 Nov 6. doi: 10.1111/dom.16045.
     PubMed     Abstract available
     
     
     
569. LEE CH, Lui DT, Mak LY, Fong CH, et al
     Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.
     Diabetes Obes Metab. 2024 Nov 5. doi: 10.1111/dom.16049.
     PubMed     Abstract available
     
     
     
570. WONDIMKUN YA, Caughey GE, Inacio MC, Air T, et al
     Glucose-lowering medicines use before and after entry into long-term care facilities.
     Diabetes Obes Metab. 2024;26:4966-4975.
     PubMed     Abstract available
     
     
     
571. LIU Q, Celis-Morales C, Sattar N, Welsh P, et al
     Association of glycaemic control with intraocular pressure in a large general population: Results from the UK Biobank.
     Diabetes Obes Metab. 2024;26:5192-5201.
     PubMed     Abstract available
     
     
     
572. GENG L, Sun B, Chen Y
     A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations.
     Diabetes Obes Metab. 2024;26:5376-5389.
     PubMed     Abstract available
     
     
     
573. ELHENAWY YI, Abdel Kader MS, Thabet RA
     Performance of the MiniMed 780G system on mitigating menstrual cycle-dependent glycaemic variability.
     Diabetes Obes Metab. 2024;26:4916-4923.
     PubMed     Abstract available
     
     
     
574. FESTA A, Saely CH, Drexel H
     Sodium-glucose co-transporter-2 inhibitors: Writing the next chapter of a unique success story.
     Diabetes Obes Metab. 2024;26:4816-4819.
     PubMed    
     
     
     
575. HAMBLIN PS, Earnest A, Russell AW, Talic S, et al
     Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.
     Diabetes Obes Metab. 2024;26:4924-4932.
     PubMed     Abstract available
     
     
     
576. FUJIHARA K, Matsubayashi Y, Kitazawa M, Sato T, et al
     Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.
     Diabetes Obes Metab. 2024;26:5304-5311.
     PubMed     Abstract available
     
     
     
577. KNOP FK, Urva S, Rettiganti M, Benson CT, et al
     A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.
     Diabetes Obes Metab. 2024;26:5474-5478.
     PubMed    
     
     
     
578. GOEAU-BRISSONNIERE M, Rives-Lange C, Phan A, Kourti E, et al
     Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study.
     Diabetes Obes Metab. 2024;26:5488-5491.
     PubMed    
     
     
     
579. KIM TH, Lee K, Park S, Cho H, et al
     Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
     Diabetes Obes Metab. 2024;26:5183-5191.
     PubMed     Abstract available
     
     
     
580. WHELEHAN G, Bello O, Hakim O, Ladwa M, et al
     Ethnic differences in the relationship between ectopic fat deposition and insulin sensitivity in Black African and White European men across a spectrum of glucose tolerance.
     Diabetes Obes Metab. 2024;26:5211-5221.
     PubMed     Abstract available
     
     
     
581. SHEN TH, Aby ES, Vock D, Farley JF, et al
     Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.
     Diabetes Obes Metab. 2024;26:5116-5125.
     PubMed     Abstract available
     
     
     
582. SELBY NM, Taal MW
     What every clinician needs to know about chronic kidney disease: Detection, classification and epidemiology.
     Diabetes Obes Metab. 2024;26 Suppl 6:3-12.
     PubMed     Abstract available
     
     
     
583. BAKRIS G
     Mineralocorticoid receptor antagonists and reno-protection: What's the evidence & where do they fit? A guide for non-specialists.
     Diabetes Obes Metab. 2024;26 Suppl 6:33-42.
     PubMed     Abstract available
     
     
     
584. MAYNE KJ, Hanlon P, Lees JS
     Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.
     Diabetes Obes Metab. 2024;26 Suppl 6:43-54.
     PubMed     Abstract available
     
     
     October 2024
585. MA J, Dong Y, Liu J, Gao S, et al
     The role of GRB2 in diabetes, diabetes complications and related disorders.
     Diabetes Obes Metab. 2024 Oct 30. doi: 10.1111/dom.16015.
     PubMed     Abstract available
     
     
     
586. DAI N, Su X, Wang Y
     Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China.
     Diabetes Obes Metab. 2024 Oct 30. doi: 10.1111/dom.16031.
     PubMed     Abstract available
     
     
     
587. YU XF, Lim CED, Chen H
     The role of vitamin D in glycaemic control in patients with type 2 diabetes-A pilot D4D trial.
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16023.
     PubMed    
     
     
     
588. PRATTICHIZZO F, Veronesi V, Rigoni M, La Grotta R, et al
     Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study.
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16038.
     PubMed     Abstract available
     
     
     
589. HTUN HL, Lian W, Phua HP, Lim MY, et al
     Visit-to-visit HbA1c variability and risk of potentially avoidable hospitalisations in adults with type 2 diabetes receiving outpatient care at a tertiary hospital.
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16026.
     PubMed     Abstract available
     
     
     
590. WASEHUUS V, Rotbain Curovic V, Tofte N, Lindhardt M, et al
     Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16037.
     PubMed     Abstract available
     
     
     
591. ISMAIL HM, Liu J, Netherland M Jr, Hasan NA, et al
     Safety and effects of acetylated and butyrylated high-amylose maize starch on youths recently diagnosed with type 1 diabetes: A pilot study.
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16039.
     PubMed    
     
     
     
592. DONG Q, Xi Y, Brandmaier S, Fuchs M, et al
     Subphenotypes of adult-onset diabetes: Data-driven clustering in the population-based KORA cohort.
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16022.
     PubMed     Abstract available
     
     
     
593. HORIKAWA C, Takahara M, Katakami N, Takeda Y, et al
     Dietary potassium intake and its interaction with sodium intake on risk of developing cardiovascular disease in persons with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 12).
     Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16035.
     PubMed     Abstract available
     
     
     
594. ANDERSEN LL, Calatayud J, Nunez-Cortes R, Polo-Lopez A, et al
     Graded association of muscle strength with all-cause and cause-specific mortality in older adults with diabetes: Prospective cohort study across 28 countries.
     Diabetes Obes Metab. 2024 Oct 23. doi: 10.1111/dom.16019.
     PubMed     Abstract available
     
     
     
595. QIAN XX
     BreathSpec holds potential suitability for real-time detection of halitosis-associated volatile organic compounds in diabetes and other diseases.
     Diabetes Obes Metab. 2024 Oct 22. doi: 10.1111/dom.16032.
     PubMed    
     
     
     
596. DAI J, Chang J, Choi JM, Bullock A, et al
     Trends in anti-diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009-2013.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16021.
     PubMed     Abstract available
     
     
     
597. FAN X, Liu Y, Chen X, Xu Y, et al
     Synergies between diabetes and hyperhomocysteinaemia: New insights to predict and prevent adverse cardiovascular effects.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.15947.
     PubMed     Abstract available
     
     
     
598. FRIIS BRYDE NIELSEN C, Moller Thysen S, Bach Kampmann F, Hansen TW, et al
     The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16025.
     PubMed     Abstract available
     
     
     
599. CARLSSON LMS, Carlsson B, Jacobson P, Andersson-Assarsson JC, et al
     Association between delay in diabetes development and mortality in people with obesity: Up to 33 years follow-up of the prospective Swedish Obese Subjects study.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16010.
     PubMed     Abstract available
     
     
     
600. GAO L, Bian F, Pan T, Jiang H, et al
     Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16014.
     PubMed     Abstract available
     
     
     
601. ZHANG L, Shen Y, Liu H, Li W, et al
     Body mass index trajectories and time in target range after delivery and long-term type 2 diabetes risk in women with a history of gestational diabetes mellitus.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16020.
     PubMed     Abstract available
     
     
     
602. CHENG YW, Chan YH, Chuang C, Chen SW, et al
     Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium-glucose cotransporter-2 inhibitor therapy: A multicentre database analysis in Taiwan.
     Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16011.
     PubMed     Abstract available
     
     
     
603. CHEN HL, Wang IT, Tsai YW, Lee YH, et al
     Superior benefits of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors for diabetic kidney disease: A cohort study.
     Diabetes Obes Metab. 2024 Oct 18. doi: 10.1111/dom.15998.
     PubMed     Abstract available
     
     
     
604. GOURDY P, Bonadonna RC, Mauricio D, Muller-Wieland D, et al
     Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive individuals according to diabetes duration: Results from the REALI European pooled data analysis.
     Diabetes Obes Metab. 2024 Oct 17. doi: 10.1111/dom.16008.
     PubMed     Abstract available
     
     
     
605. RODRIGO-CARBO C, Madinaveitia-Nisarre L, Perez-Calahorra S, Gracia-Rubio I, et al
     Low-calorie, high-protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity.
     Diabetes Obes Metab. 2024 Oct 17. doi: 10.1111/dom.16013.
     PubMed     Abstract available
     
     
     
606. AMIN NB, Frederich R, Tsamandouras N, Haggag AZ, et al
     Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
     Diabetes Obes Metab. 2024 Oct 16. doi: 10.1111/dom.16005.
     PubMed     Abstract available
     
     
     
607. LIU M, Pei J, Zeng C, Xin Y, et al
     Association of non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus: Evidence from the ACCORD cohort.
     Diabetes Obes Metab. 2024 Oct 16. doi: 10.1111/dom.16018.
     PubMed     Abstract available
     
     
     
608. ROTBAIN CUROVIC V, Stougaard EB, Hansen TW
     Slowing the progression of diabetic and non-diabetic kidney disease: A summary of the current evidence base for sodium-glucose co-transporter-2 inhibitors.
     Diabetes Obes Metab. 2024 Oct 15. doi: 10.1111/dom.16007.
     PubMed     Abstract available
     
     
     
609. OSTROMINSKI JW, Cho SMJ, Vaduganathan M, Honigberg MC, et al
     Cause-specific death in adults with type 1 diabetes and type 2 diabetes: Insights from the UK Biobank.
     Diabetes Obes Metab. 2024 Oct 14. doi: 10.1111/dom.16009.
     PubMed    
     
     
     
610. DOVER AR, Wright RJ, Forbes S, Strachan MWJ, et al
     Change in glycated haemoglobin in adults with type 2 diabetes on basal-bolus insulin regimens following commencement of Freestyle Libre use.
     Diabetes Obes Metab. 2024 Oct 10. doi: 10.1111/dom.16003.
     PubMed    
     
     
     
611. DICKER D, Pinto D, Reges O
     Metformin continuation post-metabolic bariatric surgery and relapse of diabetes.
     Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15962.
     PubMed     Abstract available
     
     
     
612. BELL DSH, Jerkins T
     Diabetic Charcot neuroarthropathy: A threat to both limb and life.
     Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15994.
     PubMed     Abstract available
     
     
     
613. DAVIS GM, Peters AL, Bode BW, Carlson AL, et al
     Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod(R) 5 automated insulin delivery system.
     Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15993.
     PubMed     Abstract available
     
     
     
614. ZHENG C, Wu J, Li N, Wei X, et al
     Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States.
     Diabetes Obes Metab. 2024 Oct 8. doi: 10.1111/dom.15997.
     PubMed     Abstract available
     
     
     
615. HONG JH, Kim MJ, Min KW, Won JC, et al
     Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
     Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15985.
     PubMed     Abstract available
     
     
     
616. KONG X, Wang W
     Prevalence of individuals with diabetes and chronic kidney disease indicated for finerenone treatment in the United States: A National Health and Nutrition Examination Survey-based estimation.
     Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.16006.
     PubMed    
     
     
     
617. HERMANNS N, Ehrmann D, Kulzer B, Klinker L, et al
     Somatic and mental symptoms associated with dysglycaemia, diabetes-related complications and mental conditions in people with diabetes: Assessments in daily life using continuous glucose monitoring and ecological momentary assessment.
     Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15983.
     PubMed     Abstract available
     
     
     
618. KARAKUS KE, Mason E, Akturk HK
     Long-term glycaemic improvement with the initiation of an automated insulin delivery system in insulin pump-naive older adults with type 1 diabetes.
     Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15996.
     PubMed    
     
     
     
619. ZHU Y, Liu J, Wang B
     Integrated approach of machine learning, Mendelian randomization and experimental validation for biomarker discovery in diabetic nephropathy.
     Diabetes Obes Metab. 2024 Oct 6. doi: 10.1111/dom.15933.
     PubMed     Abstract available
     
     
     
620. WONG BWX, Tan DYZ, Li LJ, Yong EL, et al
     Individual and combined effects of muscle strength and visceral adiposity on incident prediabetes and type 2 diabetes in a longitudinal cohort of midlife Asian women.
     Diabetes Obes Metab. 2024 Oct 4. doi: 10.1111/dom.15995.
     PubMed     Abstract available
     
     
     
621. YUAN X, Li D, Wang K, Lauand F, et al
     iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study.
     Diabetes Obes Metab. 2024 Oct 3. doi: 10.1111/dom.15968.
     PubMed     Abstract available
     
     
     
622. SOURIJ H, Azhar K, Aziz F, Kojzar H, et al
     Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT study.
     Diabetes Obes Metab. 2024 Oct 3. doi: 10.1111/dom.15988.
     PubMed     Abstract available
     
     
     
623. CHEN W, Liu L, Hu F
     Efficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: An updated systematic review and meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2024 Oct 2. doi: 10.1111/dom.15941.
     PubMed     Abstract available
     
     
     
624. LE TN, Bright R, Truong VK, Li J, et al
     Key biomarkers in type 2 diabetes patients: A systematic review.
     Diabetes Obes Metab. 2024 Oct 2. doi: 10.1111/dom.15991.
     PubMed     Abstract available
     
     
     
625. BANO A, Kunzler J, Wehrli F, Kastrati L, et al
     Clinical evidence for high-risk CE-marked medical devices for glucose management: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024;26:4753-4766.
     PubMed     Abstract available
     
     
     
626. CZUPRYNIAK L, Mosenzon O, Rychlik I, Clodi M, et al
     Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.
     Diabetes Obes Metab. 2024;26:4165-4177.
     PubMed     Abstract available
     
     
     
627. LI T, Sang M, Wang J, Sun Z, et al
     Dark tea consumption is associated with a reduced risk of dysglycaemia and increased urinary glucose and sodium excretion in Chinese adults.
     Diabetes Obes Metab. 2024;26:4705-4712.
     PubMed     Abstract available
     
     
     
628. KASSEM S, Khalaila B, Stein N, Saliba W, et al
     Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data.
     Diabetes Obes Metab. 2024;26:4646-4652.
     PubMed     Abstract available
     
     
     
629. HASHIMOTO H, Satoh M, Nakayama S, Toyama M, et al
     Comparison of renal prognosis between dipeptidyl peptidase-4 inhibitor users and non-users.
     Diabetes Obes Metab. 2024;26:4460-4467.
     PubMed     Abstract available
     
     
     
630. LU Y, Tang H, Kotecha P, Cho H, et al
     Newer glucose-lowering drugs and risk of suicidal ideation and behaviours: A network meta-analysis of randomized outcome trials.
     Diabetes Obes Metab. 2024;26:4783-4786.
     PubMed    
     
     
     
631. JIMBA T, Kaneko H, Azegami T, Suzuki Y, et al
     Body weight change associated kidney outcomes of sodium-glucose cotransporter new users.
     Diabetes Obes Metab. 2024;26:4535-4543.
     PubMed     Abstract available
     
     
     
632. FORST T, De Block C, Del Prato S, Armani S, et al
     The role of incretin receptor agonists in the treatment of obesity.
     Diabetes Obes Metab. 2024;26:4178-4196.
     PubMed     Abstract available
     
     
     
633. HUANG P, Zhu Y, Qin J
     Research advances in understanding crosstalk between organs and pancreatic beta-cell dysfunction.
     Diabetes Obes Metab. 2024;26:4147-4164.
     PubMed     Abstract available
     
     
     
634. JOHNSON CE, Sussman WB, Weeda ER
     Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.
     Diabetes Obes Metab. 2024;26:4544-4550.
     PubMed     Abstract available
     
     
     
635. PATEL PM, Thomas D, Liu Z, Aldrich-Renner S, et al
     Systematic review of disparities in continuous glucose monitoring and insulin pump utilization in the United States: Key themes and evidentiary gaps.
     Diabetes Obes Metab. 2024;26:4293-4301.
     PubMed     Abstract available
     
     
     
636. TKAC I, Kozarova M, Stancakova Yaluri A, Javorsky M, et al
     Treatment with sodium-glucose cotransporter 2 inhibitors and risk of lower-limb amputations.
     Diabetes Obes Metab. 2024;26:4803-4805.
     PubMed    
     
     
     
637. NAGENDRA L, Dutta D, Kamrul-Hasan ABM
     Bariatric surgery and tirzepatide-Friends, not foes!
     Diabetes Obes Metab. 2024;26:4806.
     PubMed    
     
     
     
638. MATTHEWS DR
     Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.
     Diabetes Obes Metab. 2024;26 Suppl 5:3-4.
     PubMed    
     
     
     
639. NYSTROM T
     Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk.
     Diabetes Obes Metab. 2024;26 Suppl 5:35-57.
     PubMed     Abstract available
     
     
     
640. LI S, Yang B, Shang S, Jiang W, et al
     Association of hypertension and long-term blood pressure changes with new-onset diabetes in the elderly: A 10-year cohort study.
     Diabetes Obes Metab. 2024 Oct 1. doi: 10.1111/dom.15986.
     PubMed     Abstract available
     
     
     September 2024
641. KHIAR H, Leveque E, Lopez AG, Moreau-Grange L, et al
     Serum levels of the incretin-like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa-Ba-S study.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15871.
     PubMed     Abstract available
     
     
     
642. IWAMOTO Y, Kimura T, Dan K, Iwamoto H, et al
     Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic beta-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15972.
     PubMed     Abstract available
     
     
     
643. HANNAH K, Nemlekar P, Bushman JS, Norman GJ, et al
     Risk of hypoglycaemia among people with type 2 diabetes not treated with insulin: A retrospective analysis of Medicare Advantage beneficiaries.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15982.
     PubMed     Abstract available
     
     
     
644. LI H, Su W, Zheng Z, Li J, et al
     The coexistence of low muscle mass and obesity evaluated by dual energy X-ray absorptiometry, rather than low muscle mass or obesity alone, is associated with macrovascular but not microvascular complications in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15978.
     PubMed     Abstract available
     
     
     
645. DYER BP, Burton C, Rathod-Mistry T, Blagojevic-Bucknall M, et al
     Are patients with newly diagnosed frozen shoulder more likely to be diagnosed with type 2 diabetes? A cohort study in UK electronic health records.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15965.
     PubMed     Abstract available
     
     
     
646. SADEGHI S, Hosseinpanah F, Khalaj A, Ebadinejad A, et al
     Remission and relapse of diabetes after sleeve gastrectomy and one-anastomosis gastric bypass: The Tehran Obesity Treatment Study.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15974.
     PubMed     Abstract available
     
     
     
647. HU S, Wang S, Gu S, Qi C, et al
     Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15973.
     PubMed     Abstract available
     
     
     
648. SHAN S, Luo Z, Yao L, Zhou J, et al
     Cross-country inequalities in disease burden and care quality of chronic kidney disease due to type 2 diabetes mellitus, 1990-2021: Findings from the global burden of disease study 2021.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15969.
     PubMed     Abstract available
     
     
     
649. KARAKASIS P, Koufakis T, Patoulias D, Barkas F, et al
     Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15979.
     PubMed     Abstract available
     
     
     
650. LI P, Spector E, Alkhuzam K, Patel R, et al
     Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15987.
     PubMed     Abstract available
     
     
     
651. MAFFEIS C, Piona C, Morandi A, Marigliano M, et al
     Glycaemic control metrics and metabolic dysfunction-associated steatotic liver disease in children and adolescents with type 1 diabetes.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15961.
     PubMed     Abstract available
     
     
     
652. GROBMAN B, Mansur A, Lu CY
     Disparities in suicide rates among patients with diabetes in the United States.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15989.
     PubMed    
     
     
     
653. JIANG H, Zhang K, Zhang X
     Mendelian randomization analysis of the association between childhood overweight or obesity and gestational diabetes mellitus.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15975.
     PubMed     Abstract available
     
     
     
654. WATADA H, Asbjornsdottir B, Nishida T, Nishimura R, et al
     Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15960.
     PubMed     Abstract available
     
     
     
655. MARUYAMA-SAKURAI K, Tachimori H, Saito E, Kohsaka S, et al
     Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15832.
     PubMed     Abstract available
     
     
     
656. KIILAVUORI M, Varimo T, Tuomaala AK, Pulkkinen MA, et al
     Children and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system.
     Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15992.
     PubMed     Abstract available
     
     
     
657. LI J, Cui HL, Xie DD, Wang QY, et al
     Global and regional estimates of hip fracture burden associated with type 1 diabetes from 1990 to 2021.
     Diabetes Obes Metab. 2024 Sep 26. doi: 10.1111/dom.15970.
     PubMed     Abstract available
     
     
     
658. CASTANEDA J, de Galan BE, van Kuijk SMJ, Arrieta A, et al
     The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery.
     Diabetes Obes Metab. 2024 Sep 26. doi: 10.1111/dom.15955.
     PubMed     Abstract available
     
     
     
659. ELKABBANY ZA, Ismail EAR, Hamed ET, Elbarbary NS, et al
     The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: A randomized controlled trial.
     Diabetes Obes Metab. 2024 Sep 24. doi: 10.1111/dom.15958.
     PubMed     Abstract available
     
     
     
660. REN Q, Li L, Su X, Hu X, et al
     Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.
     Diabetes Obes Metab. 2024 Sep 23. doi: 10.1111/dom.15915.
     PubMed     Abstract available
     
     
     
661. REIS-BARBOSA PH, Aguila MB, Mandarim-de-Lacerda CA
     Tirzepatide, a dual receptor agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, enhances beta-cell survival and maintenance markers in obese diabetic ovariectomized mice.
     Diabetes Obes Metab. 2024 Sep 22. doi: 10.1111/dom.15937.
     PubMed    
     
     
     
662. RAZAGHIZAD A, Ni J, Marques P, Mavrakanas TA, et al
     Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.
     Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15768.
     PubMed     Abstract available
     
     
     
663. MACLEISH SA, Hood KK, Polonsky WH, Wood JR, et al
     Psychosocial outcomes with the Omnipod(R) 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.
     Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15906.
     PubMed     Abstract available
     
     
     
664. LIU Y, Chen Y, Lam SHM, Huang B, et al
     Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA-AF registry phase III.
     Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15950.
     PubMed     Abstract available
     
     
     
665. HENNIES N, Gorgens SW, Killer J, Otto T, et al
     Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study.
     Diabetes Obes Metab. 2024 Sep 19. doi: 10.1111/dom.15931.
     PubMed     Abstract available
     
     
     
666. STENBERG E, Cao Y, Ottosson J, Hedberg S, et al
     Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15952.
     PubMed     Abstract available
     
     
     
667. WIEGAND S, Becker M, Schmid S, Weghuber D, et al
     Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German-speaking countries: Analysis based on the Diabetes Prospective Follow-up Registry.
     Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15930.
     PubMed    
     
     
     
668. ZHANG TY, Zhang ZM, Wang XN, Kuang HY, et al
     Relationship between weight-adjusted-waist index and all-cause and cardiovascular mortality in individuals with type 2 diabetes.
     Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15929.
     PubMed     Abstract available
     
     
     
669. NICOLIER C, Kunzler J, Lizoain A, Kerber D, et al
     Detection of hypoglycaemia in type 1 diabetes through breath volatile organic compound profiling using gas chromatography-ion mobility spectrometry.
     Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15944.
     PubMed     Abstract available
     
     
     
670. POTTEGARD A, Andersen JH, Sondergaard J, Rasmussen L, et al
     Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.
     Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15912.
     PubMed     Abstract available
     
     
     
671. JI L, Lu Y, Shen Z, Hu P, et al
     Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
     Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15888.
     PubMed     Abstract available
     
     
     
672. TABESH M, Sacre JW, Mehta K, Chen L, et al
     The association of glycaemic risk factors and diabetes duration with risk of heart failure in people with type 2 diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Sep 13. doi: 10.1111/dom.15938.
     PubMed     Abstract available
     
     
     
673. GARG SK, Hirsch IB, Repetto E, Snell-Bergeon J, et al
     Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis.
     Diabetes Obes Metab. 2024 Sep 12. doi: 10.1111/dom.15866.
     PubMed     Abstract available
     
     
     
674. LUNDHOLM MD, Kirschling S, Hu B, Aminian A, et al
     Long-term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction-associated fatty liver disease in adults with obesity and type 2 diabetes.
     Diabetes Obes Metab. 2024 Sep 12. doi: 10.1111/dom.15932.
     PubMed    
     
     
     
675. GUO J, Tang H, Shao H, Lu Y, et al
     Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Sep 10. doi: 10.1111/dom.15943.
     PubMed     Abstract available
     
     
     
676. PIKKEMAAT M, Woodward M, Af Geijerstam P, Harrap S, et al
     Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study.
     Diabetes Obes Metab. 2024 Sep 10. doi: 10.1111/dom.15935.
     PubMed     Abstract available
     
     
     
677. LONG W, Light PE, Simpson SH
     Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study.
     Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15917.
     PubMed     Abstract available
     
     
     
678. KELLY MS, Scopelliti EM, Goodson KE, Lo CMA, et al
     Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15934.
     PubMed     Abstract available
     
     
     
679. PAI YW, Chen IC, Lin JF, Chen XH, et al
     Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
     Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15918.
     PubMed     Abstract available
     
     
     
680. MAYER CS, Fontelo P
     Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.
     Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15911.
     PubMed     Abstract available
     
     
     
681. HALUZIK M, Al-Sofiani ME, Cheng AYY, Lauand F, et al
     Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
     Diabetes Obes Metab. 2024 Sep 8. doi: 10.1111/dom.15811.
     PubMed     Abstract available
     
     
     
682. PUNTHAKEE Z, Hall S, McInnes N, Sherifali D, et al
     Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
     Diabetes Obes Metab. 2024 Sep 6. doi: 10.1111/dom.15926.
     PubMed     Abstract available
     
     
     
683. WANG S, Song S, Gao J, Duo Y, et al
     Glycated haemoglobin variability and risk of renal function decline in type 2 diabetes mellitus: An updated systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15861.
     PubMed     Abstract available
     
     
     
684. VAN DEN HEUVEL T, Castaneda J, Arrieta A, Voelker B, et al
     Generating real-world evidence on diabetes technology using the CareLink Personal data management system.
     Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15868.
     PubMed     Abstract available
     
     
     
685. CHEN MD, Deng CF, Chen PF, Li A, et al
     Non-invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15916.
     PubMed     Abstract available
     
     
     
686. VAN HULTEN V, Driessen JHM, Andersen S, Kvist A, et al
     Fracture risk revisited: Bone mineral density T-score and fracture risk in type 2 diabetes.
     Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15890.
     PubMed     Abstract available
     
     
     
687. FU L, Cheng H, Xiong J, Xiao P, et al
     Mediating role of inflammatory biomarkers in the causal effect of body composition on glycaemic traits and type 2 diabetes.
     Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15923.
     PubMed     Abstract available
     
     
     
688. MEHROTRA-VARMA S, Lu JY, Boparai MS, Henry S, et al
     Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: Up to 40 months' follow-up.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15900.
     PubMed     Abstract available
     
     
     
689. ARAI T, Atsukawa M, Tsubota A, Oikawa T, et al
     Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15898.
     PubMed     Abstract available
     
     
     
690. VAN HULTEN V, Souverein PC, Starup-Linde J, Viggers R, et al
     The association of type 2 diabetes-related characteristics with fracture risk at different sites.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15884.
     PubMed     Abstract available
     
     
     
691. JEONG IK, Choi KM, Han KA, Kim KA, et al
     Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15838.
     PubMed     Abstract available
     
     
     
692. KAFAI YAHYAVI S, Kristensen PL, Hjorthoj C, Hansen KB, et al
     The use of composite endpoints in cardiovascular outcome trials for diabetes: A review of 22 randomized clinical trials published since 2008.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15907.
     PubMed     Abstract available
     
     
     
693. BASU A, Montano-Campos F, Huang ES, Laiteerapong N, et al
     Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15878.
     PubMed     Abstract available
     
     
     
694. GIUGLIANO D, Esposito K, De Nicola L
     Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15892.
     PubMed    
     
     
     
695. SRIDHAR VS, Cosentino F, Dagogo-Jack S, McGuire DK, et al
     Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
     Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15895.
     PubMed     Abstract available
     
     
     
696. LIANG G, Lai M, Wang Y, Li N, et al
     Decreased complexity of glucose time series index associated with adverse pregnancy outcomes in gestational diabetes mellitus.
     Diabetes Obes Metab. 2024;26:3587-3596.
     PubMed     Abstract available
     
     
     
697. RASMUSSEN DGK, Hansen MK, Frederiksen P, Luo Y, et al
     Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.
     Diabetes Obes Metab. 2024;26:4060-4068.
     PubMed     Abstract available
     
     
     
698. PALMIOTTI A, Berk KA, Koehorst M, Hovingh MV, et al
     Reversal of insulin resistance in people with obesity by lifestyle-induced weight loss does not impact the proportion of circulating 12alpha-hydroxylated bile acids.
     Diabetes Obes Metab. 2024;26:4019-4029.
     PubMed     Abstract available
     
     
     
699. CARDOZA K, Kang A, Smyth B, Yi TW, et al
     Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
     Diabetes Obes Metab. 2024;26:3530-3540.
     PubMed     Abstract available
     
     
     
700. PELEKANOU C, Anastasiou CA, Mavrogianni C, Cardon G, et al
     Physical activity in relation to metabolic health and obesity: The Feel4Diabetes study.
     Diabetes Obes Metab. 2024;26:3705-3714.
     PubMed     Abstract available
     
     
     
701. XUAN X, Zhang Y, Song Y, Zhang B, et al
     Role of protein arginine methyltransferase 1 in obesity-related metabolic disorders: Research progress and implications.
     Diabetes Obes Metab. 2024;26:3491-3500.
     PubMed     Abstract available
     
     
     
702. DASH S
     Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.
     Diabetes Obes Metab. 2024;26 Suppl 4:3-15.
     PubMed     Abstract available
     
     
     
703. NEELAND IJ, Linge J, Birkenfeld AL
     Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
     Diabetes Obes Metab. 2024;26 Suppl 4:16-27.
     PubMed     Abstract available
     
     
     August 2024
704. LIARAKOS AL, Crabtree TSJ, Wilmot EG
     Patient-reported outcomes in studies of diabetes technology: What matters.
     Diabetes Obes Metab. 2024 Aug 31. doi: 10.1111/dom.15858.
     PubMed     Abstract available
     
     
     
705. LASSEN MCH, Johansen ND, Modin D, Catarig AM, et al
     Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.
     Diabetes Obes Metab. 2024 Aug 31. doi: 10.1111/dom.15872.
     PubMed     Abstract available
     
     
     
706. YEN YH, Yen FS, Ko FS, Wei JC, et al
     Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan.
     Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15908.
     PubMed     Abstract available
     
     
     
707. XU W, Wang Y, Tanuseputro P, Lam CLK, et al
     Optimizing physician-encounter frequency for type 2 diabetes patients in primary care based on cardiovascular risk assessment: A target trial emulation study.
     Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15899.
     PubMed     Abstract available
     
     
     
708. DAVIDSON MB
     Glycaemic treatment of newly diagnosed type 2 diabetes.
     Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15904.
     PubMed    
     
     
     
709. HIRSCH IB, Parkin CG, Cavaiola TS, Bergenstal RM, et al
     Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes.
     Diabetes Obes Metab. 2024 Aug 28. doi: 10.1111/dom.15883.
     PubMed     Abstract available
     
     
     
710. STEENACKERS N, Sparso T, Charleer S, De Block C, et al
     Health-related quality of life of people with type 1 diabetes: An IMI2 SOPHIA post hoc analysis of FUTURE and ADJUNCT-ONE.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15886.
     PubMed     Abstract available
     
     
     
711. SHARMA A, Mariam A, Zacherle E, Milinovich A, et al
     Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15896.
     PubMed     Abstract available
     
     
     
712. JIANG L, Lai J, Xu X, Lu Y, et al
     Reduced insulin clearance in paediatric metabolic (dysfunction)-associated fatty liver disease and its dual role in beta-cell offload and diabetes risk.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15902.
     PubMed     Abstract available
     
     
     
713. AO Y, Ye H, Liu X, Li Y, et al
     Fish oil supplementation in relation to the risk of chronic kidney disease among patients with diabetes.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15880.
     PubMed     Abstract available
     
     
     
714. DEJGAARD TF, Frandsen CS, Kielgast U, Storling J, et al
     Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15889.
     PubMed     Abstract available
     
     
     
715. TANDAY N, Zhu W, Tarasov AI, Flatt PR, et al
     [P(3)]PP, a stable, long-acting pancreatic polypeptide analogue, evokes weight lowering and pancreatic beta-cell-protective effects in obesity-associated diabetes.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15897.
     PubMed     Abstract available
     
     
     
716. WANG J, Yang J, Jiang W, Liu W, et al
     Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
     Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15860.
     PubMed     Abstract available
     
     
     
717. HUANG YN, Liao WL, Huang JY, Lin YJ, et al
     Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
     Diabetes Obes Metab. 2024 Aug 22. doi: 10.1111/dom.15869.
     PubMed     Abstract available
     
     
     
718. THABIT H, Rubio J, Karuppan M, Mubita W, et al
     Use of real-time continuous glucose monitoring in non-critical care insulin-treated inpatients under non-diabetes speciality teams in hospital: A pilot randomized controlled study.
     Diabetes Obes Metab. 2024 Aug 21. doi: 10.1111/dom.15885.
     PubMed    
     
     
     
719. ZHOU Y, Liu S, Zhang Q, Zhang S, et al
     Bidirectional association between type 2 diabetes and irritable bowel syndrome: A large-scale prospective cohort study.
     Diabetes Obes Metab. 2024 Aug 20. doi: 10.1111/dom.15852.
     PubMed     Abstract available
     
     
     
720. RASMUSSEN L, Andersen JH, Karlstad O, Giunta DH, et al
     Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
     Diabetes Obes Metab. 2024 Aug 20. doi: 10.1111/dom.15876.
     PubMed    
     
     
     
721. SAETANG T, Greeviroj P, Thavaraputta S, Santisitthanon P, et al
     The effectiveness of telemonitoring and integrated personalized diabetes management in people with insulin-treated type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15870.
     PubMed     Abstract available
     
     
     
722. GAN X, Ye Z, Zhang Y, He P, et al
     Sweetened beverages and atrial fibrillation in people with prediabetes or diabetes.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15859.
     PubMed     Abstract available
     
     
     
723. HORTON WB, Dart ME, Kavuru VS, Girton MR, et al
     Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost-effectiveness analysis.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15873.
     PubMed    
     
     
     
724. WANG Y, Chin WY, Lam CLK, Wan EYF, et al
     Trajectory of haemoglobin A1c and incidence of cardiovascular disease in patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15856.
     PubMed     Abstract available
     
     
     
725. FARZANBAKHSH S, Amini MR, Madani H, Sadri B, et al
     Safety evaluation of bi-layered allogenic keratinocyte and fibroblast skin substitute for diabetic foot ulcers-SAFESKIN-DFU: A Phase 1 clinical trial.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15843.
     PubMed     Abstract available
     
     
     
726. ASTBURY NM
     Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15855.
     PubMed     Abstract available
     
     
     
727. JI L, Gao L, Feng Z, Chen G, et al
     The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15862.
     PubMed    
     
     
     
728. MU Y
     The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
     Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15857.
     PubMed    
     
     
     
729. INOUE M, Sakanaka A, Katakami N, Furuno M, et al
     Periodontal tissue susceptibility to glycaemic control in type 2 diabetes.
     Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15835.
     PubMed     Abstract available
     
     
     
730. RITTENHOUSE BE, Alolayan S, Eguale T, Segal AR, et al
     Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was.
     Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15851.
     PubMed     Abstract available
     
     
     
731. CHEN TY, Lee HF, Chan YH, Chuang C, et al
     Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching National Cohort Study.
     Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15804.
     PubMed     Abstract available
     
     
     
732. KOTECHA P, Chen W, Donahoo WT, Jaffee M, et al
     Continuous glucose monitoring and all-cause mortality in insulin-using population with diabetes and cognitive impairment.
     Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15842.
     PubMed    
     
     
     
733. TSABAN G, Aharon-Hananel G, Shalem S, Zelicha H, et al
     The effect of Mankai plant consumption on postprandial glycaemic response among patients with type 2 diabetes: A randomized crossover trial.
     Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15840.
     PubMed     Abstract available
     
     
     
734. BOLDUC ME, Potter KJ, Olmos M, Bonhoure A, et al
     Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance.
     Diabetes Obes Metab. 2024 Aug 9. doi: 10.1111/dom.15844.
     PubMed     Abstract available
     
     
     
735. YALE JF, Major-Pedersen A, Catarig AM, Jain R, et al
     Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.
     Diabetes Obes Metab. 2024 Aug 8. doi: 10.1111/dom.15794.
     PubMed     Abstract available
     
     
     
736. GOLL N, Moszka N, Kantartzis K, Preissl H, et al
     Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes.
     Diabetes Obes Metab. 2024 Aug 8. doi: 10.1111/dom.15812.
     PubMed     Abstract available
     
     
     
737. REIS-BARBOSA PH, Marcondes-de-Castro I, Marinho TS, Aguila MB, et al
     The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
     Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15820.
     PubMed     Abstract available
     
     
     
738. CHU L, Bradley RM, Auerbach P, Abitbol A, et al
     Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor:
     Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15834.
     PubMed     Abstract available
     
     
     
739. WANG Z, Lu J
     Adapting study designs of Mendelian randomization for disease complications: Insights from type 1 diabetes complications research.
     Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15813.
     PubMed    
     
     
     
740. ANDERSEN G, Eloy R, Heise T, Gaudier M, et al
     ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.
     Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15827.
     PubMed     Abstract available
     
     
     
741. WAN EYF, Wong ZCT, Yan VKC, Chui CSL, et al
     Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
     Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15830.
     PubMed     Abstract available
     
     
     
742. HENNEY AE, Riley DR, Heague M, Hydes TJ, et al
     Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.
     Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15833.
     PubMed     Abstract available
     
     
     
743. HOLMAN N, Young B, Gregg EW, Wareham N, et al
     Trends in hospitalization for cardio-renal disease and mortality in people with type 1 diabetes in England, 2009-2019.
     Diabetes Obes Metab. 2024 Aug 5. doi: 10.1111/dom.15783.
     PubMed     Abstract available
     
     
     
744. MAJIC TENGG A, Cigrovski Berkovic M
     Immune checkpoint inhibitor-induced diabetes: Twists and turns of diabetology.
     Diabetes Obes Metab. 2024 Aug 2. doi: 10.1111/dom.15848.
     PubMed    
     
     
     
745. BABA Y, Watanabe S, Hayashi S, Sakai T, et al
     Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Aug 2. doi: 10.1111/dom.15823.
     PubMed    
     
     
     
746. DAVIDSON MB, Davidson SJ
     Real-world evidence for computerized insulin dose-adjustment algorithms in the effective use of continuous glucose monitoring by primary care clinicians.
     Diabetes Obes Metab. 2024;26:3475-3477.
     PubMed    
     
     
     
747. XIE P, Abildlund MT, Baekdal TA, He X, et al
     A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
     Diabetes Obes Metab. 2024;26:3068-3077.
     PubMed     Abstract available
     
     
     
748. TANGRI N, Ferguson TW, Bamforth RJ, Leon SJ, et al
     Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
     Diabetes Obes Metab. 2024;26:3371-3380.
     PubMed     Abstract available
     
     
     
749. CHEUNG JTK, Yang A, Wu H, Lau ESH, et al
     Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability.
     Diabetes Obes Metab. 2024;26:3339-3351.
     PubMed     Abstract available
     
     
     
750. RIESTER MR, Zullo AR, Joshi R, Daiello LA, et al
     Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
     Diabetes Obes Metab. 2024;26:3403-3417.
     PubMed     Abstract available
     
     
     
751. MOHAMMEDI K, Hess S, McQueen M, Pigeyre M, et al
     Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trial.
     Diabetes Obes Metab. 2024;26:3272-3280.
     PubMed     Abstract available
     
     
     
752. HAKARIYA H, Ohnishi M, Tanimoto T
     Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
     Diabetes Obes Metab. 2024;26:3006-3008.
     PubMed    
     
     
     
753. KLONOFF DC, Kim SH, Galindo RJ, Joseph JI, et al
     Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
     Diabetes Obes Metab. 2024;26:3128-3136.
     PubMed     Abstract available
     
     
     
754. CEFALO CMA, Riccio A, Succurro E, Marini MA, et al
     Frequency of prediabetes in individuals with increased adiposity and metabolically healthy or unhealthy phenotypes.
     Diabetes Obes Metab. 2024;26:3191-3199.
     PubMed     Abstract available
     
     
     
755. JONES KL, Marathe CS, Wu T, Rayner CK, et al
     Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure.
     Diabetes Obes Metab. 2024;26:3003-3005.
     PubMed    
     
     
     
756. ASLAM A, Chapman A, Urwin A, Ohol S, et al
     Real-world data from first UK Omnipod 5 users: A single-centre observational study.
     Diabetes Obes Metab. 2024;26:3462-3465.
     PubMed    
     
     
     
757. DIMAKOS J, Cui Y, Platt RW, Renoux C, et al
     Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population-based cohort study.
     Diabetes Obes Metab. 2024;26:3088-3098.
     PubMed     Abstract available
     
     
     
758. BERGENSTAL RM, Philis-Tsimikas A, Wysham C, Carr MC, et al
     Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
     Diabetes Obes Metab. 2024;26:3020-3030.
     PubMed     Abstract available
     
     
     
759. SILVERII GA
     Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes.
     Diabetes Obes Metab. 2024;26 Suppl 3:42-54.
     PubMed     Abstract available
     
     
     
760. SOLINI A, Trico D
     Clinical efficacy and cost-effectiveness of metformin in different patient populations: A narrative review of real-world evidence.
     Diabetes Obes Metab. 2024;26 Suppl 3:20-30.
     PubMed     Abstract available
     
     
     July 2024
761. OULHAJ A, Aziz F, Suliman A, Eller K, et al
     Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
     Diabetes Obes Metab. 2024 Jul 31. doi: 10.1111/dom.15817.
     PubMed     Abstract available
     
     
     
762. CHEN L, Wen B, Liu H, Wu H, et al
     Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study.
     Diabetes Obes Metab. 2024 Jul 29. doi: 10.1111/dom.15814.
     PubMed     Abstract available
     
     
     
763. BAK JCG, de Vries SAG, Serne EH, Groenwold RHH, et al
     Mortality patterns in Dutch diabetes outpatients.
     Diabetes Obes Metab. 2024 Jul 29. doi: 10.1111/dom.15750.
     PubMed     Abstract available
     
     
     
764. MOURA FA, Bellavia A, Berg DD, Melloni GEM, et al
     Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy.
     Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15798.
     PubMed     Abstract available
     
     
     
765. SOLIMAN Y, Everett K, Shulman R, Austin PC, et al
     Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada.
     Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15799.
     PubMed     Abstract available
     
     
     
766. ZHENG K, Azhie A, You X, Naghibzadeh M, et al
     Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.
     Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15769.
     PubMed     Abstract available
     
     
     
767. PARK S, Ballreich J, Ward T, Shi L, et al
     Cost-effectiveness analysis of a digital diabetes-prevention programme versus an in-person diabetes-prevention programme in people with prediabetes in the United States.
     Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15807.
     PubMed     Abstract available
     
     
     
768. CHERUBINI V, Mozzillo E, Iafusco D, Bonfanti R, et al
     Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy.
     Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15779.
     PubMed     Abstract available
     
     
     
769. KWAK SH, Han KA, Kim ES, Choi SH, et al
     Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.
     Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15738.
     PubMed     Abstract available
     
     
     
770. CHAUDHRY K, Karalliedde J
     Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial.
     Diabetes Obes Metab. 2024 Jul 23. doi: 10.1111/dom.15765.
     PubMed     Abstract available
     
     
     
771. SHAMIM MA, Patil AN, Amin U, Roy T, et al
     Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
     Diabetes Obes Metab. 2024 Jul 23. doi: 10.1111/dom.15777.
     PubMed     Abstract available
     
     
     
772. IWAMOTO H, Kimura T, Fushimi Y, Iwamoto M, et al
     Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
     Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15784.
     PubMed     Abstract available
     
     
     
773. REZENDE LFM, de Almeida-Pittito B, Wahrhaftig J, Matos B, et al
     Time trends in hypertension and diabetes prevalence by body mass index categories in Brazilian adults from 2006 to 2023.
     Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15780.
     PubMed     Abstract available
     
     
     
774. SIRIYOTHA S, Lukkunaprasit T, Looareesuwan P, Kunakorntham P, et al
     Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data.
     Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15793.
     PubMed     Abstract available
     
     
     
775. CHEN AX, Fletcher R, Neuen BL, Neal B, et al
     An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15751.
     PubMed     Abstract available
     
     
     
776. LIN DS, Lo HY, Huang KC, Lin TT, et al
     Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.
     Diabetes Obes Metab. 2024 Jul 19. doi: 10.1111/dom.15788.
     PubMed     Abstract available
     
     
     
777. NEUPANE S, Florkowski WJ, Dhakal U, Dhakal C, et al
     Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States.
     Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15797.
     PubMed    
     
     
     
778. ESCOBAR VASCO MA, Fantaye SH, Raghunathan S, Solis-Herrera C, et al
     The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease.
     Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15773.
     PubMed     Abstract available
     
     
     
779. ZHANG YY, Chen BX, Yang Q, Wan Q, et al
     The causal relationship between plasma protein-to-protein ratios and type 2 diabetes and its complications: Proteomics mendelian randomization study.
     Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15792.
     PubMed     Abstract available
     
     
     
780. PIONA C, Passanisi S, Bombaci B, Marigliano M, et al
     Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes.
     Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15791.
     PubMed    
     
     
     
781. ZHAO L, Zeng Q, Zhou X, Tang L, et al
     Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study.
     Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15758.
     PubMed     Abstract available
     
     
     
782. WANG W, Qiao J, Zhang L, Zhang J, et al
     Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: A population-based cross-sectional screening study.
     Diabetes Obes Metab. 2024 Jul 17. doi: 10.1111/dom.15763.
     PubMed     Abstract available
     
     
     
783. LI J, Zhang R, Zhang C, Liu G, et al
     Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age.
     Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15770.
     PubMed    
     
     
     
784. LI J, Sun Y, Yu B, Cai L, et al
     Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status.
     Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15782.
     PubMed     Abstract available
     
     
     
785. RIZZI A, Tartaglione L, Lucaccini Paoli L, Leo ML, et al
     Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
     Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15766.
     PubMed     Abstract available
     
     
     
786. DONG W, Wan EYF, Fong DYT, Tan KC, et al
     Development and validation of 10-year risk prediction models of cardiovascular disease in Chinese type 2 diabetes mellitus patients in primary care using interpretable machine learning-based methods.
     Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15745.
     PubMed     Abstract available
     
     
     
787. SCHAEFER E, Lang A, Kupriyanova Y, Bodis KB, et al
     Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower visceral and hepatic lipid content in recent-onset type 1 diabetes and type 2 diabetes.
     Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15772.
     PubMed     Abstract available
     
     
     
788. CHAN JCN, Yang A, Chu N, Chow E, et al
     Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin.
     Diabetes Obes Metab. 2024 Jul 11. doi: 10.1111/dom.15700.
     PubMed     Abstract available
     
     
     
789. LI W, Qin R, Tang Z, Wang C, et al
     Inhibition of inflammation and apoptosis through the cyclic GMP-AMP synthase-stimulator of interferon genes pathway by stress granules after ALKBH5 demethylase activation during diabetic myocardial ischaemia-reperfusion injury.
     Diabetes Obes Metab. 2024 Jul 11. doi: 10.1111/dom.15743.
     PubMed     Abstract available
     
     
     
790. WEIR MR
     Cardiovascular risk reduction in type 2 diabetes: What the non-specialist needs to know about current guidelines.
     Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15764.
     PubMed     Abstract available
     
     
     
791. KAZIBWE R, Singleton M, Bancks MP, Namutebi J, et al
     Efficacy of Aspirin for primary prevention among adults with high-risk type 2 diabetes in the ACCORD trial.
     Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15753.
     PubMed     Abstract available
     
     
     
792. AL-OZAIRI E, Irshad M, AlKandari J, Mashankar A, et al
     Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
     Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15760.
     PubMed     Abstract available
     
     
     
793. ABBASI M, Heath B, McGinness L
     Advances in metformin-delivery systems for diabetes and obesity management.
     Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15759.
     PubMed     Abstract available
     
     
     
794. DE KLERK JA, Beulens JWJ, Bijkerk R, van Zonneveld AJ, et al
     Circulating small non-coding RNAs are associated with the insulin-resistant and obesity-related type 2 diabetes clusters.
     Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15786.
     PubMed     Abstract available
     
     
     
795. AUZANNEAU M, Seufert J, Zimny S, Haak T, et al
     Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany.
     Diabetes Obes Metab. 2024 Jul 9. doi: 10.1111/dom.15741.
     PubMed    
     
     
     
796. BRIEDITIS E, Li X, Sundquist K, Jansaker F, et al
     Vulvovaginal candidiasis and type 2 diabetes: A nationwide retrospective cohort study.
     Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15757.
     PubMed     Abstract available
     
     
     
797. HOU T, Li Y, Yan Q, Zhou Y, et al
     The interaction effect between BMI, diabetes and age at diabetes onset on the risk of thyroid cancer: A population-based cohort study in Shanghai, China.
     Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15746.
     PubMed     Abstract available
     
     
     
798. 
     Correction to "Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study".
     Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15806.
     PubMed    
     
     
     
799. HAN KA, Hwang YC, Moon SJ, Cho HC, et al
     Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
     Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15717.
     PubMed     Abstract available
     
     
     
800. PETRIE JR
     Metformin beyond type 2 diabetes: Emerging and potential new indications.
     Diabetes Obes Metab. 2024 Jul 4. doi: 10.1111/dom.15756.
     PubMed     Abstract available
     
     
     
801. LI P, Kianmehr H, Guan D, Kulshreshtha A, et al
     Renal function as an effect modifier of intensive glucose control in delaying cognitive function decline among individuals with type 2 diabetes: A revisit to the ACCORD MIND trial.
     Diabetes Obes Metab. 2024 Jul 4. doi: 10.1111/dom.15744.
     PubMed     Abstract available
     
     
     
802. ZHANG D, Zhu J, Wewer Albrechtsen NJ, Rayner CK, et al
     Impairments of insulin and glucagon sensitivity in Chinese women with gestational diabetes mellitus.
     Diabetes Obes Metab. 2024 Jul 3. doi: 10.1111/dom.15740.
     PubMed     Abstract available
     
     
     
803. KHALAFI M, Habibi Maleki A, Symonds ME, Rosenkranz SK, et al
     The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Jul 2. doi: 10.1111/dom.15730.
     PubMed     Abstract available
     
     
     
804. SUN M, Lu Z, Chen WM, Lv S, et al
     Metformin monotherapy versus predominantly older non-metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management.
     Diabetes Obes Metab. 2024 Jul 2. doi: 10.1111/dom.15739.
     PubMed     Abstract available
     
     
     
805. CHANG ML, Tai J, Cheng JS, Chen WT, et al
     Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.
     Diabetes Obes Metab. 2024;26:2969-2978.
     PubMed     Abstract available
     
     
     
806. ALMEIDA OP, Fong Z, Hill Almeida LM, Sanfilippo FM, et al
     Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
     Diabetes Obes Metab. 2024;26:2925-2932.
     PubMed     Abstract available
     
     
     
807. WHITE T, Selvarajah V, Wolfhagen-Sand F, Svangard N, et al
     Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
     Diabetes Obes Metab. 2024;26:2722-2731.
     PubMed     Abstract available
     
     
     
808. ZHANG J, Xu S, Liu X, Zhang J, et al
     Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.
     Diabetes Obes Metab. 2024;26:2752-2760.
     PubMed     Abstract available
     
     
     
809. BUTTICE L, Ghani M, Suthakar J, Gnanalingham S, et al
     The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2024;26:2706-2721.
     PubMed     Abstract available
     
     
     
810. GOLDENBERG RM
     A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
     Diabetes Obes Metab. 2024;26:2997-2999.
     PubMed    
     
     
     
811. BAJAJ HS, Asbjornsdottir B, Bari TJ, Begtrup K, et al
     Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
     Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15726.
     PubMed     Abstract available
     
     
     
812. QUAST DR, Lancaster D, Xie C, Bound MJ, et al
     Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.
     Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15736.
     PubMed     Abstract available
     
     
     
813. WERKMAN NCC, Driessen JHM, Klungel OH, Schaper NS, et al
     Incretin-based therapy and the risk of diabetic foot ulcers and related events.
     Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15721.
     PubMed     Abstract available
     
     
     
814. ZHANG X, Su Y, Zhu X
     The association of diabetes with progression of sleep-disordered breathing based on a prospective cohort.
     Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15742.
     PubMed     Abstract available
     
     
     
815. KAO YW, Yen KC, Chen SW, Chao TF, et al
     Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
     Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15734.
     PubMed     Abstract available
     
     
     June 2024
816. LUO M, Sun M, Wang T, Wei J, et al
     Type 2 diabetes, glycaemic traits, structural brain capacity and cognitive function: A Mendelian randomization analysis.
     Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15702.
     PubMed     Abstract available
     
     
     
817. HAGI K, Kochi K, Watada H, Kaku K, et al
     Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
     Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15716.
     PubMed     Abstract available
     
     
     
818. ABERER F, Haberl HC, Elsayed H, Pottler T, et al
     Accuracy of the professional flash glucose monitoring system FreeStyle Libre Pro in hospitalized individuals with type 2 diabetes mellitus receiving standardized basal-bolus insulin therapy.
     Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15719.
     PubMed    
     
     
     
819. AERNOUTS C, Belde SPW, Lambrechts J, Mertens J, et al
     Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
     Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15723.
     PubMed     Abstract available
     
     
     
820. AYESH H, Suhail S, Ayesh S, Niswender K, et al
     Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
     Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15725.
     PubMed     Abstract available
     
     
     
821. LIU M, Gu W, Chen L, Li Y, et al
     The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
     Diabetes Obes Metab. 2024 Jun 22. doi: 10.1111/dom.15724.
     PubMed     Abstract available
     
     
     
822. AJIE M, van Heck JIP, Verhulst CEM, Fabricius TW, et al
     Real-life hypoglycaemia partially blunts the inflammatory response to experimental hypoglycaemia in people with type 1 diabetes.
     Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15712.
     PubMed     Abstract available
     
     
     
823. HENNEY AE, Riley DR, O'Connor B, Hydes TJ, et al
     Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15708.
     PubMed     Abstract available
     
     
     
824. LI P, Alkhuzam K, Brown J, Zhang Y, et al
     Association between low cognitive performance and diabetes-related health indicators across racial and ethnic groups in adults with diabetes.
     Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15715.
     PubMed     Abstract available
     
     
     
825. BONNET F, Cooper ME, Kopp L, Fouque D, et al
     A review of the latest real-world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
     Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15710.
     PubMed     Abstract available
     
     
     
826. RYBA-STANISLAWOWSKA M, Slominski B, Mysliwiec M
     Association of KLF14 rs4731702 gene polymorphism with metabolic phenotype in young patients with type 1 diabetes.
     Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15707.
     PubMed     Abstract available
     
     
     
827. YANG Q, Zeng B, Hao J, Yang Q, et al
     Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis.
     Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15718.
     PubMed     Abstract available
     
     
     
828. GUPTA Y, Goyal A, Tandon N
     Implications of antenatal 1-hour postload plasma glucose (>/= 11.6 mmol/L) for postpartum diabetes and cardiometabolic risk assessment in women with gestational diabetes: Post hoc analysis from the CHIP-F study.
     Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15722.
     PubMed    
     
     
     
829. ZHOU Y, Xu M, Yin X, Gong Y, et al
     Association between new-onset atrial fibrillation and dementia among individuals with type 2 diabetes.
     Diabetes Obes Metab. 2024 Jun 14. doi: 10.1111/dom.15714.
     PubMed     Abstract available
     
     
     
830. AL-ABDULLAH L, Ahern A, Welsh P, Logue J, et al
     A predictive model for medium-term weight loss response in people with type 2 diabetes engaging in behavioural weight management interventions.
     Diabetes Obes Metab. 2024 Jun 14. doi: 10.1111/dom.15706.
     PubMed     Abstract available
     
     
     
831. WELK B, McClure JA, Carter B, Clarke C, et al
     No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
     Diabetes Obes Metab. 2024 Jun 11. doi: 10.1111/dom.15711.
     PubMed    
     
     
     
832. TINTI D, Nobili C, Baretta I, Rosso A, et al
     Paediatric type 1 diabetes mellitus: A comparison between multi-injection therapy and advanced hybrid closed-loop pump in the first year after diabetes onset.
     Diabetes Obes Metab. 2024 Jun 11. doi: 10.1111/dom.15704.
     PubMed    
     
     
     
833. KIM NH, Moon JS, Lee YH, Cho HC, et al
     Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naive patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, o
     Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15705.
     PubMed     Abstract available
     
     
     
834. DEL PRATO S, Giorgino F, Szafranski K, Poon Y, et al
     Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
     Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15703.
     PubMed     Abstract available
     
     
     
835. ZU C, Liu M, Wang G, Meng Q, et al
     Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15699.
     PubMed     Abstract available
     
     
     
836. NAPOLI R, Nicolucci A, Larosa M, Rossi MC, et al
     Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.
     Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15697.
     PubMed     Abstract available
     
     
     
837. TANG F, Wang W, Wang Y, Lee Y, et al
     Moderate resistance training reduces intermuscular adipose tissue and risk factors of atherosclerotic cardiovascular disease for elderly patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Jun 9. doi: 10.1111/dom.15684.
     PubMed     Abstract available
     
     
     
838. WINTHER JB, Holst JJ
     Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
     Diabetes Obes Metab. 2024 Jun 9. doi: 10.1111/dom.15693.
     PubMed     Abstract available
     
     
     
839. ODUTAYO A, Cosentino F, Pratley RE, Dagogo-Jack S, et al
     Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
     Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15687.
     PubMed    
     
     
     
840. SUN CJ, Nguyen E, Prentki M, Rabasa-Lhoret R, et al
     The daunting task of recruiting insulin-treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions.
     Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15688.
     PubMed    
     
     
     
841. YOSHIDA Y, Zu Y, Fan B, Li S, et al
     Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early-onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study.
     Diabetes Obes Metab. 2024 Jun 4. doi: 10.1111/dom.15681.
     PubMed     Abstract available
     
     
     
842. MARQUES P, Mavrakanas TA, Guida J, Gedeon T, et al
     Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.
     Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15691.
     PubMed     Abstract available
     
     
     
843. LONG J, Fang Q, Shi Z, Miao Z, et al
     Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin.
     Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15689.
     PubMed     Abstract available
     
     
     
844. GONZALEZ-VIDAL T, Rivas-Otero D, Ramos-Ruiz G, Agueria-Cabal P, et al
     Impact of the basal/bolus ratio on continuous glucose monitoring parameters in patients with type 1 diabetes.
     Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15690.
     PubMed    
     
     
     
845. HE Y, Kunutsor SK, Kingsnorth AP, Gillies C, et al
     Differential associations of risk factors with severe and non-severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin-treated type 1 diabetes and type 2 diabetes.
     Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15677.
     PubMed     Abstract available
     
     
     
846. THOMAS L, Martel E, Rist W, Uphues I, et al
     The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
     Diabetes Obes Metab. 2024;26:2368-2378.
     PubMed     Abstract available
     
     
     
847. MILANOVIC S, Dedic N, Lew R, Burton D, et al
     TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
     Diabetes Obes Metab. 2024;26:2466-2475.
     PubMed     Abstract available
     
     
     
848. LIU Y, Kimita W, Shamaitijiang X, Skudder-Hill L, et al
     Intra-pancreatic fat is associated with continuous glucose monitoring metrics.
     Diabetes Obes Metab. 2024;26:2359-2367.
     PubMed     Abstract available
     
     
     
849. STRATMANN B, Eggers B, Mattern Y, de Carvalho TS, et al
     Maladaptive response following glucose overload in GLUT4-overexpressing H9C2 cardiomyoblasts.
     Diabetes Obes Metab. 2024;26:2379-2389.
     PubMed     Abstract available
     
     
     
850. LUIZ MM, Maximo RO, de Oliveira DC, Ramirez PC, et al
     Could poor glycaemic control be a predictor of walking speed decline in older adults? Evidence from the English Longitudinal Study of Ageing.
     Diabetes Obes Metab. 2024;26:2349-2358.
     PubMed     Abstract available
     
     
     
851. PULKKINEN MA, Varimo TJ, Hakonen ET, Hero MT, et al
     During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range.
     Diabetes Obes Metab. 2024;26:2431-2438.
     PubMed     Abstract available
     
     
     
852. ABDELMALEK MF, Harrison SA, Sanyal AJ
     The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
     Diabetes Obes Metab. 2024;26:2001-2016.
     PubMed     Abstract available
     
     
     
853. HASHEMY H, Nguyen A, Khafagy R, Roshandel D, et al
     Analyses of potential causal contributors to increased waist/hip ratio-associated cardiometabolic disease: A combined and sex-stratified Mendelian randomization study.
     Diabetes Obes Metab. 2024;26:2284-2291.
     PubMed     Abstract available
     
     
     
854. TOSHIMITSU T, Gotou A, Sashihara T, Hojo K, et al
     Ingesting probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 improves glycaemic control in adults with prediabetes in a randomized, double-blind, placebo-controlled trial.
     Diabetes Obes Metab. 2024;26:2239-2247.
     PubMed     Abstract available
     
     
     
855. SILVERII GA, Marinelli C, Mannucci E, Rotella F, et al
     Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2024;26:2505-2508.
     PubMed    
     
     
     
856. PETERMANN-ROCHA F, Apolinar E, Nazar G, Diaz-Toro F, et al
     Associations of diabesity with all-cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study.
     Diabetes Obes Metab. 2024;26:2199-2208.
     PubMed     Abstract available
     
     
     May 2024
857. KHAWAGI WY, Al-Kuraishy HM, Hussein NR, Al-Gareeb AI, et al
     Depression and type 2 diabetes: A causal relationship and mechanistic pathway.
     Diabetes Obes Metab. 2024 May 27. doi: 10.1111/dom.15630.
     PubMed     Abstract available
     
     
     
858. BAILEY CJ
     Metformin: Therapeutic profile in the treatment of type 2 diabetes.
     Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15663.
     PubMed     Abstract available
     
     
     
859. BUCKLEY A, Suliman S, Allum M, Mohammed N, et al
     Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
     Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15680.
     PubMed     Abstract available
     
     
     
860. WANG D, Chen Z, Wu Y, Ren J, et al
     Association between two novel anthropometric measures and type 2 diabetes in a Chinese population.
     Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15651.
     PubMed     Abstract available
     
     
     
861. SUN Y, Li W, Zhou Y, Wang B, et al
     Long-term changes in frailty and incident type 2 diabetes: A prospective cohort study based on the UK Biobank.
     Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15676.
     PubMed     Abstract available
     
     
     
862. SVENSSON CH, Fabricius TW, Verhulst CEM, Kristensen PL, et al
     Association between recent exposure to continuous glucose monitoring-recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes.
     Diabetes Obes Metab. 2024 May 22. doi: 10.1111/dom.15649.
     PubMed     Abstract available
     
     
     
863. SUGIMOTO T, Saji N, Omura T, Tokuda H, et al
     Cross-sectional association of continuous glucose monitoring-derived metrics with cerebral small vessel disease in older adults with type 2 diabetes.
     Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15659.
     PubMed     Abstract available
     
     
     
864. TSUKAMOTO S, Kobayashi K, Toyoda M, Tone A, et al
     Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
     Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652.
     PubMed     Abstract available
     
     
     
865. LEITER LA, Raal FJ, Schwartz GG, Koenig W, et al
     Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
     Diabetes Obes Metab. 2024 May 17. doi: 10.1111/dom.15650.
     PubMed     Abstract available
     
     
     
866. SEGEV O, Raz I, Gerstein HC, Aviezer H, et al
     Development and first-stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes.
     Diabetes Obes Metab. 2024 May 17. doi: 10.1111/dom.15657.
     PubMed     Abstract available
     
     
     
867. BUCKERIDGE C, Tsamandouras N, Carvajal-Gonzalez S, Brown LS, et al
     Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
     Diabetes Obes Metab. 2024 May 16. doi: 10.1111/dom.15643.
     PubMed     Abstract available
     
     
     
868. GUO K, Ye J, Li J, Huang J, et al
     Effects of gut microbiome on type 1 diabetes susceptibility and complications: A large-scale bidirectional Mendelian randomization and external validation study.
     Diabetes Obes Metab. 2024 May 16. doi: 10.1111/dom.15658.
     PubMed     Abstract available
     
     
     
869. BOURRON O, Mohammedi K, De Keizer J, Schneider F, et al
     A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 May 15. doi: 10.1111/dom.15656.
     PubMed     Abstract available
     
     
     
870. GREENE E, Green CL, Hurst J, MacIver NJ, et al
     Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes.
     Diabetes Obes Metab. 2024 May 14. doi: 10.1111/dom.15655.
     PubMed     Abstract available
     
     
     
871. HU S, Shi C, Ma Y, Wang S, et al
     Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
     Diabetes Obes Metab. 2024 May 13. doi: 10.1111/dom.15645.
     PubMed     Abstract available
     
     
     
872. ALMUALLEM S, Ali AK, Vourtzoumis P, Demyttenaere S, et al
     Validation of the Individualized Metabolic Surgery score in predicting long-term remission of diabetes after duodenal switch-type procedures.
     Diabetes Obes Metab. 2024 May 9. doi: 10.1111/dom.15647.
     PubMed     Abstract available
     
     
     
873. KANAOKA T, Wakui H, Yano Y, Nagasu H, et al
     Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database.
     Diabetes Obes Metab. 2024 May 8. doi: 10.1111/dom.15611.
     PubMed     Abstract available
     
     
     
874. MORIOKA T, Takeuchi M, Ozeki A, Emoto M, et al
     A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
     Diabetes Obes Metab. 2024 May 7. doi: 10.1111/dom.15644.
     PubMed     Abstract available
     
     
     
875. SHIKAMURA M, Takayama A, Takeuchi M, Kawakami K, et al
     Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A
     Diabetes Obes Metab. 2024 May 6. doi: 10.1111/dom.15632.
     PubMed     Abstract available
     
     
     
876. TAKAHASHI A, Nomoto H, Onishi K, Manda S, et al
     A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
     Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15639.
     PubMed    
     
     
     
877. YANG M, Yue H, Xu Q, Shao S, et al
     Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.
     Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15641.
     PubMed     Abstract available
     
     
     
878. SMATI S, Sotin T, Deniel P, Ducheix S, et al
     Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes.
     Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15634.
     PubMed    
     
     
     
879. TIRADO-AGUILAR OA, Martinez-Cruz N, Arce-Sanchez L, Borboa-Olivares H, et al
     Earlier detection of gestational diabetes impacts on medication requirements, neonatal and maternal outcomes.
     Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15633.
     PubMed     Abstract available
     
     
     
880. XIANG C, Sun Y, Luo Y, Xie C, et al
     Gastric emptying is slower in women than men with type 2 diabetes and impacts on postprandial glycaemia.
     Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15635.
     PubMed     Abstract available
     
     
     
881. SUN Y, Luo Y, Xiang C, Xie C, et al
     Gastric emptying in newly diagnosed, treatment-naive Han Chinese with type 2 diabetes and the impact of 4-week insulin pump therapy.
     Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15626.
     PubMed     Abstract available
     
     
     
882. CHEN J, Li YT, Niu Z, He Z, et al
     Investigating the causal association of generalized and abdominal obesity with microvascular complications in patients with type 2 diabetes: A community-based prospective study.
     Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15598.
     PubMed     Abstract available
     
     
     
883. LI S, Pan S, Jiang S, Shin JI, et al
     Prescription medication use among patients with type 2 diabetes in the United States: 1999-2020.
     Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15619.
     PubMed     Abstract available
     
     
     
884. LASSEN MCH, Johansen ND, Modin D, Nealon J, et al
     Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
     Diabetes Obes Metab. 2024;26:1821-1829.
     PubMed     Abstract available
     
     
     
885. THIRUMALAI A, Chao JH, Kaleru T, Dong X, et al
     Bridging dose of U-100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice-daily glargine users.
     Diabetes Obes Metab. 2024;26:1868-1876.
     PubMed     Abstract available
     
     
     
886. TAN YH, Tan WL, Eichinger V, Ruch B, et al
     Blood glucose control using a mobile health application in Singapore, Philippines and Hong Kong: a retrospective real-world data analysis.
     Diabetes Obes Metab. 2024;26:1990-1992.
     PubMed    
     
     
     
887. WU Y, Zhang C, Duan S, Li Y, et al
     TEAD1, MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population.
     Diabetes Obes Metab. 2024;26:1775-1788.
     PubMed     Abstract available
     
     
     
888. SALERNO PRVO, Qian A, Dong W, Deo S, et al
     County-level socio-environmental factors and obesity prevalence in the United States.
     Diabetes Obes Metab. 2024;26:1766-1774.
     PubMed     Abstract available
     
     
     
889. YEW MJ, Heywood SE, Ng J, West OM, et al
     ACAD10 is not required for metformin's metabolic actions or for maintenance of whole-body metabolism in C57BL/6J mice.
     Diabetes Obes Metab. 2024;26:1731-1745.
     PubMed     Abstract available
     
     
     
890. GILBERT MP, Skelly J, Hernandez AF, Green JB, et al
     Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
     Diabetes Obes Metab. 2024;26:1714-1722.
     PubMed     Abstract available
     
     
     
891. DIALLO A, Diallo MF, Carlos-Bolumbu M, Galtier F, et al
     Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024;26:1980-1985.
     PubMed     Abstract available
     
     
     
892. CHAN SY, Zhang H, Wong JT, Chang HF, et al
     Higher early pregnancy plasma myo-inositol associates with increased postprandial glycaemia later in pregnancy: Secondary analyses of the NiPPeR randomized controlled trial.
     Diabetes Obes Metab. 2024;26:1658-1669.
     PubMed     Abstract available
     
     
     
893. DE GERMAY S, Pambrun E, Pariente A, Grenet G, et al
     Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
     Diabetes Obes Metab. 2024;26:1678-1686.
     PubMed     Abstract available
     
     
     
894. SOURIJ C, Oulhaj A, Aziz F, Tripolt NJ, et al
     Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial.
     Diabetes Obes Metab. 2024;26:1971-1975.
     PubMed    
     
     
     
895. VERNSTROM L, Gullaksen S, Sorensen SS, Funck KL, et al
     Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
     Diabetes Obes Metab. 2024;26:1624-1635.
     PubMed     Abstract available
     
     
     April 2024
896. SU J, Fan X, Li M, Yu H, et al
     Association of lifestyle with reduced stroke risk in 41 314 individuals with diabetes: Two prospective cohort studies in China.
     Diabetes Obes Metab. 2024 Apr 29. doi: 10.1111/dom.15606.
     PubMed     Abstract available
     
     
     
897. SEUFERT J, Freemantle N, Guja C, Haluzik M, et al
     Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.
     Diabetes Obes Metab. 2024 Apr 29. doi: 10.1111/dom.15609.
     PubMed    
     
     
     
898. NAKHLEH A, Abdul-Ghani M, Gazit S, Gross A, et al
     Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
     Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15623.
     PubMed     Abstract available
     
     
     
899. MICHALOPOULOU M, Piernas C, Jebb SA, Gao M, et al
     Association of gestational diabetes with long-term risk of premature mortality, and cardiovascular outcomes and risk factors: A retrospective cohort analysis in the UK Biobank.
     Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15612.
     PubMed     Abstract available
     
     
     
900. REED J, Dong T, Eaton E, Friswold J, et al
     Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
     Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15608.
     PubMed     Abstract available
     
     
     
901. IWAMOTO Y, Kimura T, Shimoda M, Morimoto Y, et al
     C-peptide index at 2 h post-meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes.
     Diabetes Obes Metab. 2024 Apr 22. doi: 10.1111/dom.15595.
     PubMed     Abstract available
     
     
     
902. BIAN YC, Meng J, Hu T, Ma S, et al
     Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
     Diabetes Obes Metab. 2024 Apr 22. doi: 10.1111/dom.15605.
     PubMed     Abstract available
     
     
     
903. KIM JH, Lyu YS, Kim B, Kim MK, et al
     Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history.
     Diabetes Obes Metab. 2024 Apr 21. doi: 10.1111/dom.15565.
     PubMed     Abstract available
     
     
     
904. 
     Correction to "Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time".
     Diabetes Obes Metab. 2024 Apr 19. doi: 10.1111/dom.15618.
     PubMed    
     
     
     
905. MALIK RA, Hwu CM, Jammah AA, Arteaga-Diaz JM, et al
     Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
     Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15599.
     PubMed     Abstract available
     
     
     
906. WILSON M, Al-Hamid A, Abbas I, Birkett J, et al
     Identification of diagnostic biomarkers used in the diagnosis of cardiovascular diseases and diabetes mellitus: A systematic review of quantitative studies.
     Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15593.
     PubMed     Abstract available
     
     
     
907. HU Y, Li X, Wang X, Ma H, et al
     Smoking timing, genetic susceptibility and the risk of incident type 2 diabetes: A cohort study from the UK Biobank.
     Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15603.
     PubMed     Abstract available
     
     
     
908. DE OLIVEIRA COSTA J, Lin J, Milder TY, Greenfield JR, et al
     Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
     Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15597.
     PubMed     Abstract available
     
     
     
909. JEONG SI, Ban MS, Hwang JG, Park MK, et al
     The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
     Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15573.
     PubMed     Abstract available
     
     
     
910. WANG Y, Jiang C, Dong X, Chen M, et al
     Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
     Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15596.
     PubMed     Abstract available
     
     
     
911. DENG S, Hu X, Zhang X
     Association of single-point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes.
     Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15600.
     PubMed     Abstract available
     
     
     
912. IRLIK K, Aldosari H, Hendel M, Kwiendacz H, et al
     Artificial intelligence-enhanced electrocardiogram analysis for identifying cardiac autonomic neuropathy in patients with diabetes.
     Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15578.
     PubMed     Abstract available
     
     
     
913. GRANDO ALVES G, Cunha L, Henkes Machado R, Lins de Menezes V, et al
     Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
     Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15581.
     PubMed     Abstract available
     
     
     
914. GUO L, Tian F, Liu L, Chen M, et al
     Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
     Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15601.
     PubMed     Abstract available
     
     
     
915. GUO L, Xi Y, Li L, Guo K, et al
     Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
     Diabetes Obes Metab. 2024 Apr 10. doi: 10.1111/dom.15590.
     PubMed    
     
     
     
916. SAID F, Arnott C, Voors AA, Heerspink HJL, et al
     Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
     Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15592.
     PubMed     Abstract available
     
     
     
917. SIMON SL, Snell-Bergeon JK, Schafer M, Barker AJ, et al
     Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR-T1D study.
     Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15582.
     PubMed     Abstract available
     
     
     
918. VIVIAN EM, Chewning BA, Voils CI, Brown RL, et al
     Healthy Outcomes through Peer Educators: Feasibility of a peer support diabetes prevention programme for African-American grandmother caregivers.
     Diabetes Obes Metab. 2024 Apr 3. doi: 10.1111/dom.15574.
     PubMed     Abstract available
     
     
     
919. CHEN GL, Liu Y, Gao XF, Wu KQ, et al
     Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
     Diabetes Obes Metab. 2024;26:1395-1406.
     PubMed     Abstract available
     
     
     
920. GUY A, Azab AN, Liberty IF, Afawi Z, et al
     Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
     Diabetes Obes Metab. 2024;26:1346-1354.
     PubMed     Abstract available
     
     
     
921. LAU D, Gamble JM
     Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?
     Diabetes Obes Metab. 2024;26:1150-1156.
     PubMed    
     
     
     
922. HOPE DCD, Ansari S, Choudhury S, Alexiadou K, et al
     Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
     Diabetes Obes Metab. 2024;26:1479-1491.
     PubMed     Abstract available
     
     
     
923. BAZYDLO-GUZENDA K, Jarus-Dziedzic K, Gierczak-Pachulska A, Buda P, et al
     First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
     Diabetes Obes Metab. 2024;26:1376-1385.
     PubMed     Abstract available
     
     
     
924. CUKIERMAN-YAFFE T, Ramasundarahettige C, Bosch J, Gerstein HC, et al
     Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the ORIGIN trial.
     Diabetes Obes Metab. 2024;26:1180-1187.
     PubMed     Abstract available
     
     
     
925. NERILD HH, Bronden A, Haddouchi AE, Ellegaard AM, et al
     Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
     Diabetes Obes Metab. 2024;26:1252-1263.
     PubMed     Abstract available
     
     
     
926. TOMLINSON JW
     Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.
     Diabetes Obes Metab. 2024;26 Suppl 2:13-24.
     PubMed     Abstract available
     
     
     
927. GOLUBIC R, Kennet J, Parker V, Robertson D, et al
     Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15579.
     PubMed     Abstract available
     
     
     
928. LUO J, Zhao X, Li Q, Zou B, et al
     Evaluating the global impact of low physical activity on type 2 diabetes: Insights from the global burden of disease 2019 study.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15568.
     PubMed     Abstract available
     
     
     
929. SAFDAR NZ, Alobaid AM, Hopkins M, Dempsey PC, et al
     Short, frequent, light-intensity walking activity improves postprandial vascular-inflammatory biomarkers in people with type 1 diabetes: The SIT-LESS randomized controlled trial.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15564.
     PubMed     Abstract available
     
     
     
930. KUHNE T, Wallace E, Herzig D, Helleputte S, et al
     Combined intake of caffeine and low-dose glucose to reduce exercise-related hypoglycaemia in individuals with type 1 diabetes on ultra-long-acting insulin degludec: A randomized, controlled, double-blind, cross-over trial.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15580.
     PubMed     Abstract available
     
     
     
931. DARSALIA V, Vercalsteren E, Karampatsi D, Romanitan MO, et al
     The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15577.
     PubMed    
     
     
     
932. CHRISTOFIDES EA, Puente O, Norwood P, Denham D, et al
     Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus(R)) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15560.
     PubMed     Abstract available
     
     
     
933. HUANG ZG, Gao JW, Zhang HF, You S, et al
     Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15583.
     PubMed     Abstract available
     
     
     
934. TALHA KM, Green J, Filippatos G, Pocock S, et al
     Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15572.
     PubMed     Abstract available
     
     
     
935. MAHMOUD F, Mueller T, Mullen A, Sainsbury C, et al
     Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15584.
     PubMed     Abstract available
     
     
     
936. ANSON M, Henney AE, Zhao SS, Ibarburu GH, et al
     Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated dat
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15576.
     PubMed     Abstract available
     
     
     
937. KANBAY M, Copur S, Topcu AU, Guldan M, et al
     An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15575.
     PubMed     Abstract available
     
     
     
938. HODGSON A, Gillies CL, Highton P, Haddon L, et al
     Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort st
     Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15571.
     PubMed    
     
     
     March 2024
939. 
     Correction to 'In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank'.
     Diabetes Obes Metab. 2024 Mar 27. doi: 10.1111/dom.15591.
     PubMed    
     
     
     
940. SUZUKI Y, Kaneko H, Nagasawa H, Okada A, et al
     Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
     Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15561.
     PubMed     Abstract available
     
     
     
941. CARIOU B, Linge J, Neeland IJ, Dahlqvist Leinhard O, et al
     Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
     Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15566.
     PubMed     Abstract available
     
     
     
942. ZHANG Y, Yang D, Jia Q, Yan J, et al
     The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15557.
     PubMed     Abstract available
     
     
     
943. BELL DSH, Jerkins T
     The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
     Diabetes Obes Metab. 2024 Mar 22. doi: 10.1111/dom.15559.
     PubMed     Abstract available
     
     
     
944. RODBARD HW, Barnard-Kelly K, Pfeiffer AFH, Mauersberger C, et al
     Practical strategies to manage obesity in type 2 diabetes.
     Diabetes Obes Metab. 2024 Mar 21. doi: 10.1111/dom.15556.
     PubMed     Abstract available
     
     
     
945. RIVERA FB, Lumbang GNO, Gaid DRM, Cruz LLA, et al
     Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
     Diabetes Obes Metab. 2024 Mar 20. doi: 10.1111/dom.15529.
     PubMed     Abstract available
     
     
     
946. DEN BROK EJ, Svensson CH, Panagiotou M, van Greevenbroek MMJ, et al
     The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta-analysis.
     Diabetes Obes Metab. 2024 Mar 19. doi: 10.1111/dom.15521.
     PubMed     Abstract available
     
     
     
947. BORNSTEIN SR, de Zeeuw D, Heerspink HJL, Schulze F, et al
     Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
     Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15518.
     PubMed     Abstract available
     
     
     
948. SHI C, Tan Y, Hu S, Qin Y, et al
     Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
     Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15552.
     PubMed    
     
     
     
949. PENG M, He S, Wang J, An Y, et al
     Efficacy of 1-hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes-related complications: A post hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study.
     Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15547.
     PubMed     Abstract available
     
     
     
950. LAU D, Pearson GJ, Raggi P, Klarenbach S, et al
     Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost-effective in select individuals.
     Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15558.
     PubMed    
     
     
     
951. FADINI GP, Bonora BM, Ghiani M, Anichini R, et al
     Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
     Diabetes Obes Metab. 2024 Mar 13. doi: 10.1111/dom.15554.
     PubMed     Abstract available
     
     
     
952. JAIN AB, Reichert SM, Amadid H, Braae UC, et al
     Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
     Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15493.
     PubMed     Abstract available
     
     
     
953. NYSTROM T, Andersson Franko M, Ludvigsson J, Lind M, et al
     Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes.
     Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15545.
     PubMed    
     
     
     
954. ZHAO H, Wu Y, Xie Y, Li Y, et al
     Hydrogel dressings for diabetic foot ulcer: A systematic review and meta-analysis.
     Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15544.
     PubMed     Abstract available
     
     
     
955. DOMAZET SL, Olesen TB, Stidsen JV, Svensson CK, et al
     Low-grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators.
     Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15514.
     PubMed     Abstract available
     
     
     
956. HELMINK MAG, Hageman SHJ, Eliasson B, Sattar N, et al
     Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
     Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15531.
     PubMed     Abstract available
     
     
     
957. SOHN TS, Han KA, Kim Y, Lee BW, et al
     A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
     Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15537.
     PubMed     Abstract available
     
     
     
958. POPOVIC DS, Patoulias D, Karakasis P, Koufakis T, et al
     Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes.
     Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15535.
     PubMed    
     
     
     
959. YANG J, Shangguan Q, Xie G, Yang M, et al
     Sex-specific associations between haemoglobin glycation index and the risk of cardiovascular and all-cause mortality in individuals with pre-diabetes and diabetes: A large prospective cohort study.
     Diabetes Obes Metab. 2024 Mar 7. doi: 10.1111/dom.15541.
     PubMed     Abstract available
     
     
     
960. IVERSEN E, Christensen KM, Walls AB, Eickhoff MK, et al
     Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.
     Diabetes Obes Metab. 2024 Mar 6. doi: 10.1111/dom.15536.
     PubMed    
     
     
     
961. HUANG Y, Wang S, Cai C, Huang X, et al
     Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease.
     Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15492.
     PubMed     Abstract available
     
     
     
962. TURNER LV, Riddell MC
     Pre-dinner walks may be superior to post-dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed-loop insulin delivery systems.
     Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15532.
     PubMed    
     
     
     
963. HOYT JA, Cozzi E, D'Alessio DA, Thompson CC, et al
     A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
     Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15533.
     PubMed     Abstract available
     
     
     
964. BATDORF HM, Lawes LL, Cassagne GA, Fontenot MS, et al
     Accelerated onset of diabetes in non-obese diabetic mice fed a refined high-fat diet.
     Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15522.
     PubMed     Abstract available
     
     
     
965. REDDY M, Oliver N
     The role of real-time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management.
     Diabetes Obes Metab. 2024;26 Suppl 1:46-56.
     PubMed     Abstract available
     
     
     February 2024
966. LIM S, Lee SH, Min KW, Lee CB, et al
     A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
     Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15526.
     PubMed     Abstract available
     
     
     
967. VARGAS KG, Rutten T, Siemes B, Brockmeyer M, et al
     Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.
     Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15519.
     PubMed     Abstract available
     
     
     
968. WILLIG MR, Stinson EJ, Looker HC, Piaggi P, et al
     Insulin resistance before type 2 diabetes onset is associated with increased risk of albuminuria after diabetes onset: A prospective cohort study.
     Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15505.
     PubMed     Abstract available
     
     
     
969. SWIFT C, Frazer M, Gronroos NN, Sargent A, et al
     Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
     Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15516.
     PubMed     Abstract available
     
     
     
970. BONNET F, Balkau B, Lambert O, Diawara Y, et al
     The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD-REIN cohort study.
     Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15507.
     PubMed     Abstract available
     
     
     
971. ZHAO Y, Han M, Qie R, Zhang Y, et al
     Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China-PAR project.
     Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15508.
     PubMed     Abstract available
     
     
     
972. IIJIMA H, Gouda M, Hida H, Mori-Anai K, et al
     Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.
     Diabetes Obes Metab. 2024 Feb 27. doi: 10.1111/dom.15461.
     PubMed     Abstract available
     
     
     
973. KUNUTSOR SK, Balasubramanian VG, Zaccardi F, Gillies CL, et al
     Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
     Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15511.
     PubMed     Abstract available
     
     
     
974. SHAO X, Lu J, Tao R, Wu L, et al
     Clinically relevant stratification of patients with type 2 diabetes by using continuous glucose monitoring data.
     Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15512.
     PubMed     Abstract available
     
     
     
975. SHEN W, Cai L, Wang B, Li J, et al
     Associations of a proinflammatory diet, habitual salt intake, and the onset of type 2 diabetes: A prospective cohort study from the UK Biobank.
     Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15517.
     PubMed     Abstract available